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INTRODUCTION 
The pleasant effects of opium were already known 6000 years ago and 
opium has been used for medical purposes for at least 3500 years. Opium, 
and its r.1ain constituent morphine, evoke a feeling of well-being and 
always relieve pain of any origin, in other words, a perfect analgesic 
and euphoric drug. However, there are unpleasant repercussions. Thus, 
the pleasant effects are followed by a period of dysphoria. With the 
first, moderate dose of opiate this rebound is not important. But euphoric 
and analgesic effects disappear with repeated administration unless the 
dose is steadily increased. When the opiate is withcirawn after repeated 
administration of high doses, the dysphoric rebound wi 11 gain dangerous 
proportions and this is one of the reasons for continued (addicted) use 
of the opiate. Thus, the perfect analgesic and euphoric drug produces 
a perfect dependence. One of the most important stimuli to the promotion 
of research into the mechanism of action of opiates is the desire to 
control opiate-dependence. Such control would help two groups of users: 
those who need a strong analgesic would not necessarily become dependent 
and those who become dependent would not necessarily always need opiates. 
The acute effects of morphine are highly interrelated phenomena such as 
analgesia and euphoria, while dependence is ascribed to an adaptation 
of the cells of the body. In order to relate or dissociate these effects 
of opiates it is necessary to analyse the eel lular and molecular events 
related to the acute effects of the opiate. If these eel lular and mole-
cular events are the same as those underlying opiate-dependence, it wil 1 
not be possible to dissociate the analgesic and euphoric effects of 
opiates from their ability to produce dependence. However, if it appears 
that differences do exist between the mechanism of these two opiate-
induced phenomena then control of opiate-dependence may be possible. 
In the experiments described here, the effects of acute morphine 
administration on dopaminergic neurons in the rat were investigated. 
Dopamine is an important neurotransmitter in 1 imbic and extrapyramidal 
brain areas and plays an important role in the integration of emotional 
responses. Furthermore, the analgesic and rewarding (euphoric?) properties 
of morphine have been related inter alea to interactions with dopaminer-
gic systems. An attempt has been made to analyse molecular mechanisms 
involved in the action of morphine on dopaminergic neurons in different 
brain areas and to analyse the relation of both these actions and be-
havioural responses to acute morphine administration. 
PART I 
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ACUTE MORPHINE ADMINISTRATION 
When morphine is administered for the first time to man or animal, 
a vast variety of responses can be evoked. Peripheral effects of morphine 
include constipation, reduced secretion of a number of endocrine glands, 
bronchoconstriction, dilation of capillaries and stimulation of the 
uterus (1). The appearance of these and also of the central effects of 
morphine is mainly dependent on the species and dose of morphine. The 
above-mentioned effects are of peripheral origin, but it is quite clear, 
that these effects are mediated through an action on the nervous system. 
This brings, therefore, the mechanism of peripheral and central effects 
closer together. Thus, bes'1des research on central effects~· the 
action of morphine has also been investigated using less complex peri-
pheral models. The intestine provides an excel lent preparation to study 
interactions of morphine with cholinergic and serotonergic neurotrans-
mission (2, 3, 4). 
Central effects of morphine include analgesia, respiratory depression, 
depression of spinal reflexes, depression or stimulation of locomotion, 
nausea, vomiting, pupillary constriction (pin point pupil), Straub tail 
(in mice), release of antidiuretic hormone, hyperglycaemia and hypo- or 
hyperthermia (1, 5). Again the effects depend on species and dose of 
morphine. 
In spite of many attempts, no success has been obtained in ascribing 
the effects of morphine on these physiological systems to the interaction 
of this drug with one clearly defined type of neuron, whether the 
classification be morphological, anatomical or chemical. The subcellular 
and molecular mechanisms accounted for in the following sections are 
therefore, mostly indirectly related to the effect of morphine on the 
physiological systems described above. 
BIPHASIC EFFECTS 
Some responses to morphine show a biphasic character in relation to 
time and dose. In rats a high dose of morphine first induces depression 
and later stimulation of locomotor activity (6-8). Low doses of morphine 
only produce the stimulatory response (6, 8-10). Moreover, upon repeated 
treatment with high doses of morphine, the depression of locomotor 
activity diminishes, while the stimulation increases and is observable 
at an earlier period of time after the administration of morphine (6). 
Other biphasic responses (8), like changes in temperature (11), self-
stimulation rate (12) and electrophysiological ly recorded neuronal 
firing (13), show similar characteristics. Specific molecular or cellular 
events have been cal led in to account for these biphasic effects (7, 8). 
The most important observation in all these biphasic responses., however, 
is that no tolerance appears for the stimulant action in contrast to 
the depressant effect. Moreover, the stimulant effects are not anta-
gonized by naloxone, a pure opiate antagonist (13, 14). This latter 
observation has led to the opinion that the stimulatory effects are non-
specific. It may very well be, however, that the observed biphasic res-
ponses provide an important clue to the understanding of the dependence 
producing properties of morphine (8). 
METABOLISM OF MORPHINE 
The metabolism of morphine and related compounds has been studied 
extensively in various species (15, 16). It was suggested on the basis 
of such studies, that heroin (diacetylmorphine) may be potent, because it 
enters the brain very rapidly. The active component would not 
be heroin itself, but either 6-monoacetylmorphine (17) or morphine 
itself (18). 
Only recently, however, the metabolism of morphine has been studied 
in relation to its analgesic activity (19, 20). DahlstrOm et a1. (19) 
provided a computer-designed model, which related the time-course of 
morphine distribution in restricted brain regions to different analgesic 
responses. 
Another recent report showed that one of the principal biotrans-
formations of morphine, N-demethylation, is localized in sites with 
high opiate receptor concentrations (21). This observation may have an 
important impact on the understanding of the conformation of the opiate 
receptor and the pharmacokinetics of opiates. 
BRAIN SITES OF MORPHINE ACTION 
The localization of morphine effects to restricted brain areas has 
been explored extensively in relation to analgesia and abstinence signs. 
Evidence is accumulating that the mesencephalic periaqueductal gray 
area is an important site for the analgesic action of morphine (22, 23). 
This localization in a rather restricted area was explained by an inter-
action of morphine with specific pain pathways. The sensitive sites in 
the periaqueductal gray are closely related to the midbrain raphe nuclei, 
the major eel 1 body areas of central serotonergic neurons. Lesions (24, 
25) and stimulation (26) of these nuclei have marked effects on analgesic 
responses to morphine. These data suggest that specific pathways from 
opiate-sensitive sites in the periaqueductal gray to the raphe nuclei 
are of major importance in morphine 1 s analgesic action. In an extensive 
account of these data it was also emphasized,however, that direct spinal 
effects of morphine may contribute considerably to its analgesic action 
after systemic administration (23). 
The specific brain sites thought to be involved in morphine abstinence 
signs have been studied by means of lesions (27) and application of a 
morphine antagonist in dependent rats (28, 29). The picture emerging from 
these studies is not quite clear for several reasons. ln an early report 
the medial thalamus was advanced as a major site. However, the evidence 
was inconclusive since mainly ''wet dog shakes'' (one of the abstinence 
signs in rats) were quantified (28). From other reports it appears that 
a variety of signs may be elicited more easily from several different 
brain regions (27, 30). Moreover, 11wet dog shakes 11 may also be antagonized 
in other brain regions by morphine (31). It thus appears that the 
thalamus, periaqueductal gray, preoptic area, locus coeruleus and hypo-
5 
6 
thalamus are involved in induction or mediation of various abstinence 
signs. 
NEUROTRANSMITTERS 
The question of whether morphine interacts with a specific neuro-
transmitter or not, has been studied extensively. A number of recent 
reviews deal with the results of such studies (32-40). Actually, morphine 
seems to interact with all the neurotransmitters investigated. In most 
cases the effect of morphine on the levels of the transmitters were 
studied. Since this does not permit firm conclusions concerning the real 
effect of morphine, it was appreciated that investigations of the turn-
over of transmitters would yield more information. 
Acetylcholine (Ach) 
A decrease in Ach turnover rate has been reported in the rat and 
cat cortex (8, 41), and in the rat n. accumbens (41), but not in the 
rat striatum (8, 41). Reduced release of Ach from the cortex of 
anaesthesized rats and cats has been observed by several investigators 
(8). Increased cortical release of Ach, however, has been reported to 
occur in unanaesthesized cats (41). Whether or not contradictory results 
can be explained by biphasic effects on Ach release, as suggested by 
Domino et al. (8), remains to be established. A clear involvement of Ach 
in certain physiological effects of acute ooiate administration can not be 
concluded from the present state of knowled9e (40). 
Serotonin 
As mentioned before, serotonin may play a major role in the mediation 
of analgesic effects of morphine. Studies of serotonin turnover have 
shown effects of morphine, but several contradictory results and theore-
tical objections to the results reported hamper a clear interpretation. 
There is no doubt that morphine interferes with serotonergic neurotrans-
mission, but the implications of the reported results are quite obscure, 
as discussed by Eidelberg (40). 
Ca techo 1 ami nes 
An account of the effects on dopaminergic neurotransmission will be 
given in some of the following sections. Since profound effects on DA 
turnover were found, the effects on noradrenergic neurotransmission seem 
to be neglected to a certain extent. This may be due to the fact that 
measurement of NA turnover goes hand in hand with measurement of DA 
turnover. The turnover of NA seems to be increased by morphine in mice 
(43), while the same appears to apply to the rat, but only in the medulla/ 
pons and not in whole rat brain (44). This latter effect may 1 ink up 
with the observed effect of morphine on the locus coeruleus, a major 
site of NA cell bodies in the medulla (45) and also a major site of 
opiate receptors (vide infra). 
Other Neurotransmitters 
Few reports are available on the role of other putative transmitters 
in the ~ctions of morphine. The reasons for this lack of attention are 
obvious. The transmitters described above are reasonably well defined and 
more or less accepted as such. Investigations on putative neurotrans-
mitters leave the question open as to whether the observed effects 
really are involved with changes in neurotransmission. Thus, Sherman and 
Gebhart (46) investigated the effects of morphine, in relation to painful 
stimuli, on the levels of aspartate, GABA and glutamate, three putative 
amino-acid neurotransmitters (4 7). They observed decreased glutamate 
levels in the periaqueductal gray after application of a painful 
stimulus, an effect which is apparently not related to stress in general. 
since it was not observed after immobilization stress. Morphine, however, 
induced a rise in glutamate in the same brain area and also abel ished 
the effect of the painful stimulus on glutamate levels. This suggests a 
role for glutamate in the analgesic action of morphine. As discussed 
by the authors, however, the role of glutamate as a neurotransmitter is 
not clear and, therefore, the relevance of these findings is not clear 
either (46). 
GABA has been implicated in the spinal effects of morphine (48). 
Manipulation of GABA levels antagonized the effects of morphine on DA 
metabolism (49). Direct effects on GABA-ergic neurotransmission are 
extremely difficult to assess and information in this field is lacking. 
ADENYLATE CYCLASE 
Collier and Roy (50, 51) observed that morphine blocks the stimulation 
of cAMP formation by prostaglandin E(PGE) in brain tissue homogenates. 
They suggested that this may be the prime site of opiate action. In reaching 
this hypothesis an important consideration was, that morphine affects 
many neurotransmitters. A mechanism involving al 1 of them might account for 
its universal effects. cAMP functions as a second messenger in many hormone-
receptor interactions (52), probably also in the interaction of catechol-
amines in the CNS with their putative receptors (53, 54, 55). The findings 
of Collier and Roy were confirmed with clonal cells of central nervous 
origin, which permit more control led experiments (56, 57). A mechanism of 
opiate tolerance and dependence based on the effects on cAMP and adenylate 
cyclase was proposed (57). Morphine does not seem to interact, however, at 
the same site on the adenyl ate cyclase as PGE (58). Moreover, the role of 
PGE-stimulated adenylate cyclase in central neurotransmission is not clear, 
although PG's have been reported to modulate neurotransmitter release (59). 
Thus, the PGE-stimulated adenylate cyclase may be a molecular substrate for 
the central effects of morphine, but the implIcations for physiological 
effects of morphine have yet to be assessed, perhaps in relation to the 
opiate receptors and endorphines described below. 
OPIATE RECEPTORS 
Specific opiate receptors in nervous tissue were postulated many 
years ago, but their direct demonstration was only achieved recently, 
due to technical difficulties (60, 61, 62). Since that time, however, an 
enormous number of reports have been published on the properties of 
these receptors. The information avai ]able has been cited in some recent 
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DOPAMINERGIC NEURON SYSTEMS 
ApplIcation of fluorescence histochemical techniques as developed by 
Falck et al. (1-3) resulted in a stereotaxic mapping of monoamine pathways 
in the rat brain (review: ~). At that time three main dopaminergic 
systems were discerned: 
-the nigrostriatal DA system, with cell bodies in the substantia 
nigra (A9) and nerve terminals mainly in the caudate-putamen complex, 
but also in the central nucleus of the amygdala; 
- the mesal imbic DA system, with cell bodies in the ventral tegmental 
area (A10) adjacent to the substantia nigra, and nerve terminals in 
limbic forebrain structures like then. accumbens (septi), then. inter-
stitial is striae terminal is and the tuberculum olfactorium; 
- the tubero-infundibular DA system, with cell bodies in then. 
arcuatus (A12) of the hypothalamus and nerve terminals in the median 
~minence. 
A modification of the fluorescence histochemical technique, using 
glyoxylic acid, allowed for the discrimination of DA pathways, which were 
undetectable before (S).Recently, two other dopaminergic systems were 
described utilizing this technique: 
-the mesocortical DA system (6,7) with cell bodies in the substantia 
nigra and ventral tegmentum (A9, AlO) and nerve terminals in various 
neocortical areas, 1 ike frontal cortex, anterior cingulate cortex, 
pyriform cortex and entorhinal cortex; 
-the incerto-hypothalamic DA system (8), with cell bodies in the 
caudal thalamus, the posterior and rostral periventricular hypothalamus 
and the medial zona incerta (All, 13, 14) and with nerve terminals in 
hypothalamic, preoptic and possibly septal nuclei. 
Moreover, the mesal imbic DA system has been analyzed in more detail 
(5). A projection from the ventral tegmentum (A10) to the lateral 
septal nucleus was described (9), which also seems to contain nerve 
terminals to the incerto-hypothalamic system. In addition, the nigra-
striatal and mesal imbic projections seem to be less strictly separated 
than previously considered. This is also indicated by the fact that 
mesocortical projections originate from the cell body areas of both 
these systems. 
It is evident from these more recent observations that dopaminergic 
projections in the telencephalon are more widespread than realized 
before. Notably the cortical projections introduce new aspects in the 
role of DA in the brain, since direct influence on neocortical function 
implicate direct influence at another level of information processing. 
The histochemical definition of different DA systems has been 
paralleled by their functional definition. The nigrostriatal DA system 
belongs to the basal ganglia, a part of the extrapyramidal motor system. 
The basal ganglia are regarded as the highest sensory-motor integrating 
system at the subcortical level. Thus the nigrostriatal DA system is 
implicated in extrapyramidal dysfunctions like Parkinson 1 s disease 
in humans and catalepsy in laboratory animals 1 ike rats (review: 10). 
Classicaly, the extrapyramidal motor system was regarded as an indepen-
dent system converging on the spinal motor apparatus, while the separate 
pyramidal motor system was assumed to descend directly from the motor 
cortex to the spinal cord. It is, however, clear that this simple 
picture can not be regarded as correct any more. The anatomical con-
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Abbreviations: C., nucleus caudatus; F.R., formatlo reticularis; G.P., 
globus pallidus; G.P.E., globus pallidus, pars externa; G.P.I., globus palli-
dus, pars interna; H.L., lateral habenular nucleus; I., intralamina nuclei; 
M., motor neuron; P., putamen; R., nucleus ruber; S.N., substantia nigra; 
SUBTH., corpus subtha 1 ami cum; TECT., tectum mesencepha 1 i; THAL., tha 1 amus; 
T.P.P., nucleus tegmenti pedunculopontinus, pars compacta; V.A., nucleus 
ventralis anterior; V.L., nucleus ventralis lateral'1s. 
(From ref. 11, fig_ 6)_ 
For a detailed description of fiber connections see ref. 11. 
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nections and interrelations have recently been reviewed (11). It appears 
that the pyramidal and extrapyramidal systems are closely connected: both 
contain fibers descending from the motor cortex and other connections 
exist in thalamic and subthalamic nuclei and in the reticular formation. 
Fig. 1 (from 11) gives an impression of these connections and also of 
a number of circuits existing in these systems. 
While the extrapyramidal DA system may be involved in Parkinsonism, 
the mesal imbic DA system has been implicated in schizophrenia. The 
involvement of DA systems in schizophrenia was gathered from the ob-
servation that some drugs which changed dopaminergic neurotransmission, 
also marked effects on the symptoms of schizophrenia. Thus neuroleptic 
drugs, regarded as DA receptor blockers (12), alleviate such symptoms. 
Besides this action they often induce Parkinson-] ike symptoms. It was 
suggested that these side effects may be related to DA receptor blockade 
in the striatum (the extrapyramidal system), while the beneficial effect 
on schizophrenic symptoms was ascribed to DA receptor-blockade in the 
mesolimbic DA system (13, 14). 
At present the value of this hypothesis can not be fully appreciated. 
A number of reports indicate quantitative differences in effects of 
neuroleptic drugs on mesal imbic and nigrostriatal DA systems, which 
parallel their quantitative differences in antipsychotic and extra-
pyramidal effects (14-17). This supports the validity of functional 
distinction between mesal imbic and nigrostriatal DA systems. On the other 
hand, it has been suggested that the relation between mesal imbic DA and 
antipsychotic activity may not be as intimate as suggested above (16, 18, 
19). Evidence has been reviewed that balances between various neurotrans-
mitter systems, including DA, may be of more importance than the state of 
activity of a single system (20). Restricting the DA systems to a 
functional division into mesal imbic and nigrostriatal DA may also be too 
simple. Thus, the typical extrapyramidal symptom of catalepsy may be 
related to mesolimbic structures (21). Moreover, the various structures 
of the mesal imbic system show different reactions to various neuroleptics 
in behavioural as well as biochemical parameters (16, 22). From the 
anatomical point of view the distinction between mesal imbic and extra-
pyramidal structures is also not very strict. Powel 1 and Leman (22) 
concluded from an analysis of connections of the (mesal imbic) n. accumbens, 
that it may serve as a bridge between 1 imbic and extrapyramidal motor 
systems. Besides the described functions, DA systems have been reported 
to be directly involved in the mediation of reward (23-25) and in memory 
canso 1 i dati on (26). 
It seems, therefore, that the knowledge of DA systems has increased 
in recent years to the effect that they are far more widespread in 
anatomical and functional sense than appreciated before. At the same time 
knowledge about specific functions of DA systems in extrapyramidal motor 
regulation and psychotic behaviour may not have made as much progress as 
was anticipated, perhaps because these functions are less specifically 
mediated by these systems than presumed. 
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DOPAMINE TURNOVER AND THE DYNAMICS OF DOPAMINERGIC NEUROTRANSMISSION: 
A CRITICAL SURVEY OF METHODS 
SUMMARY 
Several in vivo methods to study dopaminergic neurotransmission are 
reviewed, with the aim of defining the processes at the molecular level 
which can be studied using each method. This may provide a basis for the 
evaluation of effects of drugs and other manipulations. Also, the 1 imi-
tations of each method and their implIcations for dopamine turnover and 
functional activity are discussed. It is concluded that drug-effects, ob-
served with any of the present methods, can not be interpreted in terms 
of changes in dopamine turnover or functional activity of dopaminergic 
neurons without additional information obtained using other methods. 
INTRODUCTION 
Many experimental approaches have been introduced to study dopa-
minergic neurotransmission. Over the course of several years more than 
20 parameters have been put forward that might provide information about 
the functional activity of dopaminergic neurotransmission under normal 
and drug altered states. Many of these parameters are claimed to be 
measures of DA turnover, on the basis that increased/decreased DA turn-
over is an indication of increased/decreased functional activity of DA 
neurons and vice versa. 
Turnover in an open system refers to the velocity at which a sub-
stance is formed and broken down while the system is in a steady state. 
Thus, DA turnover refers to the velocity at which DA is synthesized and 
degraded while its concentration does not change. !t has to be assumed 
then, that the relevant transformations take place in one compartment. 
The essential property of a neurotransmitter 1 ike DA is, however, that it 
can be released from the neuron. The assumption that only one com-
partment is involved, is therefore not valid. It might be assumed, 
however, that DA is only degraded when released and 1 ikewise only syn-
thesized to replenish the released DA. 
The relation between synthesis, release and catabolIsm would be such, 
that a change in any one process might be associated with a similar 
change in the other processes. It would be sufficient then to measure 
one of these processes to permit a conclusion about the overal 1 activity 
of the system, i.e. the functional activity (1). This approach may be 
valid in studying the turnover in the physiological situation, since it 
seems justified to assume that the physiological processes are indeed in 
balance. When studying the effect of drugs or other exogenous stimuli, 
however, the aim is mostly to detect a disturbance of the physiological 
system. It can not be assumed a priori therefore, that the balance 
between the various processes is not disturbed. Thus, observed drug-
induced changes in DA turnover often do not represent a re1 iable index 
of changes in functional activity. Apart from this, most of the methods 
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~~~~~~~t~hre brainj 
POSTSYNAPTIC 
ELEMENT 
~· Dopaminergic nerve ending with synaptic cleft and postsynaptic 
element. The cellular and molecular events assumed to be of significance 
for dopamine turnover and for the activity of DA as a transmitter are 
indicated. Tyrosine hydroxylase is shown separately, because it is assumed 
to be the rate-1 imiting enzyme of DA biosynthesis. The activity of the 
enzyme is regulated by the cofactor (C) and product (DA) (modified from 
ref. 33). Whether the presynaptic DA really exists as separate pools for 
release and reuptake is not certain (see text). The numbers associated 
with the arrows refer to the processes which are directly measured using 
the methods summarized in table 1. 
Abbreviations: TYR: tyrosine; C: cofactor(a pter1n); DA: dopamine; DOPA: 
l-dihydroxyphenylalanine; ATP: adenosinetriphosphate; cAMP: cyclic-
adenosinemonophosphate; 3MT: 3-methoxy-tyraMine; DOPAC: dihydroxyphenyl-
acetlc acid; HVA: 3-methoxy-4-hydroxyphenylacetic acid, homovanl 11 ic 
acid. 
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employed are often not a reliable index of the turnover of DA under the 
conditions to be studied. 
Nevertheless, all the methods used provide a considerable amount of 
information on the changes occuring in and around dopaminergic neurons 
when the impact of the results is restricted to the actual process which 
is studied. The purpose of the present review is to survey the molecular 
events which are actually measured using several common in vivo methods 
and to indicate the other parameters on which their reliability depends. 
This wi 11 serve then to evaluate some of the limitations of these methods 
for assessing effects of drugs or of other manipulations on dopaminergic 
neurons. 
In addition,a short account of in vitro techniques with a direct 
bearing on in vivo studies is Included. Since most studies are performed 
in rats, the data apply mostly to this species with some reference to 
mice and cats. 
SUMMARY OF METHODS 
Fig. 1 shows a dopaminergic nerve ending with synaptic cleft and 
postsynaptic element. The eel lular and molecular events assumed to be of 
significance for neurotransmission are represented schematically. The 
conversion of tyrosine, via dopamine, to its major catabolites is shown 
with special attention being paid to the enzyme tyrosine hydroxylase 
(E.C. 1.14.3. a), the rate-limiting enzyme in DA biosynthesis (2-4). The 
presynaptic DA is presented as separate pools for release and reuptake, 
because it seems that newly synthesized DA may be preferentially re-
leased (5.6). The problem of presynaptic DA compartmentation, however, is 
the subject of cons i derab 1 e debate (6-8). As a resu 1 t, very 1 itt 1 e 
significance should be attached to the break-down of DA being related to 
a single pool in the present scheme, or to other compartmental divisions. 
The eel lular location of the catabolites DOPAC, 3MT and HVA is not 
detailed for similar reasons (9,10). 
The numbers on the subsequent 1 ist of currently available methods 
refer to the primary molecular event(s) with which they are connected, 
as shown in fig. 1. An attempt is made to discern which processes are 
actually measured and which processes are often presumed to be measured. 
METHOD 
conversion of label led 
tyrosine to DA 
Tab 1 e 1. 
IN VIVO 
PROCESSES ACTUALLY 
MEASURED 
DA biosynthesis 
(TH activity) 
11 label led precursor method 11 
PROCESSES SUPPOSED 
TO BE MEASURED 
DA turnover 
19 
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SYNTHESIS 
OF 
DOPAMINE 
CATABOLISM 
OF 
DOPAMINE 
METABOLISM OF DOPAMINE 
HO~CH2 -?H-COOH 
NH2 l TYROSINE H\'DROXYLASE 
Transported from the periphery (j) 
TYROSINE 
DOPA 
DOPAMINE 
3MT 
DO PAC 
HVA 
Transported to the periphery 
® 
Fig. 2. Metabolism of Dopamine. Q)Tyrosine can be transported from the 
periphery to dopaminergic neurons, but tyrosine can also be formed from 
phenylalanine "1n the CNS. (f)HVA is transported to the periphery. DOPAC may 
be converted to HVA, but also transported to the periphery (10). Both these 
metabolites are possibly conjugated before transport (53). Abbreviations: 
DOPA: L-dihydroxyphenylalanine; 3MT: 3-methoxytyramine; OOPAC: dihydroxy-
phenylacetic acid; HVA: 3-methoxy-4-hydroxy-phenylacetic acid, homovanill ic 
acid; MAO: monoamineoxidase; COMT: catechol-0-methyltransferase. 
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METHOD 
accumulation of DOPA 
after inhibition of 
DOPA-decarboxylase 
11 DOPA-accumu 1 at ion 
me thod 11 
3,4 concentration of HVA 
and/or DOPAC 
5 accumulation of HVA 
after inhibition of 
transport 
11 Probenecid method 11 
6 
7 
8 
9 
1 D 
II 
13 
14 
accumulation of 3MT 
after MAO-inhibition 
disappearance of DOPAC 
after MAO-inhibition 
disappearance of HVA 
after inhibition of 
MAO and COMT 
disappearance of DA 
after inhibition of TH 
accumulation of DA in 
fluid superfusing 
brain tissue 
concentration of cAMP 
conversion of label led 
tyrosine to DOPA or DA 
in tissue preparations 
uptake of labelled DA 
into slices or synapto-
somes 
Tab 1 e 1 (cant i nued) 
PROCESSES ACTUALLY 
MEASURED 
Tyrosine hydroxylation 
net result of formation, 
break-down, conjugation 
and transport of HVA 
and/or DO PAC 
formation (and conju-
gat ion?) of HVA 
formation of 3MT 
net result of conver-
sion to HVA, conjuga-
tion and transport 
conjugation and 
transport of HVA 
catabolism of DA 
net result of release 
and catabolism of DA 
net result of formation 
and break-down of cAMP 
IN VITRO 
TH activity and kinetic 
parameters 
PROCESSES SUPPOSED 
TO BE MEASURED 
DA biosynthesis 
DA turnover 
DA catabolism 
DA metabolism 
DA turnover 
DA catabolism 
DA metabolism 
DA turnover 
DA release 
DA catabolism 
DA metabolism 
DA turnover 
DA catabolism 
DA metabolism 
DA turnover 
DA turnover, 
impulse-flow-induced 
DA release 
neuronal release of 
DA 
DA-receptor 
stimulation 
net result of uptake and reuptake of released 
efflux of DA DA 
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METHOD 
conversion of ATP to 
cAMP, stimulation by DA 
11 specific11 binding of 
labelled DA to membrane 
preparations 
Table 1 (continued) 
PROCESSES ACTUALLY 
MEASURED 
DA-sensitive adenylate 
cyclase 
affinity for putative 
DA-receptor 
17 accumulation of labelled release of DA 
DA from tissue prepara~ 
tions into bathing fluid 
PROCESSES SUPPOSED 
TO BE MEASURED 
DA-receptor stimu-
lation 
IN VIVO CONVERSION OF LABELLED TYROSINE TO DA (LABELLED PRECURSOR METHOD) 
(14c)- or (3H)- Tyrosine is administered intravenous and the accumu-
lation of labelled DA measured (11, 12, 13). This parameter, therefore, 
is an indication of the rate of OA biosynthesis. Since the method is 
based on steady state kinetics (12), several conditions have to be met in 
the first instance to obtain meaningful results: 
-the steady state levels of tyrosine in plasma and brain tissue must 
not be disturbed; 
-the steady state level of DA has to be maintained; 
-the specific activity of tyrosine has to be measured,as the incorpo-
ration of the label into DAis related to the amount of labelled precursor 
available. 
These conditions can be met and the method seems to provide then a 
stable measure of relative DA biosynthesis in vivo in untreated experimen-
tal animals (12, 13). No absolute value, however, is obtainable,since 
some of the label led DA is degraded even after a short pulse label of 
10-15 min (14). Moreover, it is assumed that the specific activity of 
tyrosine represents the precursor pool of DA. Since tyrosine is only 
metabolized to DA to a minor extent, this assumption is not necessarily 
valid. The observation that the specific activity of tyrosine and 
catecholamine formation from label led tyrosine depends on the time of 
day at which the experiment is performed, emphasizes the importance of 
this factor (15). 
The method, therefore, provides a measure of DA bios nthesis in vivo, 
and Its reliability depends on whether i the transport of tyrosine into 
the relevant metabolic compartment, i i) the degradation of DA and iii) the 
steady state of tyrosine and DA levels are not changed. 
The method is used then to assess drug effects. Neuroleptics, for 
example, increase the conversion of labelled tyrosine to DA (11, 16, 17). 
Since tyrosine and DA steady state levels are not disturbed (11), the 
conclusion that DA turnover is increased seems to be correct. This does 
not mean, however, that the functional activity of dopaminergic systems 
is increased. Most probably the increase in DA biosynthesis is a con-
sequence of DA receptor blockade (18, 19). Thus the inference that 
the observed synthesis increase indicates increased DA turnover may be 
correct, whereas the conclusion that functional activity is increased is 
incorrect. 
Lesions of the dopaminergic eel 1 bodies in the substantia nigra also 
cause a tremendous increase in the accumulation of label led DA (20-23). 
In this case, however, the observed synthesis increase can not be ex-
plained as an increased DA turnover, since DA concentrations also in-
crease rapidly (21, 22, 24) and the degradation of DA seems to be inter-
rupted for a short time (25, 26). Thus, neither increased DA turnover 
nor increased functional activity can be concluded from the observed 
increase in the incorporation of label led tyrosine into DA. 
Several modHications of the described method are known. The labelled 
tyrosine may be infused instead of administered as a pulse (11, 27). 
Since the aim of steady states in the label led tyrosine and catecholamine 
pools is not even achieved within 60 min (11), this method does not seem 
to be superior. Moreover, the procedure is more complicated. The absence 
of steady states after 60 min shows, that mixing of the tyrosine pools 
in blood, ext race] lular fluids and neurons is slow. It may be expected 
therefore, that the specific activity of tyrosine in brain tissue, 
obtained in pulse label experiments, does not represent the precursor 
of DA (vide supra). 
3,5(3H)-tyrosine may also be introduced locally into the CNS to 
form (3H)-H20 upon hydroxylation (28). It is difficult to be sure then 
that steady state concentrations of tyrosine are maintained and that the 
labelled precursor is reproducibly distributed. The method does not provide 
an absol~te measure of TH in vivo because of diffusion of (3H)-Hz0 
(7, 28). It also provides data forTH activity in both dopaminergic 
and noradrenergic neurons, though this might not be a serious drawback 
when used in the striatum, since in this structure relatively little 
noradrenaline is present. An advantage of this method is the large 
amount of radioactivity that can reach the CNS. 
More modifications are available, but the characteristics do not 
differ widely from the ones described. 
In conclusion the label led precursor method provides under conditions 
that can be reasonably wel 1 control led, a relative measure of in vivo DA 
biosynthesis. When the effects of drugs or other manipulations are studied, 
the results obtained may be biased by changes in tyrosine transport and de-
gradation of DA. The implIcations for DA turnover and functional activity 
can only be evaluated in conjunction with other methods. 
IN VIVO ACCUMULATION OF DOPA AFTER DOPA-DECARBOXYLASE INHIBITION (BY 
NSD 1015 OR RO 4 4602) 
Another method to measure TH activity in vivo was introduced by 
Carlsson et al. (29). The accumulation of DOPA after inhibition of its 
conversion to DA is measured and assumed to reflect the conversion of 
tyrosine to DOPA. Several conditions have to be met in the first in-
stance to obtain meaningful results: 
-inhibition of DOPA-decarboxylase has to be rapid and complete; 
-disruption of the steady state levels of DOPA, DA and its meta-
bel ites must not affect TH activity; 
-steady state levels of tyrosine must not be disturbed. 
The first point is not entirely clear. The enzyme inhibition, in 
fact, seems to be rapid, since DOPA accumulates immediately (23). Whether 
the inhibition is complete or not, can not easily be evaluated from the 
data ava'1lable. The levels of DAdo not decline for up to 30 min after 
23 
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NSD-1015 administration, although this would be expected when the syn-
thesis of DA is inhibited. The lack of DA loss may be due then to an 
additional inhibitory effect of NSD-1015 on DA breakdown by MAO (29), 
which might subsequently result in decreased TH activity (14, 29, 30). On 
the other hand, an incomplete inhibition of DOPA-decarboxylase could 
account for the lack of DA loss. 
Linear accumulation of DOPA for 30 min is taken as an indication that 
DOPA itself does not affect TH activity. In view of the variability of 
DOPA levels obtained, very severe deviations from 1 inearity would be 
necessary to be detectable in an experiment. Moreover, other data suggest 
that DOPA-decarboxylase-inhibition does indeed affect tyrosine hydroxy-
lation in vivo (28, 31). Whether or not the observed increase in endo-
genous tyrosine is of significance for the present method is not clarified 
(23). 
Thus, a number of theoretical objections to the present method have 
not yet been disposed of. No absolute indication of DA biosynthesis can 
be obtained, therefore. This is also i Jlustrated by the lower rate of DA 
synthesis which is obtained, when compared with other methods (29, 31). 
Moreover, some practical points merit attention. In order to measure TH 
activity in DA neurons, the method is only applicable to structures which 
are relatively abundant in these neurons, in comparison to noradrenergic 
neurons, since the contribution of noradrenergic neurons can ther, be 
neglected. Furthermore, the brain tissue of several rats has to be 
combined because of the low levels of DOPA (32). 
Thus, the method may provide a measure of TH activity in vivo and its 
rel iabi 1 ity depends mainly on possible interfering changes in tyrosine 
hydroxylation induced by DOPA itself, DA or altered precursor availability. 
The method has been used to assess the effect of transsection of ascen-
ding DA fibers on TH activity (23) and leads to qualitatively similar re-
sults as the labelled precursor method (vide supra). It has also been used 
to evaluate the effect of y-butyrolacton (GBL) or y-hydroxybutyrate (GHB), 
drugs 1o1hich seem to have a similar effect on DA biosynthesis as cerebral 
hemisection (21, 24, 33). 
In evaluating such unequivocal effects on DA biosynthesis the label led 
precursor method and DOPA accumulation method provide similar results. 
Javoy et al. (34), however, obtained different results with these two 
methods when evaluating atropine-induced effects on DA biosynthesis. 
Atropine blocks acetylcholine receptors and since an intimate interaction 
between cholinergic and dopaminergic systems exists in the striatum, 
atropine also changes dopaminergic neurotransmission. Thus 5 mg/kg atropine 
increased the accumulation of labelled DA,but was without effect on DOPA-
accumulation. Whatever the interpretation of the mechanism of action 
of atropine may be, some observations merit attention. Utilizing the 
label led precursor method, atropine was also observed to reduce endo-
genous tyrosine and label led tyrosine levels. Although the specific 
activity of tyrosine was unchanged, these observations raise the suspicion 
that the real tyrosine precursor pool could be changed by atropine 
treatment (vide supra). The endogenous tyrosine concentration, on the 
other hand, was not changed by atropine, when the DOPA-accumulation 
method was uti 1 ized. But this implies a relative reduction in endogenous 
tyrosine levels, since tyrosine concentrations are normally increased 
after inhibition of DOPA-decarboxylase (29, 34). With the latter method 
no DA concentrations were reported (34). Thus, atropine treatment may 
bias measurement of DA biosynthesis with either one or both methods 
uti 1 i zed, because of changes in precursor ava i 1 ab i 1 i ty. S i nee both methods 
are used to measure DA biosynthesis and application of the results of 
either method to the interpretation of DA turnover has to be carried out 
with caution, it might be dangerous to draw conclusions from differences 
in results obtained with both methods (34). 
In conclusion, the DOPA-accumulation method provides a measure of 
in vivo DA biosynthesis. In the evaluation of drug effects it should be 
observed that inhibition of DOPA-decarboxylase by NSD-1015 already results 
in changes of TH activity and that this may interfere with the drug 
effect. Results can not be generalized to DA turnover or to the functional 
activity of the dopaminergic neurons. 
IN VIVO CONCENTRATION, ACCUMULATION OR DISAPPEARANCE OF DA CATABOLITES 
HVA, DOPAC AND 3MT 
A number of different methods have been developed concentrating on 
the measurement of one or more DA catabol ites. The frequent use of such 
methods was triggered by the observations of increased levels of al 1 DA 
catabol ites induced by chlorpromazine (18, 35). Only recently, however, 
kinetic analyses of changes in catabolite levels have been reported 
to provide a theoretical foundation for the use of these methods (10, 36, 
37). The methods employed can be divided into those analysing concen-
trations without interference with synthesis, breakdown or transport of 
the substance studied and those assessing accumulation or disappearance 
of the substance after interruption of synthesis, breakdown, transport or 
a combination of these. The former approach is most often applied in 
drug studies (vide infra). Since measurement of basic catabolite levels, 
without other parameters, however, does not provide information about 
their turnover, the latter approach was uti] ized to perform kinetic 
analyses. 
IN VIVO CONCENTRATION OF HVA AND DOPAC 
HVA and DOPAC are present in normal brain (38, 39) while 3MT is 
almost undetectable (40). Positive values for 3MT in normal brain may 
be due to postmortem accumulat'1on (41). Increased HVA and DOPAC levels, 
such as those obtained after chlorpromazine treatment, are observed with 
most neuroleptics 1 ike haloperidol, thioridazine, clozapine, loxapine, 
pimozine and many others (e.g. 42-51). 
This provides a pragmatic basis for the evaluation of drug effects 
similar to neuroleptics. It is, however, not clear why increased cata-
bolism should result in increased concentrations of catabolites. A 
tempting suggestion is that the active transport out of the brain of 
acid catabolites is easily saturable (52). The transport of HVA would 
then be unable to keep up with its enhanced formation induced by neuro-
leptics. HVA, however, also seems to be conjugated in brain tissue to a 
significant extent (53). The same considerations apply to DOPAC, since 
it may also be transported out of the brain (10) and conjugated (53). 
Moreover, DOPAC is converted to HVA. Thus, increased concentrations of 
HVA and DOPAC seem to provide a measure of increased catabolism '1n vivo, 
and its reliability for measuring drug effects seems to depend on whether 
i) the transport out of the brain, i i) conjugation and iii) degradation 
(i.e. of DOPAC to HVA) are not changed. 
Most often increased catabolism of DA is taken as an indication of 
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increased metabolism of DA, thus suggesting that the synthesis is also 
increased. In the case of neuroleptics, which probably only Interfere with 
presynaptic mechanisms indirectly, i.e. via physiological feedback 
mechanisms (54, 55), this may hold true. Although assessing changes in HVA 
(and DOPAC) levels may provide, therefore, important information about 
the effects of various neuroleptics. It may be hazardous, however, to 
relate the potency of different neuroleptics to increase HVA and DOPAC 
concentrations to their behavioural potency (e.g. 48) and also to relate 
the potency to increase HVA and DOPAC concentrations in different brain 
structures to their potency to block DA receptors in these structures 
(42, 51). These relations may not be correct, because the often subtle 
differences between various neuroleptics in increasing HVA and DOPAC 
concentrations may very well be related to effects on e.g. transport or 
conjugation of the catabol ites. These mechanisms may differ in various 
brain structures (10, 49). 
Roth and coworkers, on the other hand, correlated changes in the 
levels of DOPAC with changes in the impulse flow of dopaminergic neurons 
(25, 32, 56). This correlation seems to apply in many cases. Nevertheless, 
changes in one of these parameters may not always be associated with 
changes in the other parameter. Apomorphine, for example, reduces DOPAC 
levels· in the striatum even after interruption of the impulse flow by 
cerebral hemisection (26). Under these conditions DA biosynthesis is 
decreased by apomorphine (22), which may account for the decrease in 
DOPAC levels. The decrease in DOPAC levels, however, is not associated 
with decreased impulse flow. 
In conclusion, measurement of drug-induced changes in catabolite 
concentrations provides a rough measure of DA catabolism. An advantage 
of the method is that no other intervention than drug administration is 
necessary. Special attention should be paid to possible interferences 
of drugs with the transport of the catabolites from the brain and with 
the conjugation of the catabol ites (see also paragraph on disappearance 
of catabol ites). However, information concerning these mechanisms is 
very scarce. To evaluate effects on DA turnover or functional activity 
of dopaminergic neurons,additional information is necessary. 
IN VIVO ACCUMULATION OF HVA AFTER INHIBITION OF ITS TRANSPORT BY 
PROBENECID (PROBENECID METHOD) 
The active transport of acids from the brain is inhibited by pro-
benecid (57), which results in accumulation of HVA (9, 58) but not of 
DOPAC (9). The accumulation of HVA may be a better measure of HVA for-
mation than the assay of mere HVA concentrations. Several conditions 
have to be met to obtain meaningful results: 
-inhibition of transport has to be complete; 
-formation of HVA must not be influenced by the increase of its 
levels. 
Whether these conditions are met is not entirely clear. Westerink 
and Kerf (10) observed an accumulation of HVA of only 2 nmol/g/h in rat 
striatum with the probenecid method, while other methods result in 
values of about 20 nmol/g/h. This may indicate that,at least in the rat, 
one or both of the conditions are not met. The probenecid method thus 
provides a measure of HVA formation. It is mostly used in studies of 
DA catabolism in human CSF. For animal studies it may be of less value, 
because DOPAC cannot be studied in the same way, although it has been 
suggested that the transport of conjugated DOPAC is also very sensitive 
to probenecid (53). Moreover, the transport inhibition of HVA may dHfer 
in various brain regions (49, 59). 
IN VIVO ACCUMULATION OF 3MT AFTER MAO INHIBITION (WITH PARGYLINE) 
Recently Kehr (60) introduced a method, based on the assay of 3MT, 
which is uti! ized after inhibition of MAO to block al 1 other catabolic 
pathways of DA. 3MT is almost absent in normal brain tissue, but rapidly 
accumulates after pargyline administration (40, 60). The method provides 
a measure of DA catabolism, i.e. methylation. Since it is obvious that not 
all DA is catabolized to 3MT but also to DOPAC under normal conditions, 
the method does not provide a measure of normal DA catabolism. In fact, 
it was not introduced as such, but it was suggested that the accumulation 
of 3MT is an indication of impulse-flow-induced DA release in rat brain 
in vivo (60), linking up with the suggestions of Roffler-Tarlov et al. 
(9) on compartmentation of DA catabolism. Several experimental data (60), 
however, seem to be incompatible with this concept: 
-3MT accumulation was increased after cerebral hemisection which 
interrupts DA release; 
-DA synthesis inhibition prevented almost entirely 3MT-accumulation 
during inhibition of DA release by cerebral hemisection; 
-haloperidol-induced increase in 3MT was largely reduced by DA 
synthesis inhibition, while DA levels decreased in the same experiment 
indicating DA release. 
These data seem to indicate that 3MT accumulation may be taken as 
much as an indication of DA biosynthesis as of DA release. Moreover, 
pargyline may not entirely inhibit MAO (30, 40), but does reduce DA bio-
synthesis within 10 min (23, 30). 
In conclusion, unless the latter objections are dealt with, the method 
does not provide an absolute measure of one of the metabolic pathways 
of DA. Generalised conclusions on DA turnover or functional activity 
based on this method thus seem premature. 
IN VIVO DISAPPEARANCE OF DOPAC AND/OR HVA AFTER INHIBITION OF MAO 
AND/OR COMT 
In this experimental approach the formation of catabol ites is pre-
vented by inhibition of the enzymes involved in their formation and the 
disappearance of the catabolite is measured. The method provides, there-
fore, a measure of degradation and/or transport of the studied catabolite. 
Conditions for obtaining meaningful results are: 
-the enzyme has to be entirely inhibited; 
-disturbance of the steady state levels must not influence the first 
order kinetics of disappearance of catabol ites. 
As mentioned before, pargyline, the colllTlonest MAO-inhibitor, may not 
eni:irely block MAO (30, 40). Furthermore, the disturbance of steady state 
levels of catabol ites may not change the kinetics of their disappearance 
(10, 37). The influence of pargyline on DA biosynthesis (23, 30) is of 
less importance in this method, because changes in DA biosynthesis do not 
influence the catabolite pools after inhibition of catabolite formation 
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by MAO. 
Furthermore, the decline of HVA after MAO inhibition wil 1 be delayed 
by de novo formation of HVA from DOPAC, but one can correct for this, 
either by also inhibiting COMT (10) or by analysing HVA disappearance 
when formation from DOPAC has declined to negligible amounts.(lO, 37). 
Consequently, the only draw-back seems to be the general toxicity of the 
inhibitors used. Thus, the method provides a measure of disappearance of 
catabol i tes in vivo, and its re 1 i ab i 1 i ty seems to depend on whether the 
synthesis inhibition is complete or not. 
The rate of disappearance of DOPAC is calculated to be about 20-24 
nmol/g/h for rat striatum (10, 37 and calculated from data of 25), probably 
reflecting the total rate of disappearance of DA catabolites (10). As-
suming steady state kinetics, under control conditions this may reflect 
total DA turnover and is close to values obtained with the labelled 
precursor method (13, 61) and J:MpT method (13) (vide infra). Nevertheless, 
this observation is rather surprising, since, by this method it is 
actually the rate of disappearance of catabol ites which is measured, 
while when using the label led precursor method, the rate of the DA 
synthesis is measured and when using the aMpT method the rate of dis-
appearance of DA is measured. 
The latter two methods may yield similar values, since the concen-
tration of DA is maintained within narrow 1 imits by feedback mechanisms 
on DA biosynthesis, thus equilibrating loss of DA and its biosynthesis. 
When the disappearance of catabol ites is measured, however, MAO (or 1'1AO 
and COMT) are inhibited. This implies that changes in DA biosynthesis, 
the presumed rate-1 imiting step in DA turnover, have no influence on the 
disappearance of catabol ites. Therefore, another rate-1 imiting step, 
entirely independent of the regulation of synthesis and release of DA, 
is involved in the disappearance of catabol ites. This may also be deduced 
from the observation that DOPAC and HVA concentr·ations are considerably 
higher than zero, since these would have been almost zero if DA release 
would have been the only rate-1 imiting step in the chain of events 
leading up to removal of catabol ites from the brain. Since DOPAC and HVA, 
but not 3MT concentrations are considerable, it may be speculated that 
transport or conjugation of acid metabolites is the rate-1 imiting step 
involved. !n any case, this rate-limiting process will include a step 
involving low substrate affinity resulting in accumulation of catabol ites 
up to levels at which a balance exists between the turnover of DA and of 
catabol ites, and thus producing similar turnover rates, as discussed 
above. 
Some important conclusions can be drawn from this concept. Evaluation 
of effects of drugs on the disappearance of DOPAC and HVA after MAO (or 
MAO and COMT) inhibition has, for this reason, no bearing on the effect 
of the drug on DA turnover. On the other hand, it would be of value as 
additional information for studies of drug effects on HVA and/or DOPAC 
levels, since changes may be induced by interference with (the rate-1 imiting 
step,of) catabolite removal instead of, or in addition to, interference 
with DA turnover. Furthermore, it may be speculated that the profound 
differences in steady state levels of catabolites relative to DA and to 
each other in different species (62) point to differences in catabolic 
pathways, possibly caused by differences in the rate-1 imiting step of 
catabolite disappearance. 
!n conclusion, measurement of the disappearance of DA catabol ites 
in vivo, when their formation is inhibited, provides information on the 
kinetics and pathways of DA catabolIsm. Assessment of drug effects on 
these parameters, however, can not provide any information about DA 
turnover or functional activity. 
IN VIVO DISAPPEARANCE OF DA AFTER INHIBITION OF ITS SYNTHESIS BY aMpT 
(SYNTHESIS INHIBITION METHOD) 
The decline in OA levels can be measured after administration of a 
potent blocker, QMpT of TH, the rate-) imiting enzyme of DA biosynthesis. 
In a strict sense, this decline is a measure of DA catabolism, since OA 
disappears as a result of catabolism. The method was introduced to 
obtain a generalized measurement of both DA synthesis rate and DA turn-
over, assuming steady state kinetics (l), i.e. assuming a balance between 
synthesis, release and catabolism (see Introduction). Although results have 
been obtained which were in reasonable agreement with other methods 
( labe 11 ed precursor method, disappearance of catabol i tes, vi de supra), 
several conditions have to be met to validate the method: 
-the enzyme inhibition must be instantaneous and complete in vivo; 
-aMpT must not interfere with DA dec) ine; 
-the disturbance of DA steady state levels must not influence the 
kinetics of its decline. 
It has been shown that in vivo the enzyme inhibition is complete 
(63), but not instantaneous, since 15 min after aMpT administration the 
inhibition is only about 60% (13, 63, 64). Moreover, ciMpT, or its 
metabolites, seem to interfere with DA decline during the first 20-40 
min after its administration (13). The impact of these observations is 
not entirely clear, since they provoked discussion on the fundamental 
problem of compartmentalization of DA (5, 6, 8, 13), which is beyond the 
scope of this review. However, it is clear that a b'1phasic decl'1ne in 
DA levels is obtained, during which the first rapid phase is important 
only up to 20 min after aMpT treatment (5, 13). 
The synthesis inhibition method as introduced by Brodie 
et al. (1), was then applied to drug stud'1es. The underlying concept was 
to administer the drug to be studied, which wou.ld then induce a new 
steady state of DA synthesis, release and catabolism, and then to administer 
~MpT. Assuming steady state kinetics, one could apply the drug effect on 
OA decl'1ne to DA biosynthesis and turnover (e.g. 42, 65-68). However, the 
disappearance of DA is measured while its synthesis is impaired. The value 
of this indirect assessment of drug effects on DA biosynthesis and turn-
over is thus seriously questioned by the observations described above. 
Moreover, it does not seem warranted to assume that the drug induces a 
new steady state. It does not seem justified, therefore, to apply the 
results to a discussion of DA biosynthesis and turnover. 
A modified synthesis inhibition method was introduced to avoid 
these pitfalls. Thus the drug to be studied was administered at least 
30 min after aMpT, when complete inhibition of DA synthesis was achieved 
(66, 69, 70, 71). This precludes any interpretation in terms of DA bio-
synthesis and DA turnover, since the drug can not change OA biosynthesis. 
Andfn et al. (72) emphasized the importance of impulse flow for the 
disappearance of DA as a result of aMpT administration. Studying drug 
effects, however, it may be more accurate to state that the method 
provides a measure of DA disappearance, consisting of release and cata-
bo 1 ism and pass i b 1 y reuptake, and that its re 1 i ab i 1 i ty depends on whether 
i) disturbance of DA steady state levels has an influence on the kinetics 
of its own dec] ine and whether i i) newly synthesized OA is of particular 
importance. The first point is a serious draw-back of the method. DA 
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levels decline exponentially, because the available DA diminishes, and thus 
less DA wil 1 be released into the synaptic cleft. Since rapid feedback 
mechanisms are also in operation, which are regulated by the amount of 
DA reaching synaptic receptors (66, 73), it may. very well be possible 
that the normal release of DA is changed after aMpT treatment. As to the 
second point, a possible separate pool of newly synthesized DA with high 
turnover wi 11 be entirely depleted 30 min after treatment with ~MpT (5, 6, 
7, 70), since its turnover time is less than 10 min (5). The drug effects 
studied are, therefore, concerned with the storage pool (70, 74), or, 
alternatively, when not taking recourse to a particular theory, they are 
concerned with effects on DA release (and catabolism) which are entirely 
unrelated to DA biosynthesis. 
!t has been observed that morphine does not affect the decline in 
DA levels in the rat striatum, when applying the modified synthesis 
inhibition method (63, 69), whereas it increases DA decline when utilizing 
the conventional method (67, 69, 75). This illustrates the fact that 
different results may be obtained with the two methods. The difference 
in this instance may be due to the fact that morphine markedly increases 
DA biosynthesis (76-78), which effect is eliminated utilizing the modified 
synthesis inhibition method but not utilizing the conventional method. 
In conclusion, the conventional synthesis inhibition method seems to 
be of value only in control conditions. The modified method does provide 
a measure of DA catabolism which is probably related to release of DA. 
This distinction, however, has to be evaluated with the aid of other 
methods. Effects of drugs on these parameters can be studied when special 
attention is paid to the interference with receptor-mediated feedback 
because of declining DA levels. The effects obtained are not related to 
newly synthesized DA and those effects which depend on the presence of 
newly synthesized DA wi 11 be missed, therefore. The implications for DA 
turnover and functional activity have to be evaluated in conjunction 
with other data. 
IN VIVO RELEASE OF DA 
Many attempts have been made to measure DA release directly, since 
this is a crucial event in neurotransmission. It has often been claimed 
that methods such as those described above, provide an indirect index of 
DA release. The only way to avoid the pitfalls involved in interpreting 
the results obtained by these methods, is to measure DA release directly. 
For that purpose extracellular DA has to be trapped in one way or another 
when it is released from the neuron. In vivo methods aiming at this goal 
involve superfusion of brain tissue and analysis of DA in the perfusion 
fluid. Since al 1 variations of these methods are technically difficult 
and time consuming, they are not in general use. Moreover, the specificity 
of results obtained is sometimes difficult to assess, since many artefacts 
are possible (79). Nevertheless, it seems to be the only approach available 
to obtain dir-ect information about DA release in vivo. 
Superfusion of DA rich brain tissue can be achieved by perfusion of 
the lateral ventricles bordering parts of the caudate nucleus (80-82), 
by superfusion of the caudate nucleus using a cup technique after removal 
of cortical tissue (83-85) or by the use of a push-pull canula placed 
into the brain tissue (86-88). A 11 these techniques involve ahaesthes i a 
and fairly extensive surgery in the cats, which are utilized because 
of their size. With the first method the DA has to be released into the 
ventricle and it is uncertain whether this reflects neuronal release. 
The DA in the perfusion fluid is most commonly measured by radio-
isotopic techniques. Introduction of the label by application of radio-
active DA itself may not label the appropriate transmitter pool. Therefore, 
it is preferable to introduce the label by addition of radioactive 
tyrosine to the perfusion fluid. Systemic application does not yield 
measurable amounts of DA. Local introduction of label as well as drugs 
will result in a gradient declining from the place of perfusion. It is 
not known whether this uneven distribution affects the results obtained. 
Similarly it is not known whether the results obtained locally can be 
appl led to the whole structure studied. It has been observed with super-
fusion of striatal tissue that transsection of the nigrostriatal bundle 
not only inhibited DA release, but also DA biosynthesis (83). This latter 
observation is in conflict with many other reports (20-23), and may 
indicate that the results of the superfusion study can not be applied 
to the whole striatum. 
The recently developed highly sensitive radioenzymatic assay of DA 
(89) made possible the measurement of authentic DA in the perfusion 
fluid (88). This may be a major advantage, since the pitfalls of radio-
active label! ing techniques are avoided. 
Changes in released DA induced by various stimuli, are only detec-
table when they occur relatively slow. This may hamper the interpretation 
of results, especially when shortlasting or biphasic responses are induced. 
In conclusion, superfusion of brain tissue seems to be the only 
technique avai !able to measure DA release in vivo. Results obtained, however, 
are hazardous to interpret. Special attention has to be paid to the spe-
cificity of the release measured and the time course of responses (79). 
IN VIVO cAMP CONCENTRATIONS 
Evidence has been presented by in vitro experiments that the striatum 
may contain aDA-sensitive adenylate cyclase which may function as aDA 
receptor (90, 91). Adopting this concept Costa et al. showed that some 
DA agonists increased considerably the in vivo levels of cAMP in DA rich 
brain tissue (8, 54, 92, 61). The response was blocked by haloperidol, 
a receptor blocker (61, 92). Therefore, the method may be an important 
tool for the evaluation of DA receptor activity in vivo. On the other 
hand, the method has not yet been characterized extensively with respect 
to 
-specificity for DA-receptor interaction; 
-localization (pre- or postsynaptic or neither); 
-time course of changes in cAMP levels. 
The fact that in vitro DA-sensitive adenylate cyclase seems to be 
reasonably specific for DA does not imply that the in vivo observed 
changes of cAMP levels induced by DA agonists and antagonists are DA-
specific phenomena. The relative sensitivity to other drugs has to be 
assessed (93). In striatal slices the increase in cAMP elicited by DA, 
is distinguishable from the increase induced by NA. This latter increase, 
however, is predominant (94) and the existence of aDA-specific adenylate 
cyclase in the striatum has even been doubted (95). 
The implications of results for the functional activity of dopa-
minergic neurons depend on the localization of the presumed receptor. The 
DA-sensitive adenylate cyclase (96) which is assayed in vitro seems to be 
localized postsynaptically. However, this can not be taken as evidence 
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that the in vivo changes of cAMP levels are related to postsynaptic DA 
receptors. Because cAMP turnover in vivo is very rapid, an effect on 
cAMP levels can easily be missed (93). 
In conclusion, changes in cAMP levels may present a measure of in vivo 
DA receptor stimulation, but the specificity and reliability of this method 
has to be investigated more extensively. 
IN VITRO METHODS 
The aim of the present review is to survey methods which provide direct 
·Information about in vivo processes. Information about specific processes 
like (re)uptake, receptor affinity, enzyme kinetics etc., however, can only 
be obtained in vitro. These data are indispensable for the evaluation 
of in vivo processes and effects of drugs. The in vitro methods are 
discussed here only in relation to the direct information they offer 
for in vivo studies. 
IN VITRO TYROSINE HYDROXYLASE (TH) ACTIVITY 
The in vitro method which has probably the most direct bearing on 
the turnover of DA in vivo, is the assay and kinetic analysis of TH 
activity. To a (striatal) tissue prepara~ion (slices, synaptosomes, 
membrane-free supernatant) radioactively labelled tyrosine is added and 
and the conversion to DA during in vitro incubation is measured. When 
the label is recovered in (3H)-H20, which is formed during the conversion 
of tyrosine to L-DOPA, the activity of TH is directly measured (7, 97). 
Often, however, (14c)-C02 is measured, which is formed during the sub-
sequent conversion of DOPA to LJA (98, 99). Utilizing these techniques, 
quite a lot of information about the regulation of DA biosynthesis has 
been obtained (31, 100-103 and references therein). Among other things 
it appeared that the activity of TH is under the regulatory influence 
of both the cofactor, an unconjugated pterin,and the product DA and other 
catechol s. 
Many studies were performed with the soluble enzyme, which is only 
one of several species normally present and which possess widely dif-
ferent kinetic characteristics (102). Moreover, the artificial cofactor 
DMPH4 is most often used instead of the putative natural cofactor, which 
displays different kinetic characteristics (100). A number of other 
factors, 1 ike ionic compos1 t1on of the assay medium, are kept constant, 
while they may vary in vivo and affect TH and possibly change drug effects 
(1 04, 1 05). 
It has been observed, for example, that TH activity of the soluble 
enzyme preparation is increased by an acute lesion of the nigrostriatal 
pathway (104), or by cerebral hemisection (106), while the opposite effect 
was observed in a synaptosomal preparation (105). Simi Jar lesions result 
in increased DA biosynthesis in vivo (20-23). Injection of amphetamine, 
on the other hand produced an increase in biosynthesis of DA in vivo 
about 30 min after injection (33, 54, 107, 108), but failed to change TH 
activity in the soluble enzyme preparation (54) and even decreased TH 
activity in synaptosomes (102, 109, 110). When added in vitro, however, 
TH activity in the synaptosomal preparation is increased by amphetamine 
(109, 110). Similarly, morphine did not affect TH activity in the soluble 
enzyme preparation (54, 111), while DA synthesis is stimulated in vivo 
(54, 76, 78). Whatever these manipulations may affect in vivo, these 
examples shaw that in vitro TH activity does not always reflect changes 
of DA biosynthesis in vivo. In some of these cases a factor may be involved 
in vivo, which is lost in the in vitro assay. Some factors of significance 
for DA biosynthesis in vivo and which are lost in vitro, may be: 
-accumulation or disappearance of DA which acts as (feedback) inhibitor 
of TH; 
-changes in cofactor levels; 
-changes in different forms of TH, such as shifts in the equilibrium 
of soluble and membrane bound TH; 
-changes in ionic environment (e.g. calcium); 
-changes in precursor availability; 
-changes in 02-pressure. 
In conclusion, in vitro assay of TH activity and analysis of its kinetic 
characteristics may provide information about the molecular mechanisms of 
changes in DA biosynthesis in vivo. Since changes in vivo, however, may 
be lost or altered in vitro, application of the results obtained in vitro 
to the interpretation of effects in vivo is not always justified. 
IN VITRO UPTAKE OF DA 
It is assumed that much of the DA which is released, is inactivated 
by reuptake into the neuron. Drugs may affect DA turnover and functional 
activity by interaction with this mechanism. The uptake of radioactive DA 
into synaptosomes or slices of striatal tissue, may provide information 
about effects of drugs on this parameter. It is, however, well-known, 
that DA can also be taken up extraneuronally in the CNS, although the 
function of such a mechanism is not entirely clear (112). Moreover, most 
drugs exhibit effects on DA uptake at one concentration or another and 
the relative potency in vivo may not always be assessed easily (e.g. 113). 
Furthermore, uptake of DAis not easily distinguished from DA release by 
such methods (114). 
IN VITRO DA-SENSITIVE ADENYLATE CYCLASE 
DA-sensitive adenylate cyclase activity can be assayed in vitro and 
may reflect DA receptor activity (90, 91). Possibly the enzyme is located 
postsynaptically (96) and may, therefore, provide information about the 
activity of drugs on postsyn~ptic DA receptors. 
IN VITRO DA RECEPTOR BINDING 
Radioactively label led DA or haloperidol can be bound to membrane 
material of synaptosomal tissue preparations (115). This may reflect 
binding to the (postsynaptic?) DA receptor, when a number of controls, 
such as exclusion of aspecific binding, have been obtained (116). The 
receptor binding reflects the affinity for the binding site of the re-
ceptor. Some reports suggest that the DA receptor may exist in two con-
formations, one binding DA agonists, and the other binding DA antagonists 
(115, 116). Although a correlation of binding characteristics of neuro-
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leptics in vitro with their antipsychotic actiVIty in vivo has been 
suggested {TT7J: the implications of the method for in vivo activity 
has yet to be assessed. The method wi 11 not provide information about 
intrinsic activity, but only about receptor affinity. 
IN VITRO DA RELEASE 
Radioactively label led DA can be released in vitro from tissue prepara-
tions by drugs or field stimulation (79, 118). A number of conditions 
for such release seem to be simi Jar to those for physiological release 
(79). Recently a method was presented with which the release of newly 
synthesized DA and the synthesis rate of DA can be measured at the same 
time in striatal slices (7, 21). (3,5-3H)-Tyrosine was superfused over the 
slices and (3H)-Hz0 and (3H)-DA measured in the superfusate. (3H)-Hz0 is 
formed from the (3-3H) during conversion of tyrosine to DOPA, while the 
(S-3H) is left behind in the DA molecule. Therefore, analysis of 
(3H)-H 20 in the incubation medium provides a measure of DA synthesis and (3H)-DA of DA release. DA release is almost nil in this situation, but can 
be stimulated by increasing K+ concentration (119), which causes depola-
rization of the membranes. There were, however, marked differences from 
results of other investigations (105) which ask for evaluation. 
The in vitro studies of DA release complement the in vivo experiments 
and allow control led studies to be made, which are impossible in vivo. 
Interpretation Of results in relation to in vivo processes, however, 
is not always possible (79). 
CONCLUDING REMARKS 
A survey has been made of methods which can be used to study various 
in vivo processes involved in the functional activity of dopaminergic 
neurons. Important processes involved are DA biosynthesis, release and 
catabolism. Each of these processes may be regulated by a number of 
mechanisms. DA biosynthesis, for example, may be regulated by intraneuronal 
product (DA) inhibition (6), by presynaptic receptors or by postsynaptic 
receptors via transsynaptic mediators (32) or via impulse flow, i.e. 
neuronal activity (40, 55). It seems that all these mechanisms can operate 
in the normal brain. Which regulatory mechanism is most important may 
depend on the way in which the physiological balance is altered by drugs or 
other manipulations. 
It has been observed, for example, that the increase of DA bio-
synthesis and change of TH kinetic characteristics is prevented by halo-
peridol, a DA receptor blocking agent (18), when the nigrostriatal pathway 
is severed (106). This seems to imply, in keeping with other results 
(40, 55, 120), that striatal TH activity is regulated via impulse flow in 
the nigrostriatal DA pathway. It certainly does not imply, however, that 
haloperidol-induced changes in TH activity and kinetic characteristics 
in unlesioned neurons can not be mediated locally in the striatum by pre-
synaptic receptors or product inhibition. This is evident by the fact 
that the lesion itself brings about changes in TH activity similar to those 
induced by haloperidol (106). It can be expected therefore, that halo-
peridol-induced changes wil 1 no longer be observed when the nigrostriatal 
pathway is lesioned. Evaluation of the changes at the molecular level, 
brought about by a manipulation is necessary and often may exclude direct 
conclusions about the physiological process involved. This also implies 
that, ·for instance, antagonism of a drug effect by impairment of the 
impulse flow does not necessarily mean that the drug effect is mediated 
by the impulse flow. The point to be stressed is, that most experiments 
involve manipulations of the normal function of the d0paminergic neurons. 
Such manipulations may result in changes in set points of regulatory 
mechanisms, and in one experiment one mechanism may be most important, 
while in another experiment, involving another manipulation, also another 
regulatory mechanism may be most important. 
Thus, the presence of one regulatory mechanism does not indicate the 
absence of another, or citing Elkes (121): 11 ••••••• for I suspect, that 
while using the 11 Either/Or 11 , the language of the brain really is the 
language of the 11Also 11 and the 11 And11 • 11 Actually, the philosophical 
statement of Elkes was concerned with undue emphasis on the role of 
DA as such ..................... . 
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RAPID POSTMORTEM CHANGES IN 3,4- DIHYDROXYPHENYLACETIC ACID (DOPAC), 
A DOPAMINE METABOLITE, IN RAT STRIATUM 
INTRODUCTION 
Several experlmental approaches have been introduced to study the in 
vivo effects of drugs on dopaminergic neurons in the central nervous sY5-
tem. These include conversion of labelled precursors into dopamine, rate 
of disappearance of dopamine after inhibition of its synthesis (1) and 
estimation of metabolite concentrations (2,3). These procedures all include 
decapitation of the test animal, removal of the brain tissue, which often 
includes dissection, and extraction and assay of dopamine and/or one or 
more of its metabolites. To evaluate the reliability of such methods, short 
term postmortem changes in these substances should be studied. Carlsson 
et al. (4) reported postmortem changes in 3-methoxy-4-hydroxy-phenylethyl-
amine (3-methoxytyramine, 3-MT) and dopamine 10 and 30 min after decapita-
tion of rats, while other authors have only been concerned with considerably 
longer time intervals (5). In the present investigation postmortem changes 
in dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxy-4-
hydroxyphenyl acetic acid (homovan i 11 i c acid, HVA) have been studied from 
2t to 20 min after decapitation. 
MATERIALS AND METHODS 
Male, albino Wistar rats (TNO, Zeist, The Netherlands) weighing 120-
135 g were used. The animals were housed 5 to a cage, with standard food 
and water ad 1 ibltum. The lighting period was from 7.00 h to 21.00 h. 
Ambient temperature was approximately 18° C. 
All chemicals were reagent grade. All water used was demineralized and 
subsequently redestilled in an all glass apparatus. 
The rats were killed between 8.50 hand 9-35 h by means of a guillotine. 
The brain was removed and placed on an ice-cooled plate exactly 1 min 
after decapitation. The striata of one group of brains were dissected out, 
according to Gispen et al. (6), after exactly 0, 2-L 5, 10 or 20 min on 
the ice-cooled plate (undissected 11 incubation 11 ) and frozen in 1 iquid 
nitrogen exactly 1~ min after starting the dissection. The striata of 
another group of brains were dissected out immediately and replaced on the 
ice-cooled plate exactly 1t min after starting the dissection. These 
striata were frozen in 1 iquid nitrogen after exactly 0, 2~, 5, 10 or 20 
min on the ice-cooled plate (dissected 11 incubation 11 ). Thus, the time 
interval between decapitation and freezing of the striata was 2~ min plus 
the time during which the brain tissue was 11 incubated11 on the ice-cooled 
plate, either undissected or dissected. 
In one series of experiments the striata were weighed and homogenized 
in 1 ml 0.4 N perchloric acid. The homogenate was centrifuged at 25,000 g 
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for 10 min at 2° C and the supernatant stored at -80° C. HVA and DOPAC 
were isolated and assayed as previously described (7). The procedure 
consisted of isolation of the metabolites on smal 1 Sephadex G 10 columns 
followed by an automatic fluorimetric assay. The recoveries of 50 ng HVA 
and 50 ng DOPAC, added to 50-60 mg cerebellar tissue and run in para] lel 
throughout the isolation and assay procedure, were 81 + 9% for DOPAC and 
67 + 7% for HVA (+S.D., n = 6). The mean weight of the striata was 
59.0 ~ 6.8 mg (~S~D., n = 36). 
In another series of experiments dopamine assays were carried out on 
striata obtained in exactly the same way as in the previous experiment. 
The striata were weighed and homogenized in 10 ml o.4 perchloric acid 
containing 0.5% EDTA and 0.05% NazSz05. The homogenate was stored over 
night at -20° C and then centrifuged at 25,000 g for 10 min at zo C. 
The supernatant was filtered through Whatman no. 40 filter paper and 
transferred to 50 ml glass stoppered tubes containing 0.35 g Alz03, 
prepared according to Weil-Malherbe (8). 0.5 Ml 1M Tris pH=8.4 was added 
and after adjustment of the pH to 8.4-8.5 with 5 N and 1 N NaOH, the 
tubes were shaken for 10 min. The supernatant was discarded and the Alz03 
washed three times with at least 10 ml water. Dopamine was then eluted 
with 2.5 ml 1 N HCl (containing 10 mg/1 EDTA and 1 m;/1 ascorbic acid) and 
assayed, in duplicate, in 1 ml aliquots, according to Atack (9). 
The recovery of 0.5 g dopamine, added to brain tissue and run in 
para] lel throughout the isolation and assay procedure was 67%. The striata 
weighed 52.2 + 6.3 mg +S.D., n =50). 
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All valueS were corrected for recovery and expressed as ',.lg/g v.1et 
tissue weight. Differences between values for 0 min 11 lncubation 11 and 
values obtained after different periods of 11 incubation 11 were statistically 
evaluated by means of the test of Dunett (10) for comparison of several · 
treatments with one control. 
RESULTS 
DOPAC concentrations changed considerably 7! min or more after de-
capitation (fig. 1). An increase of 30-45% was observed in striata 
11 incubated 11 for 5, 10 or 20 min after dissection (dissected 11 incubation 11 ). 
On the other hand, a decrease of 20-30% was observed in striata removed 
from whole brains 11 incubated 11 for 10 or 20 min (undissected 14 incubation 11 ). 
HVA levels showed no significant changes. They tended to rise for the 
first 5 min of 11 incubation 11 and then to decrease after 1 tincubationlt of 
dissected striata for 10 and 20 min and of undissected brain for 10 min. 
The concentration of dopamine did not change substantially during the 
period of observation except that, after 20 min 11 incubation 11 of dissected 
striata, a 15% decrease in dopamine levels was observed, although this 
effect was not significant. 
"' 1.3 
--"' •• :::_ r2oo"c 
1.1 
0.9 
'<t-f 
0.7 \~1 DO PAC 
0.5 .--r-~2~1 HVA 
0.3 i f ? 
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0 2.5 5 10 20 
min 
Fig. 1. Postmortem changes in HVA and DOPAC in rat striatum. 
Rats-were-decapitated, the brains removed and placed on a ice-cooled 
plate exactly 1 min after decapitation. Striata were frozen in 1 iquid 
nitrogen exactly 1t min after the start of the dissection. This re-
presents the 0 min value. Values for the other time intervals indicated 
were obtained from striata 11 incubated 11 on the ice-cooled plate either 
before (undissected 11 incubation 11 ) or after dissection (dissected 
11 incubation 11 ). Values represent mean+ S.E. of 4 determinations, except 
for the 0 min value for HVA ( n = 2)~ +p< 0.05, ** p< 0.01 vs 0 min 
value. 
0 dissected, A. undissected. 
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~- Postmortem changes in dopamine in rat striatum. 
For explanation see fig. 1. Values represent mean + S.E. of 6 
determinations. 
0 dissected, A undissected. 
DISCUSSION 
The results presented show that no gross changes in dopamine, HVA 
and DOPAC concentrations occur from 2~ to 5 min after decapitation. 
Since no values can be obtained for the true concentrations at the 
moment of decapitation, levels of dopamine, HVA and DOPAC obtained 
from striata frozen within 5 min after decapitation, provide a reasonable 
alternative. However, when the period between decapitation and freezing 
of the brain tissue was extended beyond 5 min, considerable postmortem 
effects were observed for DOPAC. Remarkably,striatal DOPAC levels 
sharply increased when the striata were 11 incubated 11 at 0° C for more 
than 5 min (dissected 11 incubation 11 ), while they decreased when the 
brain was 11 incubated 11 as a whole (undissected 11 incubation 11 ). Oxidation 
of dopamine only occurred when the striatum was dissected and this may, 
therefore, reflect a difference in oxygen concentration. This is in 
agreement with the results and conclusion of Wiesel and Sedvall (5), who 
observed increases in HVA in striata when dissected and stored at 4° C 
for 6 h or more, but not when the brain was left in situ at 4° C for 
6 h or more. Whether the observed DOPAC accumulation actually results 
from oxidation of dopamine or not, can not be concluded from the time 
course of dopamine levels obtained (fig. 2), although the decrease 
after 20 min 11 incubation 11 of dissected striata points in that direction. 
It should be noted, that dopamine concentrations are more than tenfold 
greater than the DOPAC concentrations and therefore, a change in DOPAC 
levels of 50% can be accounted for by a change of as 1 ittle as 4% in 
the levels of dopamine. The decrease in dopamine after 20 min 11 incubation 11 
probably coincides with the onset of the disappearance reported by 
Wiesel and Sedvall (S) at 6 h after decapitation under similar experimen-
tal conditions. 
While DaPAC levels decreased in whole brain after 10 min, no increase 
in HVA concentration was observed. This seems to indicate, that the 
disappearing DaPAC is not a-methylated to HVA. A possible reason for 
the disappearance of the DaPAC may be the formation of a conjugate, 
as recently indicated by Gordon et al. (11), although it is not known 
whether conjugation can take place postmortem. Another observation 
also sugges~ that a-methylation did not take place to an appreciable 
extend in our experiments:namely, the massive increase in DaPAC levels 
in dissected striata was not paralleled or followed by an increase in 
HVA concentration. Although Carlsson et al. (4) observed considerable 
postmortem changes in 3-MT and dopamine in whole brain 10 or 30 min 
after decapitation, this does not contradict our results, since these 
effects occurred when the brain was left '1n situ at 37°C. However, 
when the brain was stored at 23°C for 10 or 30 min no effects on 3-MT 
or dopamine concentrations were observed (4). 
In conclusion, there seem to be no gross postmortem changes '1n 
the levels of dopamine and its acid metabolites between 2~ and 5 min 
after decapitation, under the conditions of the present experiments. 
However, at longer time intervals, dramatic changes in DaPAC levels 
were observed. These changes seem to result from oxidation and possibly 
conjugation, while a-methylation does not play an important role. 
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II 
DIFFERENTIAL EFFECT OF MORPHINE ON DOPAMINERGIC NEURONS IN FRONTAL 
CORTEX AND STRIATUM OF THE RAT 
SUMMARY 
Inhibition of dopamine synthesis by a single injection of a-methyl-
para-tyrosine (200 mg/kg, i .p.) was complete from 30 to at least 300 min. 
after administration. 
When morphine (20 mg/kg) was given intraperitoneally 30 min. after ~;tMpT 
treatment, an enhanced decline of dopamine was observed in frontal parts 
of the cortex but not in the striatum. These results indicate that mor-
phine affects dopaminergic neurons in frontal parts of the cortex in a 
way differently from those in the striatum of the rat. 
This may be caused either by a difference in the properties of dopa-
minergic nerve endings in both structures or by an effect of morphine on 
the input to the cortical system which is lacking in the striatum. 
INTRODUCTION 
Several laboratories reported that morphine enhances the synthesis 
of dopamine in the corpus striatum (1, 2, 3) and in other brain struc-
t~res of the rat (4). Many effects of drugs on the synthesis of dopamine 
seem to be initiated by compensatory mechanisms after disturbance of the 
dopaminergic system. It is postulated, for example, that neuroleptic drugs 
block dopaminergic receptors (5) and as a consequence of this blockade 
activate the synthesis of dopamine by some feedback mechanism. Kehr et al. 
(6) suggested a local feedback,whi le And~n et al. (7) proposed a feedback 
via modulation of the impulse flow at the level of the substantia nigra. 
Likewise, changes in release and catabolism of dopamine or changes in 
impulse flow can affect dopamine synthesis (8, 9). After inhibition of 
the biosynthesis of dopamine these compensatory mechanisms are blocked 
and effects on release, catabolis1n or in1pulse flow can be uncovered by 
measuring the changes in dopamine concentration. 
Tl1e present experiments evaluate the effect of morphine on dopaminer-
gic systems in the corpus striatum and in frontal parts of the cortex 
after inhibition of the dopamine synthesis by a-methyl-para-tyrosine 
( aMpT). A first series of experiments was performed to determine the 
time intervals at which aMpT exhibits max.in1al inhibition of the synthesis. 
In a second series of experiments the effect cf n:orphine during this time 
interval was investigated. 
47 
MATERIALS AND METHODS 
Animals 
Male albino Wistar rats weighing 80-110 g were used. The animals were 
housed 5 in a cage with ad libitum water and standard food. Lights were 
on from 7 a.m. to 9 p.m. 
Drugs 
-----Drug solutions were freshly prepared before each experiment in 0.9% 
NaCl. Drugs used were: a-methyl-para-tyrosine-methylester. HCl ( a:MpT, 
AB Labkemi), morphine. HCl and L-l4c-tyrosine (uniformly labeled 483 mC/ 
mmol, Radiochemical Centre, Amersham). aMpT (200 mg/kg as base) and 
morphine. HCl (20 mg/kg) were injected intraperitonea11y (5 ml/kg). 
L- 14C-tyrosine was freeze-dried, dissolved in 0.9% NaCl and injected into 
the tai I vein (300-500 uC/kg, 2 ml/kg). 
Experiment 1 
At graded intervals after adm'1nistrat·1on of o.:MpT (15, 30, 60, 120 or 
240 min) or saline (15, 60 or 240 min) L-14C-tyrosine was injected. 
The rats were decapitated 60 min after L_]_ 4 C-tyrosine administration 
and the brain without bulbi olfactori i was rapidly removed. The cerebellum 
was discarded. The rest of the brain was homogenized in 5 ml 0.4N per-
chloric acid containing 0.5% EDTA and centrifuged at 25,000 g for 15 min 
at 20C. Dopamine and tyrosine were isolated from the supernatant by 
chromatography on Dowex 50 WX 4 columns as described by Atack and Magnus-
son (10) and Atack (11). The chromatography was performed at 4oc. 
Al iquots of the eluates containing dopamine and tyrosine were added to 
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16 ml lnstagel (Packard). Radioactivity was measured by liquid scintil-
lation spectometry and corrected for quenching with an external standard. 
L-14C-dopamine and L-l4C-tyrosine were added to brain tissue samples of 
untreated rats and run in parallel through the extraction and isolation 
procedure. Experimental values were corrected for recovery of L-14c-
dopamine and contamination of L-14 C-tyrosine in the dopamine fraction. 
The percentage inhibition of dopamine s~nthesis was calculated from 
the following equation: % inhibition= C E ~ X 100, where C and E are 
values for radioactivity in the eluates containing dopamine from saline 
and o.:MpT treated rats respectively. C equals the average value from the 
three saline treated groups (15, 60 and 21+0 min before L-14c-tyrosine). 
The mean radioactivity in the dopamine fraction of these controls was 
7168 + 404 dpm (+ S.E. n=9). The results were statistically evaluated by 
analySis of variance according to Snedecor and Cochran (12). 
Experiment 2 
Morphine or saline was administered 30 min after o.:MpT treatment. 
Rats were ki 1 led by decapitation 2t hours after injection of aMpT. 
After decapitation the brain was rapidly removed without bulbi olfactori i, 
dissected, weighed and frozen in 1 iquid nitrogen within 4 min. after 
decapitation. 
Frontal cortex was dissected from the tissue frontal to a vertical 
section through the optic chiasm and anterior commissure as follows: 
tubercul i olfactori i were removed and all tissue medial to a vertical 
cut through the anterior commissure and dorsal to the corpus callosum 
(conta'1n'1ng septum, nucleus preopticus and nucleus accumbens) was dis-
carded. The frontal parts of the caudate nuclei were removed and added 
to the caudal parts of striatal tissue (13). The remaining cortical 
tissue is specified as frontal cortex. The mean tissue weight (+S.D., 
n=90) per bra"1n was: str'1atum 120.8..:!:. 10.1 mg and frontal corteX 203.1 
+ 22.0 mg. 
- Pooled frontal cortices and pooled striata of 4 rats were homo-
genized in 10 ml perchloric acid containing 0.5% EDTA. Dopamine was iso-
lated and assayed fluorimetrically as described by Atack (11). The re-
covery of 0.5 ~g dopamine added to brain tissue samples and run in 
para] lel through the procedure was 72.0 + 5.7% (mean+ S.D., n=7). The 
values were not corrected for this recovery. DifferenCes in dopamine 
levels were statistically evaluated by Studenes t-test. 
RESULTS 
The results as shown in Table I demonstrate that a single ·Injection 
of ~MpT inhibited the synthesis of dopamine for more than 95% from 30 
min after administration unti 1 the longest period of observation (4 hr). 
However, a lower percentage of inhibition (87.9%) was achieved when the 
precursor L- 14C-tyrosine was injected 15 min afterc:iMpT administration. 
Statistical evaluation of the data by an analysis of variance (Table II) 
showed a significant difference between treatments (p <0.005). 
TABLE I 
Time Course of Inhibition of Dopamine Synthesis by aMpT 
Treatment Group 
2 
3 
4 
5 
Time Schedule (min after c:iMpT) 
ln~ection of Decapitation 
L- 4C-Tyros i ne 
15 75 
30 90 
60 120 
120 180 
240 300 
% Inhibition of 
Dopamine Synthesis 
87.9 + 3.3 
97.3 + 2.4 
95.2 + 2.2 
95.8 + I .9 
96.2 + 3. I 
200 mg/kg aMpT was administered i .p. and at indicated time intervals 
thereafter L-14 C-tyrosine 1 .v .. % Inhibition of dopamine synthesis was 
calculated as described in 11 Materials and Methods 11 • Values represent mean 
+S.E.,n=3. 
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TABLE I I 
Analysis of Variance of the Data of Table \ 
Source of Variation Sum of Squares df Mean Sum 
of Squares 
F p 
between treatmentsa 168.21 4 42.05 
161.05 
33.91 <0.005 
15 t vs other groupsa 161 . 0 5 129.88 <0.005 
among other groups(2-5)a 7.16 3 2.39 1.92 >0.1 
within treatments (error) 9.91 8 I .24 
a. Treatment groups as indicated in Table I. 
Inhibition of the synthesis of dopamine in the first treatment group 
(L-l4C-tyrosine 15 min after o:MpT) significantly differed from the other 
groups (p <0.005), while no significant effect was observed within 
these other groups (p > 0.1) . The ave rage va 1 ue for the other groups a-
mounted to 96. 1%, which represents the mean inhibition from 30 min unti 1 
5 hr after administration of o:MpT. The value obtained for the first 
treatment group (87.9%) represents the mean inhibition between 15 and 
75 min after aMpT treatment. 
TABLE II I 
Effect of Morphine on the aMpT induced Decline of Dopamine 
Dopamine 
Treatment Franta 1 Cortex (ng/g) Striatum ( )Jg/g) 
None 415 + 26 (9) 4.30 + 0.21 (10) 
aMpT + Sa 1 i ne I 43 ~ 7 (6) 1.82 + 0.13 (4) 
aMpT +Morphine Ill + 7 (4)x 1.81 + 0.19 (5) 
Rats were decapitated at T-O (no treatment) or injected with aMpT (200 
mg/kg,i.p.). aMpT treated rats received saline or morphine (20 mg/kg,i.p.) 
at T=~hr and were decapitated at T=2thr. Values represent mean levels of 
dopamine+ S.E. and number of observations in parenthesis. 
x Differs-from saline control ( p <0.01). 
Assuming that the inhibition in this treatment group from 30 min unti 1 
decapitation (75 mln) '1s the same as for the other groups from 30 m'1n 
on (96.1%), the inhibition between 15 and 30 min can be calculated to 
be about 63%. 
Complete inhibition of dopamine synthesis, therefore, was achieved 
30 min but not 15 min after administration of aMpT. For this reason 
morphine was administered 30 min after aMpT and this resulted in an en-
hanced decline of dopamine in the frontal cortex (Table Ill). The level 
of dopamine obtained 2~ hours after injection of aMpT was significantly 
lower in morphine treated rats as compared to saline treated rats 
(p<D.Ol). 
However, in the striata of the same rats no difference between 
the levels of dopamine in morphine and saline treated rats was observed 
(p>0.95). 
DISCUSSION 
From 30 min until 5 hr after a single intraperitoneal injection of 
aMpT (200 mg/kg) the inhibition of dopamine synthesis was complete 
(96.1%), while only a partial inhibition was obtained from 15-30 min 
(63%). This is in agreement with the results of Doteuchi et al. (15) 
who reported a 53% inhibition of dopamine synthesis between 5 and 15 
min after administration of the same dose of aMpT. 
Morphine, when administered to rats in which dopamine biosynthesis 
was completely inhibited, had no effect on the decline of dopamine in 
the corpus striatum. A number of factors such as release generated by 
impulse flow, release generated directly at the nerve ending (tyramine-
or reserpine-] ike effects) and catabolism of dopamine determine the de-
c I ine of dopamine when its synthesis has been inhibited. The influence 
of morphine on these processes can be ruled out,as the drug had no 
effect on the decline of dopamine in the striatum. 
A single injection of morphine was shown to increase dopamine syn-
thesis in the rat striatum (1, 2, 3). Although this effect of morphine 
has been attributed to a direct influence on the biosynthesis itself 
(3,16), another possibi 1 ity should be taken into consideration. It has 
been suggested that morphine may block dopamine receptors in a way 
simi Jar to neuroleptics (17, 18). Such a blockade would enhance the 
synthesis of this amine via a local feedback or via an enhanced impulse 
flow, as proposed for neuroleptics (6, 7). The latter possibility is 
apparently not supported by the present results. However, a feedback 
at the level of the striatum is still plausible, but cannot be detected 
in our experiments due to prior aMpT treatment. 
The augmented dec] ine of dopamine by morphine in the frontal cortex 
after aMpT treatment indicates that the drug either enhances the impulse 
flow in dopaminergic neurons in this structure or that it increases 
release or breakdown of dopamine at the nerve endings. In the case of 
an enhanced impulse flow, morphine may affect the '1nput to the dopaminer-
gic neurons projecting to the frontal cortex,but not to those projecting 
to the striatum. However, a direct effect of morphine on dopamine re-
lease or catabolism at the nerve endings in the frontal cortex can not 
be excluded from the present experiments. Therefore, a second explanation 
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for the discrepancy between frontal cortex and striatum might be a dif-
ference in properties of the dopaminergic nerve endings in both structu-
res. 
In conclusion, the data presented reveal a differential effect of 
morphine on striatal and frontal cortical dopaminergic systems. Morphine 
may selectively modulate the input to the dopaminergic systems in the 
frontal cortex. Alternatively, a direct effect on dopaminergic nerve en-
dings in the frontal cortex is possible. 
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MORPHINE: A MODULATOR OF DOPAMINERGIC NEUROTRANSMISSION IN THE RAT 
1. FRONTAL CORTICAL AND STRIATAL EFFECTS 
ABSTRACT 
Morphine (20 mg/kg i .p.) increased the rate of dopamine (DA) loss by 
ca 40% in the frontal cortex of rats when the drug was administered 30 
min after treatment with the synthesis inhibitor a-methyl-para-tyrosine 
methyl ester ( aMpT). This effect was specific as it was antagonized by 
naloxone. Under the same injection schedule the rate of DA decline in 
the striatum was unaltered in one experiment and increased slightly in 
another experiment. Moreover, striatal levels of homovanillic acid (HVA) 
and 3,4-dihydroxy-phenylacetic acid (DOPAC) were unaffected by morphine 
under exactly the same experimental design. It is suggested, therefore, 
that, under conditions whereby the synthesis of DA is entirely inhibited, 
morphine ·Increases DA release ln the frontal cortex in contrast to the 
striatum. This differential effect could not be ascribed to a delayed 
inhibition of DA synthesis !n the frontal cortex when compared with the 
striatum. Subdissection of the frontal cortex showed that most of the DA 
(80%) was present in basal parts of the forebrain. 
When morphine, on the other hand, was administered before inhibition 
of DA b i osyn thesis ( 30 min before o.MpT) an increase in the rate of DA 
loss was also observed in the striatum and a more marked increase was 
seen in the frontal cortex. 
The results suggest that morphine exerts two different actions on 
dopaminergic neurons: an increase of DA biosynthesis in most or al 1 
dopaminergic structures, presumably by a direct action, and an increase 
in DA release in the frontal cortex. It is suggested that extrastriatal, 
including frontal cortical, dopaminergic structures, are of more importance 
than striatal structures for morphine-induced effects related to the 
functional activity of dopaminergic systems~ 
INTRODUCTION 
The effect of morphine administration on the activity of dopaminergic 
neurons in the central nervous system of the rat has been extensively 
studied in recent years. The enhanced turnover of dopamine (DA) induced 
by morphine in the striatum and other DA-rich brain areas has been shown, 
using several different experimental techniques. These have included 
enhanced conversion of radioactive tyrosine into DA in the corpus 
striatum (1, 2, 3) and in other brain areas (4, 5), increases in the DA 
metabolite hornovanillic acid (HVA) in the striatum (6, 7, 8), nucleus 
accumbens and tuberculum olfactorium (7), increases in 3,4-dihydroxy-
phenylacetic acid (DOPAC) in these brain structures (9) and accelerated 
decline of DA in the striatum (10, 11) and in whole rat brain (12) after 
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treatment with the synthesis inhibitor a-methyl-para-tyrosine ( aMpT). 
Since the turnover of DA is dependent on several closely 1 inked pro-
cesses 1 ike release, reuptake, synthesis and catabolism (13), the reports 
cited above do not indicate which of these components is primarily 
affected by morphine. We recently reported that morphine did not affect 
the decline in striatal DA after aMpT treatment, when the drug was ad-
ministered 30 min. after aMpT, while it increased DA decline in the frontal 
cortex under these conditions (14). The major feature of this experimental 
approach is a strict exclusion of drug effects contingent on DA biosyn-
thesis, which is not achieved when morphine is administered before aMpT 
(10, 11) or by other techniques as described above. The present experiments 
are concerned with the localization and specificity of the reported 
enhanced DA decline in the frontal cortex and the absence of this effect 
in the striatum. 
MATERIALS AND METHODS 
Male, albino Wistar rats were purchased from T.N.O. Zeist, The 
Netherlands. The animals were housed 5 in a cage with free access to 
food and water. The period of light was from 7.00 h to 21.00 h. Ambient 
temperature was ca 18° C. Al 1 animals weighed 100-135 g on the day 
before the experiment, when they were placed in a separate housing room 
where the experiments were performed. The first treatment (injection 
or decapitation) of al 1 animals was between 9.00 h and 10.30 h and 
treatments were randomized to avoid influences of diurnal fluctuations in 
DA, HVA and DDPAC. 
Drug solutions were freshly prepared before each experiment in 0.9% 
NaCl. Drugs used were: a-methyl-para-tyrosine methylester.HCl ( aMpT, AB 
Labkemi) 200 mg/kg as base, Morphine.HCl 20 mg/kg, Naloxone.HCl 1 mg/kg 
(Endo Lab.), L-(3,5-3H)-tyrosine (42 C/mmol) and S-adenosyl-L-(methyi- 3H)-
methionine (10 C/mmol), both from Radiochemical Centre Amersham. 
(3H)-tyrosine was freeze-dried and dissolved in 0.9% NaCl. All chemicals 
were reagent grade. All water used was demineralized and subsequently 
distilled in an all glass apparatus. 
EXPERIMENTAL SCHEDULES 
Assessment of DA S nthesis Inhibition 
About 1 mC of H tyrosine was injected into the tai 1 vein in a 
volume of 0.2 ml.aMpT or saline was administered 30 or 60 min before 
(3H)-tyrosine and rats were decapitated 30 min after (3H)-tyrosine 
injection. 
Morphine Experiments 
Rats were injected at t 0 with aMpT and decapitated at t=2~ h. Controls 
were decapitated at t 0 (0 HR values). Morphine or saline was administered 
30 min before aMpT (Sal + aMpT and Mar+ aMpT) or 30 min after aMpT 
(a MpT + Sa 1 and aMpT + Mar). The 0 HR control for the Mar + aMpT group 
received morphine 30 min before decapitation. Naloxone was given together 
with morphine or alone 30 min after o:MpT ( aMpT +Mar+ Nal andaMpT + Nal). 
These rats received a second injection of naloxone 60 min later, while 
groups not treated with naloxone in the same experiment received saline. 
All drugs were injected intraperitoneal ly in a volume of 5 ml/kg. 
The inject'ton schedule is summar'tzed in table 1. 
Tab 1 e 1. 
Time Schedule of Treatments (min). 
-30 0 +30 +90 + 150 Treatment 
Group (Code) 
Sa 1 i ne De capitation 
Morphine De capitation 
Sa 1 i ne a MpT 
Morphine a MpT 
a MpT Saline --/Saline 
a MpT Morphine --/Saline 
a MpT Naloxone Naloxone 
a MpT Morphine+ Naloxone 
Naloxone 
All injections were i .p. in a volume of 5 ml/kg 
Morphine: 20 mg/kg as HCl salt 
De capitation 
Decapitation 
Decapitation 
Decapitation 
Decapitation 
Decapitation 
aMpT: a-methyl-para-tyrosine-methylester.HCl, 200 mg/kg as base 
Naloxone: 1 mg/kg as HCl salt 
DISSECTION 
Dissection of the frontal cortex 
0 HR Sal 
0 HR Mar 
Sal+aMpT 
Mor+aMpT 
aMpT+Sal 
aMpT +Mar 
aMpT +Na 1 
c:MpT +Mar+ 
Nal 
After decapitat'ton the bra'tn of the rat was rapidly removed from the 
skull and placed on an ice-cooled plate for dissection. The olfactory 
tubercula and bulbi were removed by blunt dissection. Subsequently the 
frontal pole of the forebrain was separated from the rest of the brain by 
a transverse cut through the opt'tc chiasm and the anterior commissure 
(cut A, fig. 1). From the dissected frontal pole of the forebrain the 
11 fronta1 11 cortex was dissected in two steps. First, the septal and 
preoptic areas were removed. For this purpose two parasagi ttal cuts were 
made passing through the floor of the lateral ventricle and the lateral 
olfactory tract, which made it possible to remove the midline tissue by 
peeling it loose from the corpus callosum. Subsequently the striatum on 
either side was removed by means of blunt dissection sparing the basal 
parts of the forebrain. The two striata were kept and further analysed 
together with the striatal tissue obtained from the caudal half of the 
forebrain, according to the method described by Gispen et al. (15). The 
remaining tissue of the rostral pole of the forebrain will be referred to 
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as frontal cortex, which includes, however, part of the corpus callosum 
and the basal parts of the forebrain. The dissected frontal cortex and 
striata were put into 1 iquid nitrogen within 4 min after decapitation. 
Subdissection of the frontal cortex 
In one experiment the 11 frontal 11 cortex was subdivided in four parts. 
First the frontal pole of the forebrain was separated from the rest of 
the brain by the transverse cut through the anterior commissure and the 
optic chiasm as described above. The frontal pole of the forebrain was 
then divided into two parts by a transverse cut through the level of the 
genu of the corpus callosum (cut B, fig. 1). The cortical tissue rostral 
to this cut will be referred to as area 1. 
From the brain slice between the transverse cuts A and B the septal 
and preoptic area as well as both striata were removed as described 
above. The remaining cortical tissue was further subdivided into five 
parts by means of four longitudinal cuts, i.e. two parasagittal cuts 
about 1 mm from the midline, which dissected the corpus callosum and the 
medial aspects of the hemisheres (area 2, fig. 1) and two other para-
sagittal cuts which separated the basal parts of the forebrain (area 4, 
fig. 1) from the lateral convexity of the hemishere (area 3, fig. 1). 
ASSAYS AND STATISTICS 
HVA and DOPAC 
Single striata were weighed and homogenized in 1 ml 0,4 N perchloric 
acid for HVA and DOPAC assay. Homogenates were centrifuged at 25,000 g for 
10 min at 2° C. HVA and DOPAC were isolated and assayed according to 
Wester ink and Korf (9). The recoveries of 50 ng HVA and 50 ng DOPAC added 
to 50-60 mg cerebellar tissue and run in para! Jel through the total 
procedure were 67 + 7% for HVA and 81 + 9% for DOPAC (+S.D., n=6). Values 
were expressed as ~g/g wet tissue weight without correCtion for recovery. 
Fluorimetric DA Assay 
For the assay of DA the striata and frontal cortex of one rat were 
weighed. Striata of one rat and pooled frontal cortices of 4 rats were 
homogeniZed in 10 ml 0.4 N perchloric acid containing 0.5% EDTA and 0.05% 
Na2S205. Homogenates were centrifuged at 25.000 g for 10 min at 20 C. The 
supernatant was filtered through Whatman no. 40 filter paper into 50 ml 
glass stoppered tubes containing 0.35 g A1 2o3 which was prepared according 
to Weil-Malherbe (16). 0.5 Ml 1 M Tris pH= 8.4 was added and the pH 
adjusted to 8.4-8.5 with 5 N and 1 N NaOH and the tubes shaken for 10 min. 
The supernatant was discarded and the Al203 washed three times with at 
least 10 ml water. DA was eluted with 2.5 or 3 ml 1 N HCJ containing 10 mg/ 
1 EDTA and 1 mg/1 ascorbic acid and assayed fluorimetrical ly in duplo in 
1 ml al iquots according to Atack (17). The recovery of 0.5 llg DA added to 
brain tissue extracts and run in para! lel through the procedure was 
70.8 + 3.0% (+S.D., n = 13). Values were expressed as 119/g wet tissue 
weight without correction for recovery. Rate constants of amine loss were 
calculated according to Brodie et al. (18). 
Radiochemical Assay of DA and NA 
DA and NA in dissected brain areas of the frontal cortex (see Dis-
section) were assayed by a radiochemical method (19) as modified by 
Versteeg et al. (20). Briefly, the brain tissue was homogenized in 0.1 N 
perchloric acid, centrifuged and the supernatant used for assay. DA and NA 
were converted to their (3H)-methoxy derivatives by means of incubation 
with rat liver COMT in the presence of (3H)SAM. The derivatives were 
separated by extraction and paper chromatography. 
Assa of Radioactive DA and Tyrosine 
H -tyrosine and H DA in striata and frontal cortex of one rat were 
isolated as described before (14). Briefly this consisted of perchloric 
acid extraction of the brain tissue, centrifugation and chromatography of 
the supernatant on Dowex 50 WX 4 columns. Radioactivity was measured by 
1 iquid scintillation spectrometry. The percC~Eage inhibition of DA bio-
synthesis was calculated from the equation -c-- x 100, where C and E re-
present the ratios of radioactivity in the DA and tyrosine containing 
eluates from saline and aMpT treated rats respectively. 
Stat i s t i cs 
Differences between DA levels and rate constants were tested with two-
tal led Student's t-test. !n the experiment involving determination of HVA 
and DOPAC (table 5) analysis of variance (21) was performed. 
Values of p less than 0.05 were considered significant. 
Table 2 
Inhibition of Dopamine Biosynthesis by aMpT in Frontal Cortex and Striatum 
Time-interval: % n h i b t 0 n of DA 5 y n t h e 
3H-TYR inject ion 
to decaeitation Frontal Cortex b Striatum 
30 60 min 85 .:': 6 96 ;96 
60 - 90 min 89 
.:': 5 95 :': 3 
a. Values represent mean + S.E. of 3 experiments. 
b. Frontal cortices weighed 194 + 21 mg and striata 108 + 11 mg 
(mean.:::_ S.D., n = 9). 
RESULTS 
5 
b 
INHIBITION OF DA BIOSYNTHESIS BY aMpT IN FRONTAL CORTEX AND STRIATUM 
5 a 
Table 2 shows that DA biosynthesis in both the frontal cortex and 
striatum was inhibited to a similar extend 30-60 and 60-90 min after 
aMpT administration. The calculated% inhibition in the frontal cortex, 
however, did not amount to the same value as in the striatum. The amount 
of radioactive DA formed in the frontal cortex of control rats (no g,MpT) 
was considerably less than in the striatum (1410 + 385 dpm vs 13,504 + 
1,830 dpm)' while more radioactive tyros'lne was recovered in the frontal 
COrtex (93 + 9 dpm.l Q+3 V5 61 _:': 6 dpm.l 0+3). 
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Table 3. 
Effect of Morphine Administered before or after aMpT on the Decline of Dopamine in Frontal Cortex and Striatuma 
F r o n t a 1 C o r t e xb S t r i a t u mb 
Treatmentc DA concentration Rate constantd 6Rate constant DA concentration Rate constantd ~Rate constant 
groue (ng/g) (h -I) (h -1) ( )lg/g) (h -1) (h -1) 
0 H Sal 292:':23 (3) 4.38:':0.13 (9) 
0 H Mor 334:':26 (3) 4.82:':0.23 (10) 
a.MpT+Sal 148:':4 (3) 0.271:':0.0334 0.102+0.0467 1.99:':0.06 (14) 0.317:':0.0181 -0.002:':0.0247 
aMpT+Mor 115:': 4 (4)x 0.373:':0.0316x 1.99:':0.06 (13) 0.315:':0.0168 
Sal+a.MpT 160:': 9 (3) 0.241:':0.0399 0 .167:':0 .0506 2.22_!0.06 (13) 0 .271:':0 .0157 0.099:':0.0299{ 
Mor+o:MpT 120:': 4 (4)X 0.407:':0.0322x 1.91:':0.09 (12)x 0.371:':0.0254xx 
x p <0.01 vs matching saline xx p <0.002 vs matching saline f p <0.02 vs inversed treatment 
a. Values represent mean+ S.E. and number of observations are given in parenthesis. The number of 
experiments on separate days was 4. 
b. Frontal cortices weighed 208 + 18 mg and striata 115 + 8 mg (+S.D., n = 96). 
c. See table 1 for injection schedule and codes for treatment grOups. 
d. Rate constants for Sal+ O!MpT, O!MpT +Sal and O!MpT +Mar treatments were calculated utilizing the 0 H 
Sal value, while the 0 H Mar value was used for Mar+ O!MpT treatment. 
Table 4 
Effect of Morphine and Antagonism of Naloxone in Frontal Cortex and 
Striatuma. 
F r o n t a I C o r t e xb s t r l a t u m b 
Treatmentc DA level Rate constant DA level Rate constant 
grou~ (ns/s) (h-I) ( "g/g) (h-I) 
0 H Sal 248;!:10(4) 5.28;!:0.26(11) 
aMpT+Sal 119;!:8 (5) 0.297;!:0.0356 2. 74;!:0 .1 0 (17) 0.263;!:0.0237 
aMpT +Mar 86+6 (5)xf 0.427;!:0.0378xf 2.36;!:0. 10(24)x 0.325;!:0.0268X 
o: MpT +Na 1 11 0;!:11 (6) 0.339;!:0.0583 2.66;!:0 .11 (22) 0.277;!:0.0263 
aMpT+Mor+Nal 122;!:9 (5) 0.289;!:0.0370 2.60;!:0.08(16) 0.281;!:0.0217 
x. p <0.02 vs o:MpT+Sal f. p <0.01 vs aMpT+Mor+Nal 
a. Values represent mean+ S.E. and number of observations in parenthesis. 
The number of experiments on separate days was 5. 
b. Frontal cortices weighed 197 ~ 19 mg and striata 102 ~ 11 mg 
(;!:S.D., n = 115). 
c. See Table 1 for injection schedule and codes for treatment groups. 
ADMINISTRATION OF MORPHINE 30 MIN AFTERaMpT: 
EFFECT ON DA AND ANTAGONISM BY NALOXONE 
Frontal Cortex (table 3 & 4) 
Morphine administration 30 min after aMpT resulted in lower DA levels 
in the frontal cortex when compared with saline treatment. The rate 
constants of DA loss calculated from these concentrations showed an in-
crease of 38% (table 3} and 44% (table 4), after morphine treatment. 
Moreover, this effect was blocked by the specific morphine antagonist 
naloxone, which had no effect of its own (table 4). 
Strlatum (table 3, 4 & 5). 
When morphine was administered 30 min after aMpT, no effect on DA 
decline was observed in the striatum, as shown in table 3. However, 
in another ex~eriment (table 4) a decrease in the DA levels was obtained. 
Although the rate constant only increased by 24% when compared with 
44% in the frontal cortex, the difference from saline treatment was 
significant. The difference between morphine and combined morphine and 
naloxone injection, however, was not significant in the striatum. 
Moreover, it was observed, that the rate constant of DA loss in the 
striatum of saline treated rats was smaller in the experiment reported 
in table 4 when compared with that shown in table 3, while they were 
similar in the frontal cortex. 
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The concentrations of the DA metabolites HVA and DOPAC were analysed 
under exactly the same experimental schedule. Although the morphine 
injection resulted in slightly lower levels of both metabolites when 
compared with saline treatment, an analysis of variance showed no 
significant effect of treatments (HVA: F=0.25, df=3/12 and DOPAC: F=1.50, 
df=3/13, both n.s.). The HVA and DOPAC levels in the frontal cortex were 
below the 1 imit of detection 2t h after aMpT administration, thus no 
values for this brain area are reported. 
Table 5 
Effect of Morphine and Naloxone on HVA and DOPAC in Striatum after 
Synthesis Inhibition a. 
Treatment g rou~b HVA (ng/g)c OOPAC (ng/g)c 
0 H Sal 375_::41 (4) 729_::39 (4) 
o:MpT +Sa 1 141_:: 3 (3) 325_::31 (4) 
aMpT +Mar 131_::16 (4) 291_::11 (4) 
o:MpT+Nal 129_::21 (4) 271_::36 ( 4) 
o:MpT +Mor+~la 1 141 +1 0 (4) 343_::27 (4) 
a. Values represent mean+ S.E. and number of experiments in parenthesis. 
Each individual value Consists of the mean value of left and right 
stria tum. 
b. See Table 1 for injection schedule and code for treatment groups. 
c. Single striata weighed 54.8 + 7.9 mg (:!:.S.D., n = 48). 
No significant effect of treatments was detected by analysis of variance 
(see Results). 
COMPARISON OF THE EFFECT OF MORPHINE ON OA DECLINE, WHEN ADMINISTERED 
30 MIN BEFORE OR AFTER aMpT (TABLE 3) 
DA concentrations in control rats were 292+23 ng/g and 4.38+0. 13 ~g/g 
in the frontal cortex and striatum respectivelY. After 30 min p7etreatment 
with morphine a rise in DA levels of 14% in the frontal cortex and of 10% 
in the striatum was observed, but these values were not significantly 
different from controls. In the frontal cortex, significantly lower 
levels of DA were obtained when morphine was administered 30 min after, 
as well as 30 min before o:MpT, when compared with saline treatment. In 
the striatum, however, no difference was observed when morphine was 
administered 30 min after o:MpT while injection of morphine 30 min before 
o:MpT resulted in a significantly lower DA concentration than in saline 
treated rats. 
A better quantitative insight into these effects of morphine is pro-
vided by comparison of rate constants of DA loss, as calculated from the 
DA concentrations. These rate constants were of the same order of magnitude 
in frontal cortex and striatum under control conditions. Administration 
of morphine 30 min after aMpT treatment increased the rate constant by 38% 
in the frontal cortex, while after the reversed treatment, viz. morphine 
30 min before aMpT, a larger increase of 69% was observed. In the striatum, 
on the other hand, no difference in rate constants was revealed when mor-
phine was administered after aMpT, while an increase of 37% was observed 
after treatment with morphine 30 min before aMpT. Therefore, administration 
of morphine after aMpT induced an increased rate of DA loss in the frontal 
cortex and had no effect in the striatum, while inversion of the treatment 
with morphine and aMpT induced an additional increase in the rate constant 
of 31% in the frontal cortex and an increase of 37% in the striatum. This 
latter increase was statistically significant, as can be seen by comparing 
the !'IRate constants (table 3), while the increase in rate constant in the 
frontal cortex of 31% was not statistically significant. 
DISTRIBUTION OF DA AND NA IN THE FRONTAL CORTEX 
c 
~· Subdissection of the frontal cortex. See Materials and Methods 
11 Subdissection of the frontal cortex11 for detailed description. 
Abbreviations: C.A.: commissura anteriora; O.C.: optic chiasm ; STR: 
striatum; l.O.T.: lateral olfactory tract. Nuf!Jbers of the dissected areas 
correspond with table 6. Figures modified from· Gispen et al. (15}. 
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Fig. 1 shows the dissection of the frontal cortex. The areas 1 and 2 
contain the dopamine terminals of frontal cortex and anterior cingulate 
cortex respectively, while area 3 probably contains dopamine terminals in 
the transit'1on zone between neocortex and pi r"1form cortex as described 
by Lindvall et al. (22). Table 6 shows, that most of the DA (ca 80%) in the 
total frontal cortex originates from basal parts of the forebrain (area 4), 
which contains much less NA. The other areas contribute only minor amounts 
to the DA of the total frontal cortex, while they contain about 3-4 times 
as much NA. The total frontal cortex contains roughly equivalent amounts 
of DA and NA; the DA concentration (37 ng in 171 mg) of ca 216 ng/g cor-
responds well with other experiments (see table 3 & 4). 
Table 6 
Distribution of DA and NA in Dissected Ar-eas of the Frontal C.ortex. 
DA NA DA/NA 
a 
area t'1 ssue ng % ng % 
weight (mg) 
82 :+:.7 1.4+0 .1 4.2+0.6 7 .9:+:.0 .2 23 .1:+:.0 .3 0.18 
2 28. 4:+:.1. 7 1 .8+0 .3 5 .2:+:.1.1 6 .4:+:.0 .3 18.6:+:.0. 7 0.28 
3 50 +2 3 .8:+:.0 .6 1 0 .9:+:.1 . 7 17 .2:+:.0 .4 50 .4:+:.1 .2 0.22 
4 10.9:+:.0.9 30 +6 80 :+:.3 2. 7:+:.0 .3 7 .9:+:.0 .8 3. so 
Tota 1 171:+:.1 0 37:+:.6 100 34.2:+:.0.6 I 00 1.08 
a. Numbers as indicated in fig. 1. 
All values represent mean~ S.E. of the absolute amount of amine, n = 5. 
DISCUSSION 
The present experiments show that morphine, administered during 
complete inhibition of DA synthesis, enhances the decline in DA levels in 
the frontal cortex but not in the striatum (table 3). However, in the 
experiment shown in table 4 an enhanced disappearance of DA was also 
observed in the striatum. 
A possible interpretation of these contradictory observations could be 
that morph"1ne causes a marginal increase in DA loss in the striatum, which 
only occasionally exceeds the experimental error. To test this possibility 
the levels of the DA metabolites HVA and DOPAC were analysed under exactly 
the same experimental conditions, to obtain another indication of possible 
increased DA release. Morphine treatment, however, fai Jed to increase the 
concentration of either metabolite in the striatum. Moreover, no effect of 
morphine was observed on the decline in DA in five similar series of ex-
periments (table 3 (14, 23)) nor in an experiment utilizing a dose range of 
morphine from 2t to 40 mg/kg (24). The enhanced DA decline in the frontal 
cortex, on the other hand, was clearcut and reproducible (table 3 & 4 (14)). 
Morphine, therefore, does not seem to affect DA release in the striatum, 
in contrast to the frontal cortex, when the biosynthesis of DA has been 
entirely inhibited. Nevertheless, it might be possible that the rats in 
the experiment reported in table 4 belong to a different population with 
respect to the action of morphine. In favour of this suggestion is the 
smaller rate constant of DA decline observed in striata of saline treated 
rats, when compared with the values from the experiment reported in table 3, 
presumably reflecting a lower basal activity of the striatal neurons. 
lt has been reported elsewhere that morphine causes release of DA in the 
striatum when the impulse flow is inhibited (23). lt is possible that a 
similar effect is exerted by morphine when the basal activity of the 
dopaminergic neurons is as low as in the experiment reported in table 4. 
I nversed administration of morphine, i.e. 30 min before instead of 
30 min after aMpT, on the other hand, resulted in an increased DA decline 
in the striatum, which is in agreement with the observations of Puri et 
al. (11) and Sugrue (10). This enhanced loss of DA in the striatum can 
not, in all probability, be ascribed to increased DA release (25), since 
increased DA release would also have been observed when morphine was 
administered after aMpT. Moreover, the enhanced loss of DA can not be 
attributed to increased catabolism of DA (6) for the same reason and also 
because no increase was observed in metabolite levels (table 5). It has 
been suggested that catabolism of newly synthesized DA in particular, is 
stimulated by morphine (6). If so, this would not have been observed in 
the present experiments because of the prior treatment with aMpT. The 
increase in DA concentration 30 min after morphine administration (2, 12, 
26), however, seems to ·Indicate that DA biosynthesis is stimulated before 
DA catabolism, rather than the reverse. This is in accord with direct 
observations of increased DA biosynthesis in rat striatum after morphine 
treatment (1, 2, 3). Increased levels of HVA and DOPAC after morphine 
administration (6, 7, 9) might then be secondary to this increased bio-
synthesis of DA. This would also be in 1 ine with the present observation 
that there are no increases in HVA and DOPAC concentrations when the 
synthesis of DA is inhibited by aMpT. 
The stimulation of DA biosynthesis in the striatum by morphine, however, 
was not accompanied by changes in any indirect parameter of DA receptor 
stimulation (3, 27), a fact which is in accord with the present direct ob-
servation that DA is not released by morphine. We conclude, therefore, that 
morphine does not affect DA release and catabolism in the striatum, but 
directly stimulates DA biosynthesis. 
As morphine does not alter tyrosine hydroxylase activity in striatal 
homogenates (3, 28), it is tempting to suggest that the increased DA 
synthesis in vivo is caused by a factor which is lost in these in vitro 
assays. This suggestion is also substantiated by the observation of in 
creased tyrosine hydroxylation in striatal slices of mice (29). Such a 
factor wh"1ch "1s lost in vitro could be a change in precursor ava"1lability 
(2) or a shift in the equilibrium of membrane-bound and soluble tyrosine 
hydroxylase (30), but other factors may be involved as well. 
The increased biosynthesis of DA seems to be a common effect of 
morphine in al 1 dopaminergic brain structures, since it has been observed 
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in the hypothalamus, midbrain (4) and n. accumbens (5). Moreover, in-
creased levels of HVA and DOPAC, indicating increased biosynthesis of DA, 
have not only been observed in striatum and n. accumbens, but also in the 
tuberculum olfactorium (9) and in the frontal cortex (31). 
The present results suggest that apart from the general enhancement 
of DA biosynthesis, morphine also exerts another effect on dopaminergic 
neurons in the frontal cortex, since an enhanced decline in DA levels was 
also observed in this structure when morphine was administered after aMpT. 
lt might be argued, however, that this effect of morphine is due to an 
incomplete inhibition of DA synthesis at the moment of morphine injection. 
This might not have been detected in an earlier experiment in which it was 
shown that DA biosynthesis in whole rat brain is completely inhibited 30 
min after administration of a:MpT (14). The present results, however, show 
that the inhibition of DA synthesis in the frontal cortex and striatum 30 
min after a:MpT amounted to the same value as 60 min after a:MpT. The calcu-
lated inhibition in the frontal cortex did not surpass 90%, as in the 
striatum, but this can be ascribed to the 1 imitations of the techniques 
employed. The radioactive DA formed in the frontal cortex of control rats 
only amounted to about 1% of the radioactive tyrosine present, while in the 
striatum it amounted to more than 20%. Since, in a:MpT treated rats, only 
about 100 cpm was counted in the DA fraction of the frontal cortex, most or 
all of this radioactivity could be accounted for by contamination from the 
tyrosine fraction (about 30,000 cpm). Thus 1 the synthesis inhibition of 
85-90% observed in the frontal cortex is the maximal obtainable value. The 
results, therefore, do not necessarily indicate that there is a real dif-
ference in the inhibition of DA biosynthesis by a:MpT between the two struc-
tures. 
Since naloxone antagonizes the increase in DA loss in the frontal 
cortex, this effect seems to be specific for morphine. Most probably 
the increase in DA loss reflects an enhanced release of DA 1 but it is not 
possible to conclude from the present experiments whether this was due to 
an increased impulse flow or to a direct action of morphine on the nerve 
terminal. It is tempting to accept the latter explanation, since this 
would line up with morphine 1 s releasing action in the striatum 1 as ob-
served after inhibition of the impulse flow (23). 
Morphine, therefore, seems to exert two separate effects on dopa-
minergic neurons under the conditions used in these studies: i). an in-
crease in DA biosynthesis, common to most or al 1 dopaminergic brain 
structures and i i) an increased release of DA in the frontal cortex( and 
tuberculum olfactorium unpublished observations), but not in the striatum 
and then. accumbens (23). This dual effect of morphine might be an 
important clue to the interpretation of functional effects of this 
drug on dopaminergic neurons. Papeschi et al. (12) suggested, on the 
basis of similar experiments to those reported here, that it is unlikely 
that morphine alters the functional attivity of dopaminergic neurons. 
These authors studied whole rat brain and because their results are in 
keeping with our observations in the striatum 1 which contains the bulk 
of whole brain DA, their suggestion seems to apply to this brain structure. 
Since morphine enhances DA release in the frontal cortex and tuberculum 
olfactorium under the same conditions, it in fact does alter the 
functional activity of dopaminergic neurons, but not those in the striatum 
and n. accumbens. The frontal cortex and tuberculum olfactorium and 
possibly other extrastriatal structures, which were not investigated, 
are probably of more importance therefore, for morphine-induced effects 
related to the functional activity of dopaminergic systems, such as 
catalepsy (6,8). This suggestion has also been made by others (32, 33). 
In this context, it is of interest to know which dopaminergic nerve ter-
minals were actually included in the fro11tal cortex, as defined in these 
experiments. As can be seen from fig. 1 and table 6, most of the DA (80%) 
orginates from basal parts of the forebrain (area 4). Therefore, the 
results obtained with the frontal cortex in the present experiments can 
probably be ascribed to processes in this dopaminergic area and not in 
the frontal (area 1) or anterior cingulate cortex (area 2), as described 
by Lindvall et al. (22). The origin of the DA in area 4 rema'1ns to be 
established. It should be stressed that the utmost care was taken not to 
contaminate the frontal cortex with tissue from the tuberculum olfacto-
rium, n. accumbens or striatum. Moreover, the reproducibility of the 
amount of DA obtained from the frontal cortex or area 4, does not seem 
compatible with contamination by small pieces of tissue containing high 
concentrations of DA. 
Equal amounts of DA and NA were found in the total frontal cortex. 
Since the amount of DA present as the percursor of NA in noradrenergic 
neurons has been calculated to be less than 4% of the NA present(34) ,· 
more than 95% of the DA is presumed to originate from dopaminergic neurons 
in the frontal cortex. The results show that area 4 contained even con-
siderably more DA than NA, indicating that we were dealing with dopaminer-
gic neurons. 
In conclusion, morphine seems to increase DA biosynthesis, regardless 
of the dopaminergic brain structure(1-4)and also causes release of DA from 
neurons in the frontal cortex and tuberculum olfactorium, but not from 
neurons in the striatum and n. accumbens. 
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IV 
MORPHINE: A MODULATOR OF DOPAMINERGIC NEUROTRANSMISSION IN THE RAT 
2. COMPARISON WITH THE EFFECT OF HALOPERIDOL IN THE STRIATUM AND 
N. ACCUMBENS AFTER MANIPULATION OF THE IMPULSE FLOW 
ABSTRACT 
The present experiments show that. morphine administration results in 
dopamine (DA) release in the striatum, but only when the impulse flow is 
interrupted by means of a lesion of the dopaminergic eel 1 bodies or when 
the impulse flow is decreased by administration of apomorphine. Morphine 
had no effect on DA release when the impulse flow was normal nor when 
the impulse flow was increased by haloperidol treatment. Haloperidol 
increased DA release from the striatum at normal impulse flow, but this 
effect disappeared after a lesion of the dopaminergic eel 1 bodies. In 
the n. accumbens, qualitatively simi Jar drug effects were observed, 
although morphine seemed to have a stronger and haloperidol a weaker 
effect. 
These results suggest that morphine releases DA by a direct effect 
on dopaminergic neurons. It is suggested that this releasing effect is 
overwhelmed by the impulse-flow-coupled release at normal or increased 
impulse flow. An underlying mechanism for this observation is proposed. 
It is also concluded from the present resultsthat haloperidol-induced DA 
release involves a striatonigral feedback pathway rather than a local 
receptor-mediated feedback. Moreover, in our rats, DA release induced 
by morphine in the frontal cortex and tuberculum olfactorium seems to 
predominate over that in the striatum and n. accumbens under normal 
conditions. It is suggested, however, that this dominance is dependent 
on the state of activity of the dopaminergic systems involved. 
The implications of these mechanisms for behavioural effects of 
morphine are discussed. It is concluded that morphine does not have an 
independent effect on dopaminergic neurons, but is a modulator of dopa-
minergic neurotransmission and dopamine-dependent behaviour. 
INTRODUCTION 
Morphine has been reported to considerably increase the turnover of 
DA in the rat striatum (1, 2, 3, 4, 5}. Following the recent reports 
that morphine does not alt~r the rate of DA decline in the rat striatum, 
when the drug is administered 30 min after a-methyl-para-tyrosine methyl-
ester (aMpT) (6, 7, B), it was suggested that the increase in turnover 
reflects a direct stimulation of DA biosynthesis (8, 9). Since an in-
crease in the rate of DA loss was induced by morphine in the frontal 
cortex as opposed to the striatum (6, 8), it was not clear whether this 
apparent DA-releasing action of the drug in the frontal cortex was absent 
in the striatum or whether it was also present in the striatum but was 
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counteracted in one way or another. The following considerations are of 
significance in this respect. 
An effect of morphine on DA decline was occasionally obtained in the 
striatum (8) and in these experiments the striatal dopaminergic neurons 
seemed to have a lower basal activity. A possible explanation for this 
might be that morphine releases DA only when the neurons involved are 
relatively inactive. Furthermore, it has been suggested that morphine 
stimulates an inhibitory input to the nigra-striatal dopaminergic 
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neurons (10). Also Gessa et al. (11) have suggested that another narcotic 
analgesic, methadone, might have dopamine agonistic as wei 1 as anta-
gonistic properties in the rat; and Kuschinsky and Hornykiewicz (12) 
concluded that morphine releases DA in the striatum of mice, but not 
rats. This led us to the hypothesis, that morphine induces DA release 
in the striatum of the rat as in the frontal cortex, but simultaneously 
inhibits the same neurons. These effects would cancel each other out in 
normal rats. We have, therefore, analysed the effect of morphine on DA 
decline in the rat striatum after manipulation of the nervous impulse 
flow. 
It was anticipated that morphine would increase the loss of DA when 
the impulse flow was decreased, while it would inhibit DA decline during 
increased impulse flow. 
MATERIALS AND METHODS 
Male, albino Wistar rats were purchased from TNO, Zeist, The 
Netherlands. Animals used for lesion experiments weighed 195-205 g, for 
other experiments 100-135 g. The first treatment ( aMpT injection or 
decapitation) of al 1 animals was carried out between 9.00 hand 11.30 h 
and treatments were randomized. 
a-Methyl-para-tyrosine methylester.HCl ( aMpT, AB Labkemi), 200 mg/ 
kg as base and Morphine.HCl 20 mg/kg, were dissolved in 0.9% NaCl, 
Haloperidol (Janssen Pharmaceutica, Beerse, Belgium), was dissolved in 
a few drops of acetic acid, diluted with 0.9% NaCl and the pH adjusted 
to 4-5 with NaOH. Apomorphine.HCl (Sandoz A.G., Basel, Switzerland) 
was dissolved in 0.9% NaCl containing 0.2 mg/ml ascorbic acid. In the 
experiment with apomorphine this solvent was utilized for saline 
injections. 
All drugs were injected i .p. in a volume of 5 ml/kg. 
All chemicals were reagent grade. All water used was demineralized 
and subsequently disti 1 led in. an all glass apparatus. 
LESION EXPERIMENT 
Unilateral electrolytic lesions of the right mesencephalic dopaminergic 
eel 1 bodies were made stereotaxically by means of an iron electrode, 1 
mm thick, coated with epoxy varnish except for 0,5 mm at the tip. A 
current of 2 mA was passed through the electrode for 3 min. The coordinates 
of the electrode were 6.6 mm caudal, 2.0 mm lateral and 7-7 mm ventral 
from the bregma. Midbrains were removed at the end of the experiment, 
fixed in formalin and examined histologically for electrode placements. 
All rats were injected with o:MpT 25 min before the lesion was made. 
17 Min after lesioning, morphine (20 mg/kg), haloperidol (1 mg/kg) or 
saline was administered. Most animals at the moment of drug injection, 
had recovered from the 1 ight ether anaesthesia applied before lesioning. 
Rats were decapitated 2 h later. Striata and nuclei accumbens from each 
side of the brain were dissected out as described in 11Dissection11 and 
analysed separately. 
OTHER EXPERIMENTS 
After 30 min aMpT pretreatment morphine (20 mg/kg), apomorphine 
(4 mg/kg), haloperidol (3 mg/kg), saline or indicated combinations of 
these drugs were admin"1stered. Apomorph"1ne (4 mg/kg) injection was re-
peated 60 min later. Rats were decapitated 2t h after aMpT Injection. 
Combined striata of one rat were analysed after dissection as described 
in 11 Dissection 11 • 
DISSECTION 
After decapitation, the brain of the rat was rapidly removed, dis-
sected and frozen in 1 iquid nitrogen within 4 min of decapitation. 
Striata were dissected out according to Gispen et al. (13) and nuclei 
accumbens according to Hornet al. (14). 
ASSAYS AND STATISTICS 
Dissected brain areas were weighed before homogenization. Mean wet 
tissue weights are reported in the legends to the figures. 
Assay of striatal DA 
Striatal DA was isolated on Alz03 and assayed fluorimetrically as 
reported earlier (8). Recovery of 0.5 ).lg DA added to brain tissue extracts 
was 66 + 4.2% (~S.D., n = 8). 
Assay of DA inn. accumbens 
Since the fluorimetric method is not sufficiently sensitive, DA in 
n. accumbens was assayed by a radiochemical method (15) as modified by 
Versteeg et al. (16). 
Statistics 
DA concentrations are expressed as ).lg/g wet tissue weight without 
corrections for recovery. Rate constants were calculated according to 
Brodie et al. (17). 
Differences between DA levels in the lesion experiments were analysed 
by means of Duncan 1 s new multiple range test (18) and in the other 
experiments by means of two-tailed Student 1 s t-test. Differences between 
rate constants were tested with two-tailed Student 1 s t-test. Values of 
p less than 0.05 were considered significant. 
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RESULTS 
EFFECT OF MORPHINE AND HALOPERIDOL ON DA DECLINE IN STRIATUM AND N, 
ACCUMBENS AFTER A LESION OF THE MESENCEPHALIC DOPAMINERGIC CELL BODIES 
Lesion of the mesencephalic cell bodies, after inhibition of DA bio-
synthesis, reduced the decline in DA virtually to zero in both striatum 
CONTROL 
SALINE 
MORPHINE 
HALOPERIDOL 
C=:J CONTROL SIDE 
~ LESIONED SIDE 
2 
STRIATUM 
3 4 
DA p.g/g 
5 
l 
N.S. 
J 
N.$. 
.. 
N.S. 
6 
0.292 ' 0.0394 
0.011 . 0.0399 N.S. 
0.266 > 0.0329 
0.095 + 0.0274 <0.005 
0.433 . 0.0295 
0-013 ~ 0.0495 N.S. 
k(hr-1) p(k=Ol 
Fig. 1a. Effect of morphine and haloperidol on the aMpT-induced 
decline in DA in the striatum of rats with unilateral lesion of the 
mesencephalic dopaminergic eel 1 bodies. Values represent mean + S.E., 
number of observations are indicated at the base of the columnS. DA 
concentrations in the lesioned side (hatched bars) and control side 
(open bars) are given at the moment of drug administration (CONTROL, 42 1 
after aMpT) and 2 h later after saline, morphine (20 mg/kg) or haloperidol 
(1 mg/kg) treatment. See also Materials and Methods 11 Lesion Experiment 11 • 
Statistics: Duncan 1 s new multiple range test and Student 1 s t-test for 
p (k,.,O): n.s.: p >0.05; $: p <0.05; $$: p <0.01 when compared with the 
appropriate saline controls. All DA levels in control sides were signifi-
cantly different from lesioned sides and from DA levels in CONTROL 
(p<0.01). 
Mean wet tissue weight was 46.1 ~ 5.3 mg (~S.D., n"" 60). 
and n. accumbens, as shown in fig. 1. Morphine (20 mg/kg) then induced a 
loss of DA in both structures on the lesioned side, as evident from the 
fall in DA levels and from the rate constants, which were significantly 
different from zero, in contrast to saline treated rats. Haloperidol 
(1 mg/kg) was without effect on the lesioned side. This drug, however, en-
hanced the normal rate of DA loss in the control side in both structures, 
while at this side morphine was without effect. 
CONTROL 
SALINE 
MORPHINE 
HALOPERIDOL 
c=J CONTROL SIDE 
~ LESIONED SIDE 
2 3 
N.ACCUMBENS 
4 s 
OA p.g/g 
l 
N.$. 
J 
N.S. 
•• 
• 
N.S. 
0.466 ' O.OS65 
_0.011 ' 0.0493 N.S. 
0.428 '0.0341 
0.209 !0.0641 <0.01 
0.583 ! 0.0533 
0.014 : 0.0548 N.S. 
k(hr-1) p(k=o) 
Fig. lb. Effect of morphine and haloperidol on the aMpT-induced 
decline in DA in then. accumbens of rats with unilateral lesion of the 
mesencephalic dopaminergic cell bodies. Values represent mean+ S.E., 
number of observations are indicated at the base of the columnS. DA con-
centrations in the lesioned side (hatched bars) and control side (open 
bars) are given at the moment of drug administration (CONTROL, 42 1 after 
aMpT) and 2 h later, after saline, morphine (20 mg/kg) or haloperidol 
(1 mg/kg) treatment. See also Materials and Methods 11 Lesion Experiment 11 • 
Statistics: Duncan's new multiple range test and Student's t-test for 
p (k=O): n.s.: p >0.05; .$: p <0.05; ••= p <0.01 when compared with the 
appropriate saline controls. All DA levels in control sides were signifi-
cantly different from lesioned sides and from DA levels in CONTROL 
(p <0. 01). 
Mean wet tissue weight was 8.4 + 2.0 mg (~S.D., n = 48). 
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To compare the drug effects in both structures, the rate constants 
were calculated in proportion to the rate of DA decline at the control 
side after saline treatment. These control values of 0.292 h-1 in the 
striatum and 0.466 h-1 in then. accumbens were set arbitrarily at 100%. 
Morphine resulted in a relative rate of DA loss on the lesioned side of 
33% in the striatum as against 45% in the n. accumbens. Haloperidol, on 
the other hand, increased the rate constant on the unlesioned side to 
148% and 125% in the striatum and n. accumbens, respectively. 
CONTROL 
SALINE 
APOMORPHINE 
c==J SALINE 
~MORPHINE 
STRIATUM 
4 
OA ,ugfg 
N.S. 
5 
0.310 '0.0291 
0.356' 0.0326 
0.149. 0.0296 
0.210 . 0.0217 
Fig. 2. Effect of morphine on the aMpT-induced decline of DA in the 
striatum of rats, simultaneously treated with apomorphine. Values re-
present mean S.E., number of observations are indicated at the base of 
the columns. CONTROL: DA level at the moment of aMpT administration. 
DA levels 2 h after saline (open bars) or morphine (20 mg/kg, hatched 
bars) administration are given for rats simultaneously treated with 
saline or apomorphine (2 x 4 mg/kg). These drugs were injected 30 min 
after a MpT. See a 1 so Materia 1 s and Methods 110ther Experiments 11 • 
Statistics: Student 1 s t-test, n.s.: p >0.05; •: p <0.005 when compared 
with appropriate saline. DA levels of apomorphine treated rats signifi-
cantly differed from the appropriate saline controls (p <0.001). Striata 
of one rat weighed 105 + 8.3 mg (.!,S.D., n = 29). 
EFFECT OF MORPHINE ON THE DECLINE OF DA IN STRIATUM OF RATS SIMULTANEOUSLY 
TREATED WITH APOI10RPHINE OR HALOPERIDOL (FIG. 2 & 3 
The rate of DA decline in the striatum was reduced to about 50% of the 
control value by two injections of 4 mg/kg apomorphine. Morphine caused 
an increase in the rate of DA loss in apomorphine but not in saline 
treated rats (fig. 2). 
Haloperidol (3 mg/kg), on the other hand, increased the rate of DA 
loss to 162% of the control value. Simultaneous treatment with morphine 
was without effect in haloperidol as wel 1 as saline treated rats. 
C==:J SALINE 
~MORPHINE 
STRIATUM 
N.S. 
N.S. 
4 
OA !'-919 
5 6 
0.323. 0.0184 
0.351 '0.0326 
0.523. 0.0311 
0.523. 0.0276 
k (l'lr-1 ) 
Fig. 3. Effect of morphine on the aMpT-induced decline of DA in the 
striatum of rats simultaneously treated with haloperidol. Values represent 
mean+ S.E., number of observations are indicated at the base of the 
columns. CONTROL: DA level at the moment of aMpT administration. DA levels 
2 h after saline (open bars) or morphine (20 mg/kg, hatched bars) ad-
ministration are given for rats simultaneously treated with saline or 
haloperidol (3 mg/kg). These drugs were injected 30 min after aMpT. See 
also Materials and Methods 110ther Experiments 11 • 
Statistics: Student 1 s t-test, n.s.: p >0.05 when c_ompared with the 
appropriate saline. DA levels of haloperidol treated rats significantly 
differed from the appropriate saline controls ( p <0.001). Striata of one 
rat weighed 101 + 8.4 mg (~S.D., n = 34). 
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DISCUSSION 
The present results show that morphine administration results in 
release of DA in the rat striatum, when the impulse flow of the nigra-
striatal pathway is reduced. Interruption of the impulse flow, by means 
of a lesion of the cell bodies, resulted in complete inhibition of basal 
DA release. Under these conditions, morphine could not produce further 
inhibition of DA release and consequently, its releasing effect was 
uncovered. This was also the case when the basal DA release was reduced 
to about ca 50% by apomorphine. Since al 1 communication with other 
neuronal systems is presumably eliminated by interruption of the impulse 
flow, the morphine-induced release probably resulted from a direct action 
on dopaminergic neurons. At normal impulse flow, however, no release of DA 
was induced by morphine. 
These observations support the hypothesis that morphine simultaneously 
stimulates and inhibits release of DA by two independent mechanisms (see 
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Fig. 4. Impulse flow dependent 
effect of morphine on DA release 
in the striatum. Compilation 
of data of figures 1 - 3 . The 
concentration of DA 2~ h after 
aMpT treatment was set to 100% 
for each experiment and the DA 
concentration obtained from rats, 
treated in addition with other 
drugs or lesloned in addition, 
were calculated relative to this 
value. Treatments: HAL: haloperi-
dol; SAL: saline; APO: apomorphine; 
LES: lesion. All these treatments 
were either combined with SAL: 
saline or MOR: morphine treatment. 
•: p <0.05 vs corresponding 
treatment without morphine. 
See also figures 1-3. 
Introduction). If two independent effects really do exist, prior increase 
of impulse flow would be expected to result in the predominance of the 
inhibitory effect of morphine. The drug, however, had no effect when DA 
release was considerably increased with haloperidol. Therefore, there does 
not seem to be a balance between two independent effects of morphine. 
Since the drug, apparently, does induce release of DA during reduced 
impulse flow, the results probably indicate that this releasing effect is 
overwhelmed by the normal impulse-flow-coupled release itself as vizual ized 
in fig. 4. As the release induced by morphine is not additive to the 
normal release, both stimuli seem to act through a common mechanism. 
It is tempting to speculate that the 1 iberation of calcium is important 
in this respect, since effects of morphine, as well as stimulation-induced 
catecholamine release, are dependent on the presence of this ion (19). 
Morphine has also been shown to induce a rapid depletion of calcium 
from brain tissue (20). This might also account for the independent 
stimulation of DA biosynthesis exerted by morphine (see Introduction), 
since increased intrasynaptosomal calcium has been shown to activate 
tyrosine hydroxylase through increased membrane association (21). It is 
suggested, therefore, that morphine 1 iberates calcium in dopaminergic 
nerve endings resulting, separately, in increased DA biosynthesis and in 
release of DA, which is dependent on the impulse flow of the dopaminergic 
neurons. 
Acceptance of this hypothesis,in favour of that advanced in the 
Introduction, relies mainly on the observation that morphine had no effect 
when the impulse flow was increased by haloperidol (vide supra). It 
might be argued that morphine increases DA release by blockade of DA 
receptors (22). Since haloperidol blocks DA receptors, additional morphine 
treatment would then have no effect. It was observed, however, that 
haloperidol accelerated DA decline, in contrast to morphine, when the drug 
was administered after aMpT. This effect of haloperidol is probably the in-
direct result 9f receptor blockade, since haloperidol has been shown to 
increase impulse flow in the nigrostriatal pathway (23). Moreover, morphine 
caused release of DA from lesioned neurons, unlike haloperidol. These 
observations support the suggestion that morphine releases DA by a direct 
action on dopaminergic neurons rather than by receptor blockade. Thus, 
morphine does not act through the same mechanism as haloperidol .and this 
seems to val I date therefore, the suggestion that DA release, induced by 
morphine, is dependent on the impulse flow of the dopaminergic neurons. 
The observation that haloperidol accelerated DA decline when ad-
ministered after aMpT also shows that receptor blockade causes DA release 
which is independent of the increase in DA biosynthesis (24, 25), since 
DA b"1osynthesis was ent"1rely inhib'1ted in the present experiments. 
Similarly, apomorphine reduced DA release which is independent of its 
effect on DA synthesis, in contrast to the suggestion of Goldstein et al. 
(26). 
Another conclusion, concerning feedback control of DA release, can be 
drawn from the present lesion experiment. The observation that there was 
no release of DA on the lesioned side can be taken as an indication of 
the effectiveness of the lesion. !t also indicates, however, that absence 
of impulse flow and consequent lack of DA receptor stimulation does not trig-
ger any local feedback stimulation of DA release.Kehr et al. (24) observed 
feedback regulation of DA biosynthesis in the absence of impulse flow and 
therefore~postulated a receptor-mediated feedback mechanism in the 
striatum. The present results suggest that this receptor-mediated feedback 
only controls DA biosynthesis and not DA release. Moreover, it was 
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recently observed in vitro that acetylcholine induces release of DA from 
striatal slices, which are also obviously devoid of impulse flow (27). It 
was suggested that presynaptic cholinergic receptors may control or modu-
late DA release. Our results, obtained in vivo, however, do not sup-
port this hypothesis. Therefore, DA release, induced by blockade of stria-
tal DA receptors, seems to depend on a striatonigral feedback pathway, 
1 ike increased tyrosine hydroxylase activity, which is also induced by 
blockade of striatal DA receptors (28). Our observation is also in accord 
with the reported increase in the activity of nigral dopaminergic eel ls 
after haloperidol injection (23). 
The drug effects in then. accumbens were similar to those in the 
striatum. Thus haloperidol accelerated DA decline in the unlesioned side, 
while morphine induced DA release in the lesioned side. This was somewhat 
surprising since this mesolimbic brain structure might have been expected 
to react in a manner which was similar to that of the frontal cortex 
where morphine induces release of DA in unlesioned rats (6, 8). Nevertheless 
differences seem to exist between both structures, since the effect of 
haloperidol was stronger in the striatum, while the effect of morphine 
was more pronounced in then. accumbens. The reliability of these 
quantitative comparisons, however, is somewhat weakened by the fact that 
DA concentrations were assayed by different analytical techniques in both 
structures. 
Taking together the results of this and the preceding report (8), a 
complex picture of the interaction of morphine with dopaminergic neurons 
emerges. 
1. Morphine seems to stimulate DA biosynthesis directly in most or 
all dopaminergic structures (8). 
2. Morphine stimulates DA utilization (possibly release) in the 
frontal cortex and tuberculum olfactorium (unpublished results), but not 
in the striatum and n. accumbens of rats with normal impulse flow. 
3. Morphine stimulates DA utilization (probably release) in the 
striatum and n. accumbens of rats with a decreased impulse flow. 
The avera] 1 effect of morphine on dopaminergic systems, therefore, 
can not easily be predicted. It was suggested that the DA releasing effect 
of morphine in the frontal cortex (point 2) indicates that extrastriatal 
dopaminergic structures are of more importance than the striatal for 
morphine-Induced effects like catalepsy (8). 
This applies when impulse flow in the dopamlnergic neurons remains 
unchanged. When some manipulation of the rats, however, decreases impulse 
flow in dopaminergic neurons, then morphine will release DA from these 
neurons (point 3). Such a manipulation is not necessarily a lesion. 
It might be expected that a noxious stimulus would also decrease impulse 
flow in striatal dopaminergic neurons. If this were so, analgesia, in-
duced by morphine, may involve DA release in the striatum. This would be 
in keeping with results implicating stimulation of striatal dopaminergic 
neurotransmission in morphine-induced 3nalgesia (29), or at least in a 
particular analgesic response (30). The point to be stressed is that the 
role of DA in morphine-induced behaviour can not be evaluated when the 
impact of the relevant behaviour~ on the state of activity of 
dopaminergic r.eurons is not known. Morphine, therefore, does not have 
an independent effect on dopaminergic neurons, but is a modulator of 
dopaminergic neurotransmission and dopamine-dependent behaviour. Its 
actual effect on striatal DA neurons depends on the state of activity of 
these neurons. 
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APPENDIX TO PAPER IV 
In an experiment identical to the one reported in fig. 1 of paper IV 
the effect of morphine treatment combined with a lesion of the dopaminergic 
cell bodies was investigated in the frontal cortex. The aim was to assess 
whether the observed increased loss of DA in the frontal cortex was de-
pendent on the impulse flow. 
The experimental procedure was described in paper IV. Frontal cortices 
were dissected as described in paper Ill and DA was assayed using the 
radiochemical procedure outlined in paper IV. 
FRONTAL CORTEX 
CONTROL 
SALINE 
MORPHINE 
HALOPERIDOL 
0.1 
C:==J CONTROL SIDE 
~ LESIONED SIDE 
0.2 0.3 0.4 
OA !'919 
0.5 0.6 
' • ~ 
~- Effect of morphine and haloperidol on the ~MpT-induced decline 
of DA in rats with unilateral lesions of the mesencephalic dopaminergic 
cell bodies. Values represent mean+ S.E., number of observations are 
indicated at the base of the columnS. DA concentrations in the lesioned 
side (hatched bars) and control side (open bars} are given at the moment 
of drug administration (CONTROL, 42 1 after o:MpT) and 2 h later, after 
saline, morphine (20 mg/kg) or haloperidol (1 mg/kg) treatment. See also 
Materials and Methods IV 
Mean wet tissue weight was 109.1 + 13.4 mg {~S.D., n ~, 68}. 
* p <0.05, Student 1 s t-test. 
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Fig. 1 shows the result of this experiment. The concentration of DA 
on the lesioned side strongly increased in control rats when compared 
with the unlesioned side. The value of 289 + ng/g DA on the unlesioned side 
in these rats is in the range normally obsefved {II, Ill). The lesion, 
therefore, induced an almost twofold increase in DA levels in 17 min, an 
effect not observed in the striatum and n. accumbens (IV). The origin 
of this effect is obscure, since the prior blockade of DA biosynthesis 
must be assumed to prevent any increase of OA levels. It has been shown 
that DA synthesis is completely blocked during the period of observation 
(II), and this is also true in the frontal cortex (Ill). 
A possible explanation of the observed effect could be that interrup-
tion of the impulse flow abel ishes the inhibitory effect of the false 
precursor aMpT on the biosynthesis of DA. This, however, seems very 
improbable, since it would need a tremendous increase in DA biosynthes'1s 
in order to obtain in 17 min DA levels which are twice the normal. Moreover, 
this would not occur in the dopaminergic neurons projecting to the striatum 
and nucleus accumbens after the same treatment (I!!). An artifact has to 
be considered, therefore, to account for this observation. 
Whatever the cause may be for the observed increase in DA levels 
shortly after a lesion, the effects of drug treatments as shown in fig. 
can not be interpreted properly due to the observed effect of the lesion 
procedure itself. 
II 
!t has been shown that morphine does not affect DA release in the 
striatum of the rat, when the drug was administered 30 min after aMpT. 
This distinguished the striatum from the frontal cortex, where an in-
crease of DA decline was observed (II, II!). A follow-up study showed 
that morphine also had an effect on DA release in the striatum, but this 
effect was dependent on the state of activity of the neurons involved 
(IV). When the decline of DA was blocked by a lesion of the mesencephalic 
dopaminergic eel 1 bodies or inhibited by pretreatment with apomorphine, 
morphine induced loss of DA in the striatum, while at normal or increased 
impulse flow morphine had no effect (IV). In then. accumbens similar 
effects of morphine were observed. Whether other dopaminergic brain struc-
tures react alike to manipulation of the impulse flow, was not assessed. 
The present experiments provide a preliminary indication that the effect 
of morphine in the tuberculum olfactorium (T.O.) may not be dependent on 
the state of activity of dopaminergic neurons in the same way as in the 
striatum. 
The effect of morphine, in combination with haloperidol or apo-
morphine, on DA decline in the T.O. was investigated in an experiment 
identical to those described in paper IV. Pooled olfactory tubercles of 
4 rats were analysed for DA content as described elsewhere (Ill). DA 
release was increased by haloperidol In the T.O. and striatum resulting 
in concentrations of DA of 60-70% of controls. Apomorphine, on the other 
hand, inhibited DA decline, resulting in DA levels of 145-150% of con-
trols (table 1). The change in DA release by haloperidol and apomorphine 
in striatum and T.O. was similar, therefore. The effect of morphine 
treatment in relation to pretreatment with haloperidol and apomorphine 
can be read from the difference between saline and morphine treatment 
TABLE 1. 
Effect of Morphine in Combination with Haloperidol or Apomorphine on DA 
Decline in the Tuberculum Olfactorium and Striatum. a 
Pretreatment 
Tuberculum Olfactorium 
Sa 1 i ne 
Morphine 
Saline-Morphine 
p (Saline vs Morphine) 
Striatumd 
Saline 
Morphine 
Sa 1 i ne-Mo rph i ne 
p (Saline vs Morphine 
Haloperidol 
65.0;76.3 
53.1;57.7x 
15.2:!: 6.2 
61.1:!:3.0 (8) X 
60.9:!:2.8 (J)X 
0 .2+4.2 
x p <0.05 vs Saline in middle column 
Sa 1 i ne Apomorphine 
100.0+4.8 (3) b 133.4;158.ox 
88.1:!:3.1 (3) 128.8; 150. 7x 
11.9:!:5.6 5-92: 16.4 
<0.05 
100.0+2.4 (12) c 150.7:!:6.7 (7) X 
92.1:!:3-2 ( 14) 125.7:!:3.2 (8)x 
7-9:!:4.2 25. 0:!:7. 2 
<0.005 
a. Values represent DA concentration + SEM as percentage of controls 
treated 2! h before with aMpT only.-Other drugs were injected 2 h 
before decapitation. 
b. 100% = 1.51 ~g/g DA; DA concentration in untreated rats: 3.43 wQ/g. 
c. 100% = 2.58 wg/g DA; DA concentration in untreated rats: 5,71 wg/g. 
d. from IV. 
(Saline-Morphine, table 1). As reported in paper IV, the effect of morphine 
in striatum increases with decreasing activity of the neurons involved. 
Thus, in combination with haloperidol no effect was obtained, while in 
combinat"1on with apomorphine a s"1gnif"1cant "1ncrease of DA release by 
morphine was observed (table 1). In the T.O., however, only a slight 
increase of DA decline was observed when morphine was administered in 
combination with apomorphine, while a significant effect was obtained 
without pretreatment. This effect was even stronger in combination with 
haloperidol, although it was not statistically significant.(p~0.12). 
Thus, in the T.O. the effect of morphine does not seem to increase with 
decreasing impulse flow and the opposite can even not be excluded. 
Although it is difficult to draw firm conclusions on the basis of the 
present data, the observations indicate that it might be worth-while to 
study the DA releasing effect of morphine in relation to the state of 
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activity of the dopaminergic neurons in more brain structures than has so 
far been attempted. It has been suggested that such state-dependent 
effects of morphine may provide an important clue for the interpretation 
of contradictory results in different behavioural responses to the drug 
(IV). If in addition this state-dependency would differ in various brain 
structures, an accurate analysis of these interactions is indispensible 
for a correct correlation of cellular and molecular effects of morphine 
to its behavioural effects. 
v 
MORPHINE CATALEPSY IN RELATION TO STRIATAL AND EXTRASTRIATAL DOPAMINE 
ABSTRACT 
When morphine (20 mg/kg i .p.) was administered to rats 30 min after 
treatment with an inhibitor of dopamine biosynthesis (a-methyl-para-
tyrosine), it induced strong catalepsy. However, no effect on the decline 
of dopamine was observed in the striatum under these conditions. If 
morphine catalepsy is caused at the level of the striatum only dopamine 
receptor blockade is compatible with these results. On the other hand did 
morphine increase the decline of dopamine in the frontal cortex. The 
results suggest, that mesolimbic dopaminergic systems might be involved 
in the generation of morphine catalepsy. 
INTRODUCTION 
One clear-cut result of acute narcotic treatment of the rat is an in-
crease of dopamine turnover In the striatum (1 ,2). Moreover, evidence has 
been presented to correlate this effect to a definite behavioural effect of 
narcotics viz. their cataleptogenic action (3,4). Main arguments for this 
correlation are an antagonism of morphine catalepsy by dopamine agonists 
like apomorphine and L-DOPA (3) and the parallel'1sm between neuroleptic 
and narcotic catalepsy (5,4). Neuroleptics also cause a catalepsy and an 
increase in dopamine turnover. Since this catalepsy is suggested to result 
from a blockade of dopaminergic receptores in the striatum (6), narcotics 
are considered to antagonise dopaminergic transmission in the striatum, too 
(7 '5 ,3) . 
However, closer analysis of these facts also reveal a number of dis-
crepancies between the action of narcotics and neuroleptics with respect 
to catalepsy and dopamine turnover. Narcotic catalepsy is associated with 
a muscular rigidity while catalepsy induced by neuroleptics is often 
accompanied by hypotonia. Furthermore, narcotic catalepsy is more effecti-
vely antagonised by dopamine agonists than neuroleptic catalepsy (3). As 
far as dopamine turnover is concerned, several differences between the two 
groups of drugs at the molecular level are known, including effects on 
tyrosine hydroxylase, dopamine sensitiveadenylate cyclaseand quantitative 
differences with respect to synthesis rate in vivo (8,5). This led to the 
consideration, that narcotic catalepsy is a dopaminergic phenomenon of 
striatal origin, but with an underlying mechanism different from neurolep-
tic catalepsy (3,5,4). 
Recent observat'1ons '1n our laboratory, however, led us to reevaluate 
the role of striatal dopamine in narcotic catalepsy. We studied the effect 
of morphine on the decline of dopamine after a-methyl-para-tyrosine ( aMpT) 
treatment in striatum and frontal cortex. Morphine was administered to rats 
30 min after aMpT when the synthesis of dopamine is completely inhibited, 
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so that direct or indirect effects on dopamine synthesis are excluded. 
Under these experimental conditions we oSserved an enhanced decline of 
dopamine in the frontal cortex, but, on the contrary, no effect of morphine 
on dopamine in the striatum could be detected (9). This prompted us to 
study morphine catalepsy under exactly the same conditions, because, if 
an increased dopamine turnover in the striatum is a prerequisite for 
narcotic catalepsy, no catalepsy should be present when morphine is 
administered 30 min after aMpT. 
MATERIALS AND METHODS 
Male, albino Wistar rats (TNO, Zeist, The Netherlands) weighing 100-
130 g were used. The animals were housed 5 in a cage with ad 1 ibitum food 
and water. Lights were on from 7 a.m. to 9 p.m. Experiments were per-
formed between 9 a.m. and 1 p.m. 
a-Methyl-para-tyrosine-methylester.HCl (aMpT, AB Labkemi) was injected 
in a dose of 200 mg/kg as base. Morphine.HCl, naloxone (Endo Laborator'1es) 
or a combination of both was administered 30 min later. Naloxone treated 
rats received a secon'd injection 60 min later immediately after the first 
catalepsy test. All drugs were dissolved in 0.9% NaCl and injected intra-
peritonealy in a volume of 5 ml/kg. 
Catalepsy was tested 1 and 2 hr after morphine administration accord-
ing to Kuschinsky and Hornykiewicz (3). Rats were placed with their fore-
paws on a 7.5 em high bar. T~:ey were considered cataleptic when they 
remained in this position for 30 sec. 
In a separate experiment rats were decapitated 2 h after morphine 
treatment (2~ h after aMpT). Brains were removed and striata dissected 
according to Gispen et al. (10). Striatal tissue was homogenized in 10 ml 
ice-cold 0.4 N perchloric acid containing 0.5% EDTA and 0.05% Na2S205 and 
centrifuged at 25,000 g for 15 min at 20 C. Dopamine was absorbed to 
Aluminiumoxide according to Weil-Malherbe (11) and eluted with 3 ml of 1 N 
HCl (containing 1 mg/1 ascorbic acid and 10 mg/1 EDTA) in a batch procedure. 
Dopamine was assayed according to Atack (12) in 1 ml aliquots of the eluate. 
RESULTS 
Morphine in a dose of 20 mg/kg caused a significant catalepsy 60 min 
after administration (table I). This effect had disappeared after 120 min. 
When the rats were pretreated with aMpT 30 min before morphine an even 
greater number of rats showed catalepsy at 60 min and this number de-
creased but was still significant 120 min after morphine injection. aMpT, 
therefore, intensifies the catalepsy induced by morphine, while it does 
not cause any catalepsy per se. Moreover, the cataleptic effect of morphine 
was blocked by simultaneous treatment with naloxone, indicating the 
specificity of the effect (Table 1). 
Administration of graded doses of morphine did not signif'1cantly 
affect the dopamine decline in the striatum of rats pretreated with aMpT 
30 min before morphine. Dopamine concentrations dec I ined from 4.99 + 
0.22 ~g/g (mean~ S.E., n = 6) at the moment of morphine injection-
Table I 
Catalepsy !nduced by Morphine after Inhibition of Dopamine Synthesis. 
Treatment Catalepsy 
Time -30 min 0 min 60 min 120 min 
Saline 0/12 0/12 
Morphine a 7/12* 2/12 
aMpTc Sa 1 i ne 0/12 0/12 
aMpTc Morphine a 10/12* 6/12* 
o:MpTc Naloxone b 0/12 0/12 
aMpT Morphinea + 1 /12xx 1/12x 
Naloxoneb 
Fisher exact probabi1 ity test: 
* Different from saline cant ro 1 ; p < 0.01 
X Different from morphine treatment; p <0.05 
xxDifferent from morphine treatment; p < 0. 01 
a 20 mg/kg, i .p. 
b 1 mg/kg i .p. Injection was repeated immediately after first catalepsy 
test. 
c a-methyl-para-tyrosine-methylester.HCl, 200 mg/kg as base, i .p. 
to 2.1- 2.5 vQ/g (Fig. 1) 2 hr later. Because morphine causes catalepsy 
at a dose of 20 mg/kg but not at 10 mg/kg or lower, we included lower 
doses than 20 mg/kg for comparison of cataleptogenic and non-catalepto-
genic doses. Besides 40 mg/kg was included to be certain that a 
marginal effect at 20 mg/kg was not missed. However, with none of these 
doses an effect on dopamine was observed. 
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Fig. 1. Dopamine levels in rat striatum 2 h after different doses 
of morphine, administered 30 min after aMpT treatment. Values represent 
mean + S.E. of 7 or 8 determinations. None of the morphine treatments 
gave a value significantly different from control (0 mg/kg);test of 
Dunnett (13), for multiple comparison of several treatments with a 
control. 
DISCUSSION 
The present results show that morphine can induce catalepsy without 
concurrent effect on dopamine turnover in the striatum. This indicates 
that morphine catalepsy is not caused by a presynaptic effect on dopa-
minergic neurons in the striatum, 1 ike diversion of newly synthesized 
dopamine from storage sites to sites of catabolism as suggested earlier 
(3). This emerges from two observations. Firstly, o:MpT does not induce 
catalepsy at points of time that dopam'1ne synthesis is completely 
inhibited. Therefore, a deficiency of newly synthesized dopamine does 
not induce catalepsy ~- Secondly, morphine does induce catalepsy 
even when the synthesis of dopamine is completely inhibited and no 
dopamine is displaced at al 1 in the striatum. The only mechanism at 
the level of the striatum by which morphine may induce catalepsy seems 
to be a blockade of dopamine receptors as suggested by Purl et al. (7). 
Such a blockade would increase dopamine turnover via a feedback on the 
biosynthesis of dopamine. After prior synthesis inhibition by aMpT, 
then, no effect should be found on striatal dopamine turnover as shown 
in the present experiment. 
However, several observations indicate that dopamine receptor 
blockade does not seem to be the cause of narcotic catalepsy (8) or 
at least not the only cause (5). Moreover, Papeschi et al. (14, 15) 
concluded from s'rmi Jar observations as presented here that an inter-
action of morphine with dopaminergic neurotransmission is not likely 
to be the cause of catalepsy at all. This, however is not in agreement 
with the observation that morphine catalepsy is easily antagonized by 
apomorphine (3), which indicates, that it is a dopaminergic phenomenon. 
It is therefore, of significance that under these experimental con-
ditions morphine does enhance the rate of dopamine depletion in the 
frontal cortex, while no effect was detected in the striatum (9). 
A role of mesolimbic dopaminergic systems in morphine catalepsy has been 
suggested recently (16) and is in accord with our observations. 
CONCLUSION 
Although the present experiments do not exclude a blockade of 
dopamine receptors in the striatum as the cause of morphine catalepsy, 
an interaction of morphine with dopaminergic neurotransmission in 
meso] imbic areas of the rat brain should also be considered as the 
origin of the catalepsy. 
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IS MORPHINE-INDUCED CATALEPSY RELATED TO ACTIVATION OF DOPAMINERGIC NEURONS? 
ABSTRACT 
Administration of morphine (20 mg/kg, i .p.), 30 min after a-methyl-
para-tyrosine-methylester ( aMpT) resulted in marked catalepsy, which was 
maximal 40-90 min after inject'1on of morphine. Pretreatment with o.MpT 
did not alter the induction of morphine catalepsy, but prolonged its du-
ration. The effect of several drugs on the catalepsy, induced by morphine, 
after aMpT pretreatment, was investigated. Naloxone, a specific morphine 
antagonist, entirely abolished the morphine-induced catalepsy, while 
apomorphine antagonized this catalepsy for 40 min, when administered 
simultaneously with morphine. Amphetamine, on the other hand, potentiated 
morphine-induced catalepsy and also produced catalepsy directly. Moreover, 
amphetamine-induced sniffing, a major sign of stereotypic behaviour, was 
antagonized by morphine. Atropine, an anticholinergic agent, and bicuccul ine, 
a GABA-receptor blocking agent, were ineffective against morphine-induced 
catalepsy. 
Administration of haloperidol ( 1 mg/kg, i .p.), 30 min after o:MpT, 
resulted in a gradually increasing catalepsy, after repeated testing of 
the rats, but no catalepsy was observed after a single test, regardless 
of the time period between test and haloperidol administration. Thus, 
repeated testing is an important factor in the induction of catalepsy 
with haloperidol. 
The present results indicate the involvement of two dopamine (DA) 
systems in the interaction of morphine with dopaminergic agents. lt '1s 
suggested that morphine may induce catalepsy by activation of aDA 
system other than those projecting to the striatum and n. accumbens. 
The implications of this hypothesis are discussed in relation to the 
interaction of morphine with apomorphine- and amphetamine-induced catalepsy 
and stereotypic behaviour. 
INTRODUCTION 
Catalepsy induced by neuroleptics or by cholinergic agents, has been 
ascribed to an action on the striatum (1, 2). Moreover, it has been 
suggested that catalepsy, induced by different types of drugs, alv•3ys 
involves the dopaminergic (DA) system (3) and that catalepsy is always 
associated with changes in DA metabolism (4). lt has further been suggested 
that neuroleptics block DA receptors, and the resulting increase in turn-
over of DA in the striatum can be explained on the basis of a possible 
feedback mechanism (5, 6). Since opiates increase DA turnover in the 
striatum and also induce catalepsy, it was suggested that opiates may have 
a mechanism of action which is similar to neuroleptics (4, 7, 8). The 
striatal origin of morphine-induced catalepsy, however, has been questioned 
recently, since lesions of the amygdala were shown to reduce morphine-
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induced catalepsy (9). Moreover, it has been reported that morphine does 
not affect DA release in the striatum (10). In fact, these results raise 
some doubt as to whether morphine-induced catalepsy is directly related to 
DA systems . On the other hand, morphine increases DA release in the 
frontal cortex (10), which would favour the suggestion that morphine-
induced catalepsy may involve extrastriatal rather than striatal DA systems 
(9' 11 ' 12) . 
The possible relationship between dopaminergic neurotransmission and 
morphine-induced catalepsy has been assessed indirectly (11). Thus, when 
the synthesis of DA was blocked by aMpT, subsequent morphine administration 
resulted in acceleration of the dec] ine in DA levels in the frontal cortex, 
but not in the striatum (10, 11), while after the same drug treatments 
marked catalepsy was observed (11). The aim of the present study was to 
directly assess whether the morphine-induced catalepsy was related to DA 
systems or not. For this purpose, the effect of dopaminergic or other 
agents was investigated on the catalepsy induced by morphine after O:MpT 
treatment. 
MATERIALS AND METHODS 
Male albino Wistar rats were purchased from T.N.O, Zeist, the Nether-
lands. The animals were housed 4-6 to a cage, with free access to food 
and water. The period of 1 ight was from 7.00 h to 21.00 h, ambient 
temperature was ca 20° C. The animals weighed 100-150 g on the day before 
the experiment. On the day of the experiment the animals were moved to 
a sound attenuated room with background noise produced by a venti Jatar. 
The rats were placed in individual cages at least 30 min before the first 
drug, which was administered between 10.30 h and 11.30 h. 
The following drugs were used: Morphine.HCJ, a-methyl-para-tyrosine-
methylester.HCJ (aMpT, AB Labkemi), Naloxone.HCl (Endo Labs.), Apomorphine. 
HCl (Sandoz A.G.), Atropine-sulphate, Bicuccul ine (K & K Labs.), Halo-
peridol (Janssen Pharmaceutica), and Amphetamine-sulphate. Morphine, 
naloxone, amphetamine and aMpT were dissolved in 0.9% NaCl; apomorphine 
in 0.9% NaCl with 0.2 mg/ml ascorbic acid; bicuccul ine, atropine and 
haloperidol in 0.9% NaCl with 0.2 mg/ml ascorbic acid acidified to 
pH= 1.7 with HCl. Where ascorbic acid or acid drug solutions were used, 
all other drug solutions utilized throughout these particular experiments 
were also made acidic. Al 1 drugs were injected intraperitoneal Jy in a 
volume of 5 ml/kg. Drug doses refer to the salts. Treatment schedules 
were randomized. All drugs were administered 30 min after aMpT pretreat-
ment and injection of naloxone was repeated 60 min later. 
Catalepsy Test 
Catalepsy was measured by the procedure outlined by Kuschinsky and 
Hornykiewicz (8) immediately followed by a slight modification of the 
method of Shore and Doris (13). In the first procedure, both forepaws 
of the rat were placed on a 7.5 em high bar or peg. The rats were considered 
cataleptic when they remained in this position for 30 sec. In the second 
test, each front paw of the rat was placed successively on a 2.5 em and 
7.5 em high peg. A maximum of three points was assigned to a rat which 
always remained in that position for 10 sec (see also Shore and Doris, 13). 
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Since the results of both tests were similar, only the results of the 
second test are presented. The time-course of drug-induced catalepsy 
was assessed by repeated testing of the same subjects at indicated time 
intervals. 
Stereotypy 
In a double blind experiment, utilizing amphetamine and morphine 
(table 1), an experienced technician was instructed to note any behavioural 
signs observed, as wel 1 as performing the catalepsy test according to 
Kuschinsky and Hornykiewicz (8). Straub tail, piloerection and several 
signs of stereotypic behaviour were observed repeatedly, but only sniffing 
could be consistently quantified post hoc. Table 1 shows the number of 
animals in which sniffing was observed. 
Statistics 
Differences between drug treatments were evaluated by means of the 
Wilcoxon rank sum test, or Fisher exact probability test. Values of p 
less than 0.05 were considered significant. 
Table 1 
Interaction of Morphine and Amphetamine on Catalepsy and Stereotypic 
Behaviour after ~MpT Treatment.a 
1 h b 2 h b 
catale~s:r sniffing catale~s:r sniffing 
Amphetamine c + + + + 
Morphine 
( mg/k~) 
0 0 5x 0 9xx 0 2 0 6xx 
5 0 7xx 0 4f 0 4 0 2 
1 0 0 7xx 0 5x 0 3 1f 
20 4f 9x 0 ]ff 7x 1! 
Fischer exact Probabi 1 ity Test: 
X p<0.05, XX p< 0.01 VS corresponding control without amphetamine 
f p<0.05, if p< 0. 01 VS corresponding control without morphine 
a. The numbers indicate those animals which exhibited the symptoms shown 
out of a total of 9 rats. 
b. Time after amphetamine and/or morphine administration. 
c. 15 mg/kg combined w"1th morphine, ·Injected 30 min after aMpT. 
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RESULTS 
Marked catalepsy was induced by morphine (20 mg/kg) when administered 
30 min after aMpT. The catalepsy was maximal 40 to 90 min after morphine 
administration (fig. 1 & 2) and had disappeared after 180 min (not shown}. 
Pretreatment with aMpT did not change the time of onset of the catalepsy 
induced by morphine, but attenuated its disappearance (fig. 1). Catalepsy 
was not observed for up to 270 min after administration of aMpT. The 
specific morphine antagonist, naloxone, entirely abolished the morphine-
induced catalepsy. 
CATALEPSY 
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·-·-\ ~ .. o-\. 
.. 
·~.~ 
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•• 
90 
0 
.. 
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min 
~· Catalepsy induced by morphine after o.MpT pretreatment and 
antagonism with naloxone. Morphine (20 mg/kg) and naloxone (1 mg/kg) were 
administered at to, 30 min after aMpT or saline injection. At 60 min a 
second dose of naloxone (1 mg/kg) was administered. No catalepsy was ob-
served after administration of aMpT alone or in combination with naloxone. 
Number of animals per treatment group: 10. 
•-- • aMpT + Morphine 
c-c Saline+ Morphine 
&---A aMpT +Morphine+ Naloxone 
• p <0.05, ** p <0.01 vs aMpT + Morphine at the corresponding time of 
observation. 
Apomorphine (4 mg/kg), administered simultaneously with morphine 30 
min after aMpT, suppressed the morphine-induced catalepsy for 40 min 
(fig. 2), while apomorphine had no direct effect. Amphetamine, on the 
other hand, potentiated morphine-induced catalepsy when measured 1 and 2 
h after combined administration. Amphetamine, administered 30 min after 
a MpT, without morphine, also induced catalepsy (table 1). 
CATALEPSY 
2 
60 90 120 
min 
Fig. 2. Catalepsy induced by morphine after aMpT pretreatment and 
antagonism with apomorphine. Morphine (20 mg/kg) or morphine and apo-
morphine (4 mg/kg) were administered at t 0 , 30 min after aMpT injection. No catalepsy was observed after aMpT +apomorphine treatment. Number of 
animals per treatment group: 10. 
o--• aMpT +Morphine 
c--o aMpT + Morphine+ Apomorphine 
* p <0.05, **P <0.01 vs aMpT +Morphine at the corresponding time of 
observation. 
Besides catalepsy, amphetamine administration 30 min after aMpT also 
induced sniffing, a sign of stereotyped behaviour, which could be anta-
gonized by morphine (table 1). 
Neither atropine (3 mg/kg) nor bicuccul ine (2 mg/kg) had any effect 
on morphine-induced catalepsy nor did either of these drugs exert a direct 
effect of their own (not shown). 
When haloperidol (1 mg/kg) was administered 30 min after aMpT treatment, 
a gradually increasing catalepsy was observed. The catalepsy was maximal 
at about 120 min after haloperidol injection. No difference was observed 
in haloperidol-induced catalepsy after pretreatment with aMpT when com-
pared with saline pretreatment (not shown). When the rats were tested 
once only, however, no catalepsy was observed even 120 or 180 min after 
haloperidol treatment. Repeated testing, therefore, seems a major factor 
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Fig. 3. Catalepsy induced by haloperidol after aMpT pretreatment 
and the effect of repeated testing. Haloperidol (1 mg/kg) was administered 
at to, 30 min after aMpT injection. Animals were first tested for cata-
lepsy at 20, 60, 120 or 180 min after haloperidol treatment and tested 
again at the time intervals indicated. Number of animals per group: 10. 
* p <0.05 vs the group tested for the first time at 20 min after 
haloperidol injection. 
in the induction of catalepsy after haloperidol treatment. This is also 
evident from the fact that no significant differences were observed 
between the first, second or third catalepsy tests, regardless of the time 
period between test and haloperidol administration (fig. 3). Repeated 
testing of rats treated with aMpT only, however, never resulted in positive 
catalepsy scores. 
DISCUSSION 
The present experiments show that catalepsy induced by morphine after 
a MpT pretreatment, is closely related to the activity of DA systems. 
Thus, morphine-induced catalepsy was antagonized by apomorphine, which is 
in agreement with the reported antagonism produced by apomorphine on 
morphine-induced catalepsy without aMpT pretreatment (8, 12). Recently, 
a relation between GABAergic systems and neuroleptic-induced catalepsy 
has been reported, based on the findings that an increase in brain GABA 
concentrations results in potentiation of haloperidol-induced catalepsy 
(14). !f such a relationship also exists for morphine-induced catalepsy, 
the GABA receptor blocking agent bicuccul ine would be expected to anta-
gonize morphine-induced catalepsy. Such an antagonism, however, was not 
observed in the present experiments. Also the anticholinergic drug atropine 
did not influence the morphine-induced catalepsy, indicating that mus-
carinic receptors are not involved in morphine-induced catalepsy, which is 
in keeping with other reports (9, 12, 15). Although serotonergic mechanisms 
may affect morphine-induced catalepsy (16), it was suggested that a direct 
action of morphine on serotonergic systems is unlikely to account for its 
catalept"tc activ'1ty (17). Morphine-'1nduced catalepsy is most easily 
altered by dopaminergic agents and may be most closely related, therefore, 
to DA systems, a conclusion which also applies after aMpT treatment. 
TheDA systems involved in morphine-induced catalepsy, however, are 
unlikely to be those which project into the striatum or n. accumbens, as 
shown by Cos tall and Naylor (9, 18), using selective brain lesions. This 
suggestion is substantiated by the observation that morphine does not 
affect DA release in these structures (10, 19), while blockade of DA 
receptors by morphine in the same structures also seems to be unlikely 
(8, 20, 21). Since lesions of the central amygdaloid nucleus prevent 
morphine-induced catalepsy, it was suggested that this structure may 
mediate the catalepsy induced by morphine rather than the striatum or n. 
accumbens (9, 22). We observed increased release of DA in the frontal 
cortex and tuberculum olfactorium (10, 23), while no biochemical data are 
avai I able concerning the amygdala. Thus, these three structures may be 
involved in morphine-induced catalepsy in contrast to the striatum and n. 
accumbens. 
Haloperidol-induced catalepsy was also studied after aMpT pretreatment 
to compare its effects with those of morphine. Under these experimental 
conditions, haloperidol treatment, unlIke morphine treatment (19), resulted 
in increased release of DA in both the striatum and the n. accumbens. 
This observation is in agreement with previous studies indicating that 
haloperidol-induced catalepsy is mediated by striatal dopaminergic me-
chanisms (1, 9, 12), in cant rast to mar phi ne- induced cata 1 epsy. No 
potentiation of catalepsy was observed after injection of 1 mg/kg halo-
peridol into rats pretreated with o.MpT. Shore and Doris (13), however, 
reported that aMpT potentiated the catalepsy induced by 0.25 mg/kg 
haloperidol, a dose which was without effect in our hands, although the 
same test for catalepsy was used. 
Recently Stanley and Glick (24) reported that catalepsy scores, ob-
tained in haloperidol treated rats, were much higher when the subjects 
were tested repeatedly, instead of once only. Since this observation 
was made while using a rather different testing procedure, we investigated 
the influence of repeated testing with the present procedure. The results 
are in agreement with those reported by Stanley and Glick (24), and show 
that 1 mg/kg haloperidol did not produce any catalepsy in OMpT pretreated 
rats, unless the animals were tested repeatedly. !n fact, the number of 
tests seemed to be of more importance than the time which elapsed between 
haloperidol treatment and the catalepsy test. The catalepsy observed after 
repeated testing was, nevertheless, related to haloperidol itself, since 
catalepsy was not observed after repeated testing of rats treated with 
a MpT alone. These observations again point to a difference between 
neuroleptic- and morphine-induced catalepsy. !n the latter case, catalepsy 
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was almost maximal during the first test, 20 min after injection of 20 mg/ 
kg morphine, while at a lower dose of morphine (10 mg/kg) no catalepsy 
was observed, not even after repeated testing. 
Some observations seem to suggest that morphine-induced catalepsy is 
related to diminished dopaminergic activity. Thus, apomorphine antagonized 
morphine-induced catalepsy and aMpT pretreatr.:ent prolonged its duration. 
On the other hand, amphetamine and morphine acted synergistically in 
inducing catalepsy. In this context, it is significant, that amphetamine 
antagonizes the catalepsy induced by neuroleptics (1, 3), a phenomenon, 
which has been related to inhibition of DA activity. Moreover, the present 
results show that administration of amphetamine alone toaMpT pretreated 
rats results in catalepsy. It is suggested, therefore, that the catalepsy 
induced by both drugs is the result of an activation of DA systems. This 
hypothesis is in agreement with the observation that morphine increases DA 
release in the frontal cortex and tuberculum olfactorium (10, 23), which 
does not seem compatible with an antagonism of dopaminergic neurotrans-
mission. It is possible therefore, that catalepsy is brought about, on 
the one hand, by decreased activity in the striatal system (cf neuroleptic 
catalepsy) and on the other hand, by activation of DA systems in some 
extrastriatal structures {cf narcotic catalepsy). 
While amphetamine and morphine potentiated each other in the test for 
catalepsy, morphine antagonized the amphetamine-induced sniffing. Sniffing, 
a major sign of amphetamine-induced stereotypic behaviour (1 ,25), has been 
related to activation of dopaminergic neurotransmission particularly in 
the striatum (1, 25-28). Thus, two dopaminergic systems seem to be involved 
in the interaction of amphetamine and morphine. The synergism of both 
drugs in the induction of catalepsy may involve the extrastriatal dopaminer-
gic structures, mentioned above, while the amphetamine-induced stereotypic 
behaviour involves striatal DA systems and can be antagonized by morphine. 
The existence of two DA systems mediating opposite effects has also been 
suggested from experiments using a rather different approach (29, 30). 
Locomotor stimulation in the rat, for example, may be induced by the 
activation of a postulated excitatory DA system, but also by inhibition 
of a postulated inhibitory DA system (30) and a balance between both systems 
would be essential for normal psychomotor functioning (29). In this model, 
haloperidol and apomorphine were characterized as a specific antagonist 
and an agonist, respectively, of the excitatory DA system, while amphetamine 
acted as an agonist in both systems (29). These features also fit with 
the present data, if it is valid to assume that morphine activates the DA 
system which is unaffected by haloperidol and apomorphine. Accordingly, 
haloperidol may induce catalepsy by inhibition of the excitatory DA system 
and morphine by activation of the inhibitory DA system. Since a balance 
would exist between both systems, apomorphine may antagonize morphine-
induced catalepsy by activation of the former system, thus restoring the 
balance. This would not apply for amphetamine, since this drug would also 
activate the second system, thus accounting for amphetamine induced cata-
lepsy and synergism with morphine. Activation of the excitatory DA system 
by amphetamine would account for its stereotypic properties, which effect 
may be counteracted by morphine, through activation of the inhibitory 
DA system. However, since amphetamine may simultaneously induce catalepsy 
and stereotypic behaviour, the two DA systems may not directly antagonize 
each other, but may rather mediate opposite responses. This 11 physio1ogical 
antagonism 11 may lead to blockade of one behavioural response in favour of 
the other (cf stereotyplc behaviour and catalepsy). 
1n conclusion, the present results suggest that morphine may induce 
catalepsy through a DA system located in structures outside the striatum 
and n. accumbens. Moreover, it is suggested that the effects of morphine 
are the result of activation of dopaminergic neurotransmission rather than 
inhibition. This is in contrast to haloperidol, which presumably induces 
catalepsy through inhibition of striatal systems (1, 9, 12). The existence 
of two pharmacologically and anatomically distinct DA systems, as suggested 
here, may parallel the concept of two distinct types of DA receptors as 
suggested by Cools et al. (29, 30), though it has yet to be shown whether 
these classifications are mutually compatible or not. 
ACKNOWLEDGEMENT 
We are very much indebted to Mrs. v.d. Berg-Blok for her skillful 
technical assistance, to Dr. M. Parnham for correction of the manuscript 
and to Mr. C.D. Bar and N.G.O. v.d. Sloat for preparation of the 
figures. We thank Endo Lab., Brussels, for a gift of naloxone and Janssen 
Pharmaceutica, Beerse, for a gift of haloperidol. 
Th"1s work was supported by grants from the Netherlands Foundation for 
Medical Research and from the Dutch Government project: Beleidsruimte 
Hersenen en Gedrag. 
REFERENCES 
1. Fog, R., Acta Neurol. Scand. 48, Suppl. 50 (1972). 
2. Costall, B., R.J. Naylor, Neuropharmacol. 11, 645 (1972). 
3. Zettler, G., R. Thorner, Pharmacology 10,238 (1973). 
4. Gessa, G.L., A. Tagl iamonte, Neuropharmacology 14, 913 (1975). 
5. And€n, N.E., H. Corradi, K. Fuxe, U. Ungerstedt, Eur. J. Pharmacal. 
15, 193 (1971). 
6. Kehr, W., A. Carlsson, M. Lind.qvist, T. Magnusson, C.V. Atack, J. 
Pharm. Pharmac. 24, 744 (1972). 
7. Sasame, H.A., J. Perez-Cruet, G. DiChiara, A. Tagliamonte, G.L. Gessa, 
J. Neurochem. 19, 1953 (1972). 
8. Kuschinsky, K., 0. Hornykiewicz, Eur. J. Pharmacal. 19, 119 (1972). 
9. Costa11, B., R.J. Naylor, Psychopharmacologia 34,233 (1974). 
10.Moleman, P., J. Bruinvels, Life Sci. 19, 1277 (1976). 
11.Moleman, P., J. Bruinvels, Progr. Neuro-Psychopharmacol. in press. 
12.Ezrin-Waters, C., P. Muller, P. Seeman, Can. J. Physiol. Pharmacal. 
54, 516 (1976). 
13.Shore, P.A., R.L. Doris, Eur. J. Pharmacol. 30, 315 (1975). 
14.Kaariainen, I., Acta Pharmacal. Toxicol. 39, 393 (1976). 
1S.Kuschinsky, K., Naunyn Schm. Arch. Pharmacal. 281, 167 (1974). 
16.Costall, B., R.J. Naylor, J. Pharm. Pharmac. 27,67 (1975). 
l7.Groppe, G., K. Kuschinsky, Neuropharmacology 14, 659 (1975). 
18.Costall, B., R.J. Naylor, Eur. J. Pharmacol. 27,46 (1974). 
19.Moleman, P., J. Bruinvels, submitted (paper IV). 
20.Costa, E., D.L. Cheney, G. Racagni, G. Zsilla, Life Sci. 17, (1975). 
21.Carenzi, A., A. Guidotti, A. Revuelta, E. Costa, J. Pharmacal. Exp. 
Ther. 194, 311 (1975). 
97 
98 
22. Costal 1, B., R.J. Naylor, Psychopharmacologia 35, 203 (1974). 
23. Moleman, P., J. Bruinvels, submitted (paper Ill). 
24. Stanley, M.E., S.D. Glick, Neuropharmacology 15, 393 (1976). 
25. Creese, 1., S.D. Iversen, Psychopharmacologia 39, 345 (1974). 
26. Fog, R., A. Randrup, H. Pakkenberg, Psychopharmacologia 18, 346 
( 1970) . 
27. Creese, 1., S.D. Iversen, Brain Res. 83,419 (1975). 
28. Kelly, P.H., P.W. Seviour, S.D. Iversen, Brain Res. 94, 507 (1975). 
29. Cools, A.R., J.M. van Rossum, Psychopharmacologia 45, 243 (1976). 
30. Cools, A.R., in: Adv. Behav. Biology: Cocaine and other stimulants, 
Plenum Press, N.Y., Vol. 21, p. 97 (1977). 
RESULTS AND DISCUSSION 
aMpT-METHOD 
Various experimental approaches to study drug effects on dopaminergic 
neurons have been reviewed in Part I. In the present experiments a modi-
fication of the aMpT method was used. Drug induced changes, observed with 
other methods, are strongly dependent on changes in DA biosynthesis, 
while those observed with the synthesis inhibition method, as used here, 
are related to DA disappearance. Whether this disappearance can be under-
stood as release of DA onto its physiological receptors, is not certain 
(Part I). It is imperative, however, to analyse the effect of drugs with 
this method during the period of complete synthesis inhibition. For that 
reason the time course of DA synthesis inhibition was investigated. 
lt was observed that aMpT completely inhibited DA biosynthesis, as 
measured in whole rat brain, from 30 min onwards, 5 h being the longest 
period of observation (ll, table 1). Drugs were therefore administered 
in the following experiments 30 min after injection of o:MpT. 
The observation of differential effects of morphine in frontal cortex 
and striatum made it necessary to establish whether the previous obser-
vation of total inhibition of TH in whole rat brain also applied to these 
structures separately. lndeed, maximal inhibition of DA biosynthesis was 
achieved 30 min after aMpT administration in both structures (111, table 2). 
Table 1. 
DA Concentrations in Frontal Cortex and Striatum 2~h after o:MpT Treatment 
f ronta 1 cortex 
striatum 
44 + 9 (3) 
48 + 5 (6) 0.294 0.30 
a. DA as percentage of the concentration at the moment of o:MpT injection. 
Values represent mean + S.D., the number of series of experiments is 
given in parantheses. Series of experiments from paper ll, table 3; 
paper ! ! ! , table 3 & 4; paper !V, fig. 1a, 2 & 3. 
b. Corresponding mean fractional turnover rate. 
c. From Doteuchi et al. (1). 
!n rats treated 2!- h with o:MpT a rather reproducible decline of DA 
was observed throughout several series of experiments, performed over an 
extended pe.·iod of time (table 1). DA levels dropped 2~ h after o:MpT to 
44% in the frontal cortex and 48% in the striatum. 
Fig. 1 shows the relative concentrations of DA, HVA and DOPAC in the 
striatum 30 and 150 min after o:MpT administration. At 30 min DA levels 
were significantly lowered, but HVA and DOPAC levels were not. Moreover, 
the percentage DOPAC was significantly above that of DA. No differences 
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Fig. 1. aMpT-induced decline of DA, HVA and DOPAC in the striatum 
Concentrations were calculated relative to the level at the moment of 
aMpT administration (t0 ). 
o--o DA, 100% 5.11 "g/g 
e-- e HVA, I 00% = 0.38 "g/g 
&-- _. DOPAC, 100% = 0.73 "g/g 
* p <0.05 vs respective 100% value 
* p <0.05 vs respective% of DA 
Nuffiber of observations was 3-7. 
were observed by 150 min. This could point to the fact that aMpT releases 
DA during the first 20-40 min after administration (1), although elevatior 
of the catabolite levels above 100% may have been expected then at 30 min. 
These results confirm the previous observation that DA biosynthesis is 
not instantaneously inhibited. 
In most experiments morphine was administered 30 min after aMpT and 
the rats were decapitated 2 h later. Several considerations led to this 
experimental set up: 
1. The aim was to assess drug effects as shortly as possible after 
aMpT-treatment, since the rapid decline of DA, induced by the synthesis 
inhibitor (vide supra), might result in changes in neuronal activity 
(Part 1). Since complete inhibition of synthesis is essential, morphine 
was administered 30 min after aMpT. Moreover, effects of aMpT or its 
metabolites on DA release have ceased by then (1). 
2. The analgesic and cataleptic effects of 20 mg/kg morphine i .p., 
last for about 2 h (3, VI), corresponding roughly to the time course 
of morphine brain levels (4, 5). Rats were decapitated therefore 
2 h after morphine administration. 
3. Although originally the decline of DA is assessed at several time 
points after aMpT administration (6), we decided to restrict the analysis 
to one time point, i.e. 2 h after drug treatment. When intermediate time 
points are added, it is possible to evaluate the 1 inearity of the re-
gression of log(DA) vs time. Since the errors of the mean DA concentrations 
are such that only gross deviations from linearity will be detected, it 
was preferred to increase the accuracy of the determination of DA decline 
by concentrating al 1 observations at the ends of the time period to be 
covered. The consequence of this approach is that biphasic effects wil 1 
escape attention at al 1 events. 
The tables as presented in paper Ill and IV not only contain values 
for DA concentrations, but also rate constants of DA loss (k, fractional 
turnover rate: 6). In a strict sense the presentation of the fractional 
turnover rate may not be justified, since it is based on the assumption 
of a steady state. Since morphine is injected during the period of ob-
servation and morphine levels, and presumably morphine effects, there-
after are not constant with time, this condit"1on w"1ll not be met. However, 
because the decline of DA after aMpT treatment is exponential, the mere 
presentation of final DA concentrations was judged an insufficient 
description of the effects obtained. 
DA, HVA P.ND DOPAC ASSAY IN BRAIN TISSUE 
To evaluate the reliability of the assay of DA, HVA and DOPAC after 
decapitation of the rat and dissection of the brain tissue, the time 
course of their concentrations at postmortem was investigated. Effects 
were observed 7t min after decapitation for DOPAC, but not for DA and 
HVA (1). In all subsequent experiments brain tissue was frozen in liquid 
nitrogen within 4 min after decapitation, when no postmortem effects were 
apparent. 
EFFECT OF MORPHINE IN DIFFERENT DOPAMINERGIC BRAIN REGIONS 
Table 2 summarizes the effects of morphine in the frontal cortex and 
striatum, obtained in several series of experiments. The aMpT-induced 
DA decline was accelerated significantly by morphine In the frontal 
cortex, but not in the striatum. 
The increase of DA loss in the frontal cortex was prevented by naloxone, 
a specific morphine antagonist (!II, table 4). Specific opiate receptors, 
therefore, seem to be involved rather than aspecific membrane interactions. 
The frontal cortex was subdissected to localize the dopaminergic neurons 
involved. It was anticipated that the cortex rostral to the corpus 
callosum and/or the anterior cingulate cortex would account for most of 
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Table 2 
Effect of Morphine (20 mg/kg) on the Concentration of DA in the Frontal 
Cortex and Striatum after aMpT Treatment.a 
Frontal Cortex ~ Striatum ~ Reference 
78 % <0. 01 99% n. s. II, table 
78 % < 0. 01 100% n. s. Ill, table 3 
72 % < 0. 02 86% <0. 02 Ill, table 4 
105% n.s. IV, fig. 
90% n.s. IV, fig. 2 
94% n.s. IV, fig. 3 
90% n.s. v, fig. 
a. Values represent the concentration of DA (2i h after aMpT and 2 h after 
morphine treatment) as percentage of the DA concentration in saline 
treated rats. See for details the papers referred to. 
b. p Values for difference of morphine treatment from saline treatment. 
the DA present, since these areas contain the most important cortical DA 
projections in the telencephalon (7). Most DA (80%), however, was 
localized in another area (Ill, fig. 1, table 6), a part of the basal 
forebrain. The morphological imp] ications of this observation are not 
entirely clear (Ill). 
A positive drug effect can be proven beyond reasonable doubt. The 
absence of an effect, however, can only be made more probable by con-
firmation via different approaches. We analysed therefore, the concen-
trations of the DA catabol ites HVA and DOPAC in the striatum in an 
experiment identical to those reported in table 2, and found no effect 
of morphine (I I I, table 5). Furthermore a dose range of morphine (21, 5, 
10, 20 and 40 mg/kg) was administered and the dec] ine of DA analysed. 
Again no effect was observed (V, fig. 1). This last experiment also 
shows that the dose of 20 mg/kg is not just below the 1 imit of sensitivity 
of the nigrostriatal dopaminergic neurons. 
It has been discussed that possible biphasic effects wi 11 remain 
unnoticed with the present method. Since biphasic responses to morphine 
are kncwn (Part I), it may be suggested that an inhibition and subsequent 
stimulation by morphine of DA release, just happens to result in the 
absence of a difference in DA concentrations at the moment of decapitation 
of the rats in the present experiments. The results with different doses 
of morphine, however, make this seem unlikely. The duration of depressant 
and stimulant effects of morphine differs considerably with different 
doses. It would have been expected therefore, that a biphasic effect on 
DA decline would have resulted in an obvious difference in DA concentra-
tions with one dose or another. 
In other laboratories an increased dec] ine of DA levels in the 
striatum was observed when morphine was administered before aMpT (8, 9, 
10). It has been discussed in Part I that this procedure (conventional 
synthesis inhibition method) precludes an unequivocal interpretation of the 
drug effects obtained. To ascertain that our different results in the 
striatum with the modified synthesis inhibition method were not due to 
trivial factors (e.g. strain differences, analytical techniques etc) I 
reproduced these experiments. Indeed an enhanced decline of DA was observed 
in the striatum when morphine was administered 30 min before aMpT (I I I, 
table 3). It was concluded that morphine accelerates DA biosynthesis, but 
this does not seem to be of funct i ona 1 re 1 evance (I II). 
Other dopaminergic brain structures have also been studied. Then. 
accumbens seems to react to morphine as does the striatum (Ill, fig. lb), 
while the tuberculum olfactorlum resembles the frontal cortex with the ob-
servation of an increased loss of DA (IV). A dissociation of the effects 
of morphine in terms of nigrostriatal and meso] imbic/mesocortical dopaminer-
gic systems does not appear, therefore, from these data. 
The effect of morphine on the decline of DA after interruption of the 
impulse flow (IV) was investigated for several reasons: 
1. To evaluate whether the observed enhanced decline of DA in the 
frontal cortex was a direct effect on dopaminergic neurons or the result 
of modification of an input to this system. It was expected that elimination 
of the impulse flow would antagonize the effect of morphine in the frontal 
cortex in the latter case but not in the former. 
2. To test the hypothesis that morphine induces DA release in the 
striatum, as '1n the frontal cortex, but simultaneously inhibits the same 
neurons. These effects would cancel each other out in normal rats. After a 
lesion the releasing effect should be uncovered (see IV for a more exten-
sive account of this hypothesis). 
3. To compare the effect of the neuroleptic haloperidol with the effect 
of morphine in the striatum under these conditions. 
As can be seen from the appendix to paper IV, point 1 can not be 
clarified due to an effect of the lesion procedure itself, probably an 
artifact. Concerning point 2 it was observed, that morphine induced DA 
release in the striatum after interruption of the impulse flow, in contrast 
to the striatum of the intact brain side (IV, fig. la). This is contrary 
to haloperidol, which drug induces an acceleration of DA dec] ine in the 
striatum of the intact brain side. This effect of haloperidol was abolished 
by the lesion (IV, fig. la). Similar effects of both drugs were observed 
in the mesol,imbic structure, then. accumbens (IV, fig. lb), when compared 
with the striatum. 
An electrolytic lesion is quite a radical manipulation. It is 
not ex?ctly known in what condition the nerve terminals are after 
a lesion of the neuronal cell bodies. Therefore, the effect of morphine was 
also studied after decreasing the DA release to about 50% by administration 
of apomorphine. Morphine accelerated the loss of DA under these conditions, 
but not in the striatum of control rats (IV, fig. 2). When the decline of 
DA was accelerated by haloperidol, however, morphine exerted no effect 
(IV, fig. 3). It appears therefore, that morphine releases DA from the 
inactive neuron. This effect is progressively reduced in neurons with in-
creasing activity, which results in a slight but insignificant effect at 
norma·l activity and the total absence at increased activity (IV, fig. 4). 
This observation may account for the incidental observation of an increased 
DA decline in the striatum in one out of seven experiments (table 2), since 
in this experiment a lower basal activity of the striatal neurons was 
observed (Ill). 
103 
The suggestion that the observed activity-dependent effect of morphine 
in the striatum also applies to other dopaminergic systems does not seem 
justified, since the same relation did not appear from preliminary obser-
vations in the tuberculum olfactorium (appendix to paper IV). These results 
are far from conclusive because of a minimal number of observations. It 
is necessary therefore, to extend these observations and to evaluate the 
effect of morphine after 'Interruption of the impulse flow in these dopa-
minergic neurons to substantiate possible differences. The observed impulse-
flow dependency in the striatum, however, can certainly not be extra-
polated to other structures without positive indications. 
MORPHINE-INDUCED CATALEPSY 
Catalepsy is considered to be always accompanied by an increased DA 
turnover in the striatum (8, 11, 12). The observation that morphine has no 
effect on aMpT-induced DA decline in the striatum (vide supra) suggested 
that this may not always be true. Morphine-induced catalepsy was measured 
therefore, in rats pretreated with aMpT. This allowed a direct comparison 
to be made with the experiments described in the previous section. Pre-
treatment with aMpT even prolonged morphine-induced catalepsy (V, table 1; 
VI, fig. 1). Naloxone antagonized this catalepsy which shows that the 
catalepsy is specific for morphine. It was concluded therefore, that 
changes in striatal dopaminergic activity do probably not under] ie 
morphine-induced catalepsy (V). 
Experiments with apomorphine, amphetamine, atropine and bicuccul ine 
showed that dopaminergic neurons, nevertheless, play a critical role in 
the observed catalepsy (VI). Apomorphine antagonized, while amphetamine 
enhanced morphine induced catalepsy. A simple interaction between dopaminer-
gic agents and morphine-induced catalepsy does not, therefore, seem to 
exist. Since morphine may rather stimulate than inhibit dopaminergic neuro-
transmission, it was suggested that morphine-induced catalepsy may be 
connected with stimulation of extrastriatal dopaminergic neurons (VI). 
Catalepsy can also result from inhibition of dopaminergic neurons in the 
striatum, viz. by neuroleptics. Catalepsy may therefore, be mediated by 
two dopaminergic systems, i.e. by stimulation of an extrastriatal or 
inhibition of the striatal system. The existence of two contrary acting 
DA systems could account for the complicated effects of DA agonists on 
morphine-induced catalepsy (VI). 
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AN ANALYSIS OF SUBCELLULAR MECHANISMS 
Almost al 1 possible mechanisms at the subcellular level have at some 
time been proposed as a way of morphine action when interpreting 
specific results. Before propounding another view derived from the present 
results an analysis of facts seems relevant. 
Morphine stimulates DA biosynthesis (1-6) and increases the levels 
of the dopamine catabol ites HVA (7-10) and DOPAC (11) in vivo. When the 
synthesis of DA is increased in one way or another, this inevitably results 
in increased catabolite levels at a given moment. This is observed after 
treatment with neuroleptics (12-16), electrical stimulation of dopaminergic 
neurons (17-19), or inhibition of impulse flow by GHB (20-22). Whether 
the increased catabolite levels are dependent on increased DA biosynthesis 
is not assessed. Reserpine, for instance, may increase catabolite levels 
(23) and decrease DA biosynthesis (24) although the different time intervals 
investigated in these studies, leave the question still open. Neverthe-
less, there are a number of indications that increased catabolite levels 
are secondary to increased DA biosynthesis, when morphine is administered. 
30 Min after administration of morphine, DA concentrations are ele-
vated (2, 25, 26). Moreover, we d"1d not observe increased catabolite levels 
when the biosynthesis of DA was blocked by aMpT prior to morphine treatment 
(Ill). Both observations would point to an increased DA biosynthesis pre-
ceding increased catabolism rather than the reverse. The latter observation 
could be explained by assuming that newly synthesized DA is preferentially 
catabolized (7, 26). It has been suggested that aMpT not only blocks DA 
biosynthesis, but also amine transfer from a general store to releasible 
sites (27). Wester ink and Korf (28), however, observed that the increase of 
catabolite levels induced by morphine was prevented by transsection of the 
nigrostriatal bundle. Although these authors inferred from this observation 
that the effect of morphine is impulse flow dependent, another explanation 
is possible. 
Thus, elevated DA concentrations after the transsection indicate that 
DA biosynthesis may be stimulated to the extent that product feedback 
inhibition becomes the rate 1 imlting factor. Under these circumstances 
morphine may not be able to stimulate DA biosynthesis any more and this 
can account for the prevention of elevated catabolite levels. In this 
situation there is presumably enough newly synthesized DA which could be 
catabolized, but morphine has no effect. Increased DA catabolism may be 
secondary to increased DA biosynthesis induced by morphine. These obser-
vations seem to indicate that the hypothesis of Sharman (29) for etorphine 
( a morphine analogue) as elaborated by Kuschinsky and Hornykiewicz (7) 
does not hold true. These authors suggested that morphine may displace 
newly synthesized DA from storage sites to the sites of catabolism. 
Nevertheless, the basis of this hypothesis merits more attention. At the 
molecular level it was based on the observations already described, viz. 
increased DA biosynthesis and catabolism. Neuroleptics exhibit simi Jar 
presynaptic effects and in addition induce catalepsy in rats as morphine 
does. Since neuroleptics are considered to produce catalepsy by blockade 
of striatal DA receptors, it was suggested that morphine may do that too 
(30). Kuschinsky and Hornykiewicz (7) judged this possibility unlikely, 
since naloxone anta9onizes these effects of morphine but not those of 
neuroleptics and also because morphine-induced catalepsy is easily 
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antagonized by DA receptor agonists unlike neuroleptic-induced catalepsy. 
It has been shown more recently that a number of other parameters connected 
to DA receptor activity were also unaffected by morphine, in contrast to 
neuroleptics (3, 6, 31). Thus, neurolept'tcs change the kinetic parameters 
of TH in vitro, inhibit OA-stimulated adenylate cyclase, increase striatal 
Ach turnover and inhibit the increase of striatal cAMP levels elicited by 
apomorphine or amphetamine, but morphine has no effect on any of these 
parameters. To account for the morphine-induced catalepsy the hypothesis 
was put forward then that morphine may displace newly synthesized DA from 
storage sites to the sites of catabolism, thus resulting in a Jack of DA 
at receptor sites (7). This presynaptic action would then be an indirect 
DA receptor blockade. 
Since recent studies show that morphine may not induce catalepsy at 
all, via str'1atal dopaminergic mechanisms (32, 33, II, V, VI), it does 
not seem necessary to account for any lack of DA at striatal receptor sites. 
It should be stressed that the observed catalepsy was the only instigation 
for such considerations. 
Since morphine does not block DA receptors and since there is 
no analogy with neuroleptic mechanisms at the subcellular level, 
the o~~eryed effects of morphine more probably wou)d point to an ac-
tivation of dopaminergic neurotransmission, i.e. increased biosynthesis 
snd catabolism. This presynaptic stimulation, however, does not result 
in stimulation of DA receptors, s\nce it did not enhance striatal cAMP 
levels in vivo as did apomorphine and amphetamine (3). It was observed 
that morphine had no effect on o:MpT-induced DA decline in the striatum 
(II, Ill, V). Since the biosynthesis of OA is entirely inhibited and since 
all the evidence presented above only shows that morphine stimulates DA 
biosynthesis, it was suggested that the main effect of morphine in the 
striatum may be just this stimulation of OA synthesis without further 
functional consequences (Ill), i.e. release. 
This seems to apply, however, only to dopaminergic neurons with a normal 
impulse flow. When the impulse flow is decreased or entirely impaired, 
morphine increases or induces release of OA in the str'1atum (IV). In these 
experiments the biosynthesis of DA was also inhibited. A direct effect on 
dopaminergic neurons seems to be imp] icated, since al 1 input from other 
neuronal systems is most probably eliminated by a lesion. Blockade of only 
presynaptic receptors (and not postsynaptic) could account for DA release. 
These receptors, however, are already entirely deprived of OA, since no DA 
is released when the neurons are lesioned. There is therefore, no activated 
receptor to block and, in fact, the superfluous addition of the DA receptor 
blocker haloperidol has no effect in this situation (IV). I concluded that 
a molecular mechanism is involved which causes direct release of DA. 
Furthermore this mechanism becomes decreasingly effective with increasing 
impulse flow, suggesting that a common link in morphine- and impulse-flcv-J~ 
induced release is involved. 
AN UNDERLYING MECHANISM FOR STIMULATION OF DA BIOSYNTHESIS AND ACTIVITY-
DEPENDENT DA RELEASE IN THE STRIATUM BY MORPHINE 
Morphine induces a rapid depletion of calcium from a number of dis-
crete brain regions (34). This seems to be a specific opiate effect, since 
it is antagonized by naloxone and not observed with inactive stereoisomers 
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~· Liberation of intracellulair calcium by morphine as an under-
lying mechanism of changes in DA biosynthesis and DA release. In the 
normal situation the action potential causes a flux of ca2+ into the 
neuron, which is necessary for DA release. A lesion of the dopaminergic 
cell bodies abel ishes impulse flow and thus ca2+ entry and DA release. 
Furthermore, tyrosine hydroxylase (TH) is present in three configura-
tions: a soluble form (THs), an activated membrane-bound form(THMA) and an 
inhibited membrane-bound form (THMI). The enzyme activity may be regulated 
inter alea by shifts between the different conformations, and ca2+ induces 
such shifts (40). It is not known how the regulations of the enzyme activity 
is related to the impulse flow. 
Morphine stimulates an op1ate receptor (OR) which results in increased 
intracellular ca2+ levels. In the normal neuron this does not result in in-
creased DA release. However, when ca2+ entry is abolished by a lesion, the 
ca2+, !±berated by morphine, induces DA release. Note that 2 in this situa-tion Ca +only leaves the neuron, which may a~count for Ca +depletion, in-
duced by morphine. Increased intracellular Ca +also results in a shift of 
TH to the activated membrane-bound conformation. This mechanism may account 
for increased DA biosynthesis induced by morphine. The relation to impulse-
flow-induced changes in DA biosynthesis is unknown. 
Abbreviations: OR: opiate receptor; DA: dopamine; THs: tyrosine hydroxy-
lase, soluble form; THMA: tyrosine hydroxylase,activated membrane-bound 
form; THMI: tyrosine hydroxylase, inhibited membrane-bound form. 
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of opiates. Moreover, the calcium depletion induced by morphine can be 
distinguished from a similar effect by reserpine or pentobarbital (34~ 35). 
It was suggested therefore, that binding of morphine to specific opiate 
receptors (36) will induce a calcium-dissociated state resulting in 
calcium depletion. Moreover, a specific calcium pool on or within the 
synaptosomal fraction would be involved (35, 37). 
The intracellular release of calcium from presynaptic membranes may 
account for the observed effects of morphine on dopaminergic neurons, as 
indicated schematically in fig. 1. In dopaminergic neurons with a normal 
impulse flow morphine only stimulates DA biosynthesis (Ill). It has been 
shown that TH exists in a soluble and membrane bound form (38, 39). The 
latter form exhibits affinities for the pterin cofactor and for tyrosine 
which are 15 and 7 times higher, respectively, than observed with soluble 
TH. Moreover, calcium ions facilitate association of TH with striatal 
nerve ending membranes and concommitantly increase the total enzyme 
activity (40). It is tempting to speculate, therefore, that morphine 
stimulates DA biosynthesis, because 1 iberated calcium ions activate TH by 
increasing membrane association. 
The same intracellular mobi 1 isation of calcium by morphine may account 
for DA release from inactive dopaminergic neurons. The influx of calcium 
ions is necessary for the impulse-flow-induced release of transmitters, 
including DA (41). In the absence of impulse flow morphine may substitute 
to a certain extent the calcium influx by releasing intracellular calcium. 
When the impulse flow is increased considerably (e.g. with haloperidol) 
the calcium, 1 iberated by morphine, may have no effect. This appears from 
the following considerations. Calcium does not mediate transmitter release 
simply by opening the presynaptic membrane to let through the neurotrans 
mitter. Calcium induces instead the fusion between transmitter-containing 
vesicles and the synaptic membrane (42) by binding to specific membrane 
components. When fusion is effected in this way, the transmitter is re-
leased into the synaptic cleft and the emptied vesicle removed. When the 
resting state is re-established, a new fusion and transmitter release may 
start. At maximal impulse flow this chain of events may operate at maximal 
speed and additional activation by e.g. 1 iberation of intracellular calcium 
by morphine may have no effect. This mechanism may therefore, account for 
the impulse-flow-dependent release of DA by morphine. Thus, in the absence 
of impulse flow morphine wi 11 induce DA release and with increased impulse 
flow morphine will have no additional effect. At normal impulse flow, how-
ever, morphine does not release DA either, though the physiological release 
is not maximal. This may indicate that the calcium 1 iberation by morphine 
is not as effective as with the physiological mechanism. 
Whether the activation of TH by morphine is similarly dependent on 
impulse flow, is not known. It has been shown that OA biosynthesis is in-
creased during electrical stimulation of the nigrostriatal neurons (43). 
Thus, DA biosynthesis may be correlated with nervous activity. The mechanism 
of this activation is not known, but may involve also calcium (40). If so, 
the activation of DA biosynthesis by morphine may also be inversely related 
to impulse flow. The regulation of DA biosynthesis, however, is a lot more 
complicated. OA biosynthesis is increased by electrical stimulation, but 
also by lesions of the nigrostriatal pathway, i.e. by total impairment 
of impulse flow (44-46). Furthermore, activation of presynaptic receptors 
by released DA (47) and accumulation of intraneuronal DA (48) may decrease 
DA biosynthesis. Physiological changes in DA biosynthesis, therefore, are 
not simply related to impulse flow and are omitted from fig. 1, although 
they may interfere with the stimulation by morphine of DA biosynthesis. 
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Thus, the stimulation of DA biosynthesis and DA release by morphine 
may be regarded as unrelated consequences of the same molecular event. 
This may explain why in the striatum DA biosynthesis is stimulated by 
morphine without corresponding increase in DA release. Nevertheless, the 
increase in DA biosynthesis may intensify the DA releasing effect of 
morphine at decreased impulse flow, because more DA may be available 
for release. In regard to this it can not be concluded from .the present 
experiments that the increase in DA biosynthesis is always without 
functional consequences, although that may be true at normal impulse flow 
in the striatum. 
The presented mechanism of action of morphine on dopaminergic neurons 
is consistent with a number of other observations. The action of morphine 
seems, in fact, to be presynaptic as concluded from its accumulation 
in presynaptic elements (49) and the presynaptic localisation of its 
specific receptor (50, 51) and from its interaction with synaptic mecha-
nisms of various neurotransmitters (52, 53). The role of calcium in the 
effects of morphine is illustrated by the observation that the analgesic 
response is antagonized by calcium (54, 55). Moreover, ionophores for bi-
valent cations antagonized the effects of morphine,which may suggest that 
increase in intracellular calcium levels is involved (51, 55). 
The characteristics of the mechanism proposed are not specifically 
related to dopaminergic neurons. The observed calcium depletion is rather 
unHorm throughout several d'1screte brain reg'1ons, some devoid of dopa-
minergic neurons (34). The regional distribution of opiate receptors 
show high concentrations in regions with dopaminergic cell bodies or 
nerve terminals such as caudate-putamen, substantia nigra pars compacta 
and amygdala, but also in regions without dopaminergic neurons such as 
locus coeruleus, periaqueductal gray and medial thalamus (36, 56, 57). 
The underlying mechanism of calcium liberation, therefore, may apply 
to all central effector sites of :norphine. If so, the observed 
effects on dopaminergic neurons are a specific manifestation of this 
general mechanism. Nevertheless, the action of morphine does not seem to 
be so general that al 1 central neurons are affected. Whether a certain 
neuronal system is modulated by morphine, may depend on the presence of 
opiate receptors and on whether the 1 iberation of calcium by morphine 
results in a functional change of the neuron. 
In conclusion, a general molecular mechanism is proposed for the 
modulation of neurotransmission by morphine. The modulation of dopaminergic 
neurotransmission as investigated here, is a sp~cific example then of 
the consequences of this general mechanism. Because of the characteristic 
regulation of dopaminergic neurotransmission, this example can not be 
applied to other neurotransmitter systems without specific information. 
IMPLICATIONS OF THE MODULATION OF DOPAMINERGIC NEUROTRANSMISSION BY MORPHINE 
As discussed above morphine may activate dopaminergic neurotransmission 
under certain circumstances, while an inactivation is never observed. 
This agrees with most pharmacological information about morphine. A large 
body of 1 iterature has been reviewed by D.H. Clouet, which shows that 
pharmacological manipulations presumed to alter DA levels at its receptor 
11either antagonize or potentiate the pharmacological responses to acute 
administration of morphine or other opiates according to the direction of 
change in the levels of biogenic amine 11 (49). !n other words: increased DA 
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receptor stimulation may potentiate and decreased DA receptor stimulation 
may antagonize effects of morphine related to DA activity. 
The activation of dopaminergic neurotransmission by morphine, however, 
is not uniform in different brain regions and not uniform in dopaminergic 
neurons with varying impulse flow. Some implications for the behavioural 
effects of morphine wi 11 be discussed. 
When morphine is administered, DA is released only in frontal cortex 
and tuberculum olfactorium, but not in nucleus accumbens and striatum 
(II, Ill, IV). This may indicate that behavioural responses induced by 
morphine are mediated via tuberculum olfactorium or frontal cortex, rather 
than via n. accumbens or striatum, if they are dependent on DA neurotrans-
mission. The role of other brain regions, not investigated here. (e.g. 
amygdala), remains to be established. Such DA-dependent responses may 
include catalepsy (V, VI), but also locomotor stimulation and groom"1ng 
(58). 
Other responses to morphine, however, also connected to dopaminergic 
neurotransmission, are not necessarily mediated via the same systems. 
This concerns responses to morphine of an essentially different category. 
The former responses (catalepsy, locomotor stimulation, grooming) are 
directly elicited by morphine. The responses discussed now are alterations 
by morphine of behaviour induced by another external stimulus. In an 
analgesic test, for instance, first a response is evoked to an external, 
i.e. noxious, stimulus and then the effect of morphine on this imposed 
response is assessed. In this case one can not depart from the normal 
ailimal in analysing the effect of morphine, since it may very well be that 
the imposed response itself involves changes in dopaminergic activity. 
It is difficult to settle this point, because it does not seem to have been 
looked at in this way. In several reports in which the role of DA in the 
analgesic response to morphine was evaluated, no controls were included 
to evaluate the role of DA in the algesic response~ (59, 60). If 
we assume that these algesic responses involve decreased dopaminergic 
neurotransmission in the striatum, morphine will release DA in the striatum 
and this could account for the involvement of DA in the analgesic activity 
of morphine. In fact, destruction of striatal DA neurons abolishes the 
analgesia induced by morphine, while the catalepsy -not mediated by striatal 
neurons- is increased (59). 
Though purely speculative for the examples put forward, the point to be 
stressed is that it is only possible to evaluate the role of DA in parti-
cular responses to morphine, when one is aware of the state of activity of 
the neurons involved. Moreover, the DA releasing effect of morphine is not 
only different in various brain regions, but in addition it is not certain 
whether the dependency on the state of activity is uniform in all regions. 
Preliminary results suggest that this may not be the case in the tuberculum 
olfactorium when compared with the striatum (IV). 
To state the obvious, these implications for behavioural effects of 
morphine are only concerned with effects dependent on dopaminergic neuro-
transmission and only so far as dependent on dopaminergic neurotransmission. 
It is wel !-documented, for example, that the serotonergic system plays a 
most important role in the analgesic response to morphine (61-63). 
Dopaminergic systems, however, also seem to be involved, possibly 
only in particular responses to noxious stimulation (60). 
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CONCLUSIONS 
1. Morphine may stimulate, but not inhibit dopaminergic neurotransmission. 
2. In normal rats morphine induces release of DA in the frontal cortex and 
tuberculum olfactorium but not in the striatum and nucleus accumbens. 
3. Whether the release of DA in the frontal cortex and tuberculum olfacto-
rium is the result of a direct effect on dopaminergic neurons is not 
assessed. 
4. Morphine induces release of DA in the striatum and nucleus accumbens 
by a direct effect on the dopaminergic neurons with reduced impulse flow. 
5. Morphine increases DA biosynthesis by a direct effect in most or all 
brain regions which contain dopaminergic neurons, independent of possible 
DA release. 
6. An underlying mechanism for the stimulation of DA biosynthesis and DA 
release by morphine involving intraneuronal 1 iberation of calcium is 
proposed. 
]. Morphine-induced catalepsy in rats may not be related to inhibition of 
dopaminergic neurotransmission in the striatum or nucleus accumbens, 
but rather to release of DA in frontal cortex, tuberculum olfactorium 
or other brain regions not studied here. 
8. Behavioural responses involving decreased dopaminergic neurotransmission 
in the striatum or nucleus accumbens, may be antagonized by morphine 
through DA release in the striatum or nucleus accumbens. 
Wenn wir diese unsre Anschauung auch zum 
hOchsten Grade der Deutl ichkeit bringen 
kOnnten, so wOrden wir dadurch der 
Beschaffenheit der Gegenstande an sich 
selbst nicht naher kommen. 
I. Kant, Kritik der reinen Vernunft, 
Walter de Gruyter & Co, p, 43 (1968). 
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SUMMARY 
The aim of this thesis was to investigate the effects of acute 
morphine administration on dopaminergic neuron systems in the rat brain. 
The 1 iterature on the acute effects of morphine in the central nervous 
system is reviewed in Part I. This section also contains a description 
of the dopaminergic neuron systems and an extensive survey of methods 
used to study the dynamics of dopaminergic neurotransmission in vivo. 
The experimental work is described in Part I I. First the postmortem 
changes in the concentrations of dopamine and its acidic metabolites, 
dihydroxyphenylacetic acid and homovani 1 lie acid, were analysed. It was 
observed that the levels of dihydroxyphenylacetic acid changed considerably 
postmortem, 7± min and more after decapitation of the rat. 
In paper II the effect of morphine on the o:MpT-induced decline in 
dopamine levels is described. In the frontal cortex an increase in dopamine 
release was observed, while morphine had no effect in the striatum. 
Moreover, it was shown that the synthesis of dopamine was completely 
inhibited by aMpT during the period of observation. 
The differential effect of morphine in the frontal cortex and striatum 
was further analysed In paper Ill. It was shown that the increased 
dopamine release in the frontal cortex was not due to differential 
inhibition of dopamine synthesis by aMpT in the frontal cortex and 
striatum. Since the effect was antagonized by naloxone, it was concluded 
that a specific opiate action was involved. The frontal cortex was sub-
dissected to analyse the localisation of the dopaminergic neurons in-
volved. Most of the dopamine (80%) was present in basal parts of the 
forebrain. The absence of changes in dopamine release in the striatum 
was further substantiated by the observation that morphine had no effect 
on the levels of homovani 11 ic acid and dihydroxyphenylacetlc acid after 
pr lor a MpT treatment. 
In paper IV is shown that morphine also releases dopamine in the 
striatum, but only when the activity of the nigrostriatal neurons is 
decreased by lesion of the dopaminergic cell bodies in the mesencephalon 
or by prior treatment with apomorphine. Haloperidol, on the other hand, 
increased dopamine release in the striatum of normal rats, but had nO 
effect after lesion. Similar effects were observed in then. accumbens. 
It was concluded that the morphine-induced dopamine release in the 
striatum is dependent on the state of activity of the neurons involved. 
It was also suggested that haloperidol-induced dopamine release is me-
diated by a striatonigral feedback pathway. The imp] I cations of the 
effects of morphine on dopaminergic neurons for its behavioural effects 
are discussed. 
The preliminary results reported in the appendix to paper IV suggest 
that the impulse-flow-dependent effect of morphine in the striatum may 
not occur in al 1 dopaminergic brain structures. 
In paper V is shown that morphine can produce catalepsy without 
concurrent changes in dopaminergic neurotransmission in the striatum. 
It is suggested that morphine-induced catalepsy is related to extra-
striatal dopaminergic systems. 
The catalepsy induced by morphine is further analysed In paper VI. 
Pretreatment with cMpT prolonged the morphine-induced catalepsy, while 
naloxone entirely abolished it. Experiments with atropine, bicuccul ine, 
apomorphine and amphetamine suggested that dopamine plays a crucial role 
in the catalepsy induced by morphine, although this may not involve 
dopaminergic systems in the striatum and n. accumbens. It is suggested 
that two dopaminergic systems are involved in the interaction of morphine 
with dopaminergic agents. The implications of this hypothesis are dis-
cussed. 
The results are summarized and technical details are discussed in 
the Results and Discussion section. 
Part I I I contains the General Discussion. First, the evidence in-
dicating that morphine may block dopaminergic neurotransmission in the 
striatum is reviewed. It is concluded that many results argue against 
such a mechanism of opiate action and that the results of experiments 
used as evidence for this hypothesis can also be interpreted in another 
way. It '1s concluded that morphine does not inhibit but rather stimulates 
Oopaminergic neurotransmission under certain conditions and also stimu-
lates dopamine biosynthesis independently. A molecular mechanism is 
suggested which may account for the stimulation of dopamine biosynthesis 
and dopamine release induced by morphine. It is suggested that this 
mechanism involves 1 iberation of intracellular calcium. The lmpl I cations 
of these results for the interpretation of the behavioural effects of 
morphine are discussed in relation to dopamine systems. 
Finally, the conclusions of this thesis are briefly summarized. 
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SAMENVATT I NG 
Morfine en andere opiaten worden vooral gebruikt voor het draagl ijk 
maken van zware pijn en voor het opwekken van een algemeen gevoel van 
welbehagen (euforie). Deze effekten berusten op een werking in het centrale 
zenuwstelsel, waarvan de mechanismen echter nog niet bekend zijn. Als 
morfine herhaaldel ijk wordt toegediend, ontstaat een ongevoel igheid voor 
deze effekten en de dosis meet worden verhoogd (tolerantie). Dit leidt 
echter tot afhankel ijkheid, die voor een deel veroorzaakt wordt door een 
aanpassing van de cellen aan de steeds hogere doses morfine. lndien de 
toediening op zo een moment wordt gestaakt, treden onthoudingsverschijnse-
len op, die onaangenaam en vaak gevaarlijk kunnen zijn. 
De direkte effekten van morfine (pijnstil 1 ing en euforie) worden 
veroorzaakt door een complex van inwerking van morfine op de zenuwcel len 
en van de reaktie van het 1 ichaam hierop. Om te begrijpen hoe die effekten 
ontstaan, onderzoekt men hoe morfine op eel lulair en molekulair nivo in 
het centrale zenuwstelsel werkt. De veranderingen op dit nivo moeten 
daarna weer in verband worden gebracht met de effekten zoa 1 s pi j nst i 11 i ng 
en euforie. 
Het onderzoek beschreven in dit proefschrift gaat over de effekten 
van morfine op dopaminerge systemen in de hersenen van de rat. Dopamine 
is een van de stoffen die in de hersenen zorgt voor de overdracht van 
impulsen van de ene zenuwcel naar de andere, en wel in bepaalde delen van 
de hersenen. Dopamine speelt een belangrijke rol bij de integratie van 
emotionele reakties en van 1 ichaamsbewegingen die hiermee samenhangen. 
Omdat pijnsti 11 ing en euforie, veroorzaakt door morfine, o.a. met zulke 
reakties samenhangen, is onderzocht of en hoe morfine de prikkeloverdracht 
door dopamine beinvloedt. \k heb gepoogd de gevonden effekten te relateren 
zowel aan molekulaire mechanismen die eraan ten grands lag kunnen 1 iggen 
als aan gedragseffekten die erui t voort kunnen komen. 
!n Part \ wordt eerst een kart overzicht gegeven van een aantal 
effekten van morfine in het centrale zenuwstelsel. Ook zijn de dopaminerge 
zenuwbanen kart beschreven. Voorts bevat dit deel een uitgebreid overzicht 
van technieken die men bij dierexperimenteel onderzoek kan gebruiken 
om de prikkeloverdracht door dopamine te bestuderen. 
Vervolgens zijn de experimenten beschreven in Part I I. In artikel 
wordt de betrouwbaarheid van de bepal ing van dopamine en zijn zure meta-
bel ieten in hersendelen van de rat, zoals die in verdere proeven zijn 
toegepast, onderzocht. In artikel II wordt beschreven dat morfine de 
prikkeloverdracht door dopamine verschillend beinvloedt in twee verschi 1-
lende hersen-strukturen. In de frontale cortex wordt deze prikkeloverdracht 
door morfine waarschijnlijk geaktiveerd, terwijl dat in het striatum niet 
zo is. Deze gegevens worden verder uitgewerkt in artikel I I I. De specifi-
citeit van het effekt in de frontale cortex wordt o.a. aangetoond. Voorts 
werd de lokal isatie van de zenuwcellen die bij dit effekt betrokken zijn, 
onderzocht. Het bl ijkt dat deze eel len niet behoren tot de reeds nauw-
keurig omschreven dopaminerge systemen. In artikel IV wordt de werking van 
morfine vergeleken met haloperidol, een 11 tranquilizer 11 met bekende effekten 
op dopaminerge zenuwcel len. Voorts wordt aangetoond dat morfine onder 
normale omstandigheden geen effekt heeft op de dopaminerge prikkelover-
dracht in het striatum, maar wel als de aktiviteit van de zenuwcel len van 
te voren veranderd is. De konklusie wordt getrokken, dat morfine de 
dopaminerge prikkeloverdracht in het striatum misschien niet di rekt be in-
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vloedt, maar veranderingen in die overdracht dempt. In de appendix van 
artikel IV wordt besproken dat deze relatie misschien niet voor al le 
dopaminerge zenuwcellen geldt. 
Vervolgens is de relatie onderzocht tussen de bovenstaande effekten 
op dopaminerge zenuwcellen en een bepaald gedragseffekt van morfine in 
ratten, namelijk katalepsie, een vorm van bewegingsverstarring. In artikel 
V en VI wordt aangetoond, dat dit verschijnsel inderdaad samenhangt met 
verander:ngen in de dopaminerge prikkeloverdracht. Voorts wordt gesuggereerd 
dat katalepsie samenhangt met een effekt van morfine op dopaminerge zenuw-
cellen in bepaalde hersendelen, name] ijk frontale cortex, tuberculum 
olfactorium en/of amygdala, maar niet striatum en nucleus accumbens. 
Tens lotte worden de resultaten samengevat en besproken. 
In Part I I I worden de resultaten getoetst aan gegevens en hypothesen 
uit de 1 iteratuur. De hypothese wordt opgesteld en besproken, dat het 
werkingsmechanisme van morfine zou berusten op het vrijmaken van calcium-
ionen in dopaminerge zenuwcellen. Voorts wordt het verband tussen dit 
werkingsmechanisme van morfine en bepaalde gedragseffekten besproken. 
Tens lotte worden de konklusies kart samengevat, namel ijk: 
1. Morfine kan de dopaminerge prikkeloverdracht stimuleren, maar niet 
remmen. 
2. Onder normale omstandigheden verandert morfine de dopaminerge 
prikkeloverdracht in frontale cortex en tuberculum olfactorium, maar niet 
in striatum en nucleus accumbens. 
3. Het is niet duidel ijk of de verandering in dopaminerge prikkel-
overdracht in frontale cortex en tuberculum olfactorium berusten op een 
direkt effekt op die zenuwcellen of niet. 
4. Morfine veroorzaakt stimulatie van de prikkeloverdracht door do-
pamine in striatum en nucleus accumbens, aJs de aktiviteit van de dopa-
minerge zenuwcel len verminderd is. 
5. Morfine stimuleert de biosynthese van dopamine, waarschijnl ijk in 
al le dopaminerge zenuwcel len, onafhankel ijk van bovengenoemde effekten. 
6. De hypothese "1s opgesteld, dat de verkregen effekten van morfine 
berusten op vrijmaking van intracel lulair calcium. 
]. Katalepsie veroorzaakt door morfine, zou berusten op aktivering 
van dopaminerge prikkeloverdracht in frontale cortex, tuberculum olfdcto-
rium of andere hier niet onderzochte strukturen. 
8. Gedragseffekten die samengaan met vermindering van dopaminerge 
prikkeloverdracht in het striatum kunnen door morfine wel in die struktuur 
beinvloed worden in tegenstel 1 ing tot katalepsie. 
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